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ABSTRACT 
Background 
Cutting edge battlefield trauma care has allowed military personnel to survive complex 
injuries that historically would not have been possible. There is largely historical evidence 
suggesting that combat related traumatic injury (CRTI) is associated with an increased 
cardiovascular (CV) disease (CVD) risk. However, data from a contemporary military 
population with CRTI is lacking.  
Hypotheses 
The main hypotheses addressed in this thesis are: 
1. Military servicemen who have had suffered severe CRTI with limb amputations have
increased arterial stiffness compared to those less severely injured and non-injured
servicemen.
2. Combat-related traumatic amputation is associated with greater vascular inflammation
and a more adverse lipid profile than that observed with less severe combat related
injuries and with non-injured servicemen exposed to the same operational environment.
Methods 
This was a cross-sectional observational study that included the first 699 male British military 
personnel who took part in the ongoing ADVANCE (ArmeD SerVices TrAuma 
RehabilitatioN OutComE) study project. CRTI veterans with limb amputations (CRTI-A, 
n=105) and CRTI veterans without limb amputations (CRTI-NA, n=200) were compared with 
a frequency-matched healthy control population (n=394) of servicemen of similar age and 
operational exposure (Afghanistan 2003-14). Fasting serum lipids, glucose and Hs-CRP levels 
were measured using venous blood. Arterial stiffness (expressed as central [AIx] and 
peripheral [pAI] Augmentation Index), pulse wave velocity (PWV), brachial and central aortic 
blood pressure, subendocardial viability ratio (SEVR), an indirect marker of myocardial blood 
perfusion, were measured using the Vicorder device. Injury severity was determined using the 
New Injury Severity Score (NISS) and the association of injury severity score and CVD risk 
profile was assessed. 
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Results 
The mean age was 33.9 (± 5.40) [range 23-60] years with the time from injury or deployment 
to examination averaging 90.4 (± 20.99) months. The NISS were higher in the CRTI-A vs 
CRT-NA vs control 36.75 (± 18.01) vs 20.11 (± 17.9) vs 0; p<0.001 respectively. Resting 
heart rate (minute-1) was significantly higher amongst those with CRTI-A, 63.67 ( ± 12.53) vs 
CRTI-NA group 58.35 (± 9.41) and, healthy controls 56.39 (± 9.24); p<0.001, with no 
significant difference in respective HDL Cholesterol levels 1.120 (± 0.27) vs 1.249 (± 0.33) 
vs 1.252 (± 0.27) mmol/l; p<0.001. PWV, AIx or central blood pressure. The SEVR values, 
194.0 (± 43.32) vs 201.3 (± 45.07) vs 208.5 (± 63.04); p=0.0101) respectively, were 
significantly lower whereas Hs-CRP, 2.60 (± 3.81)mg/l vs 1.96 (± 2.68)mg/l vs 1.44 (± 
1.69)mg/l; p=0.0166 respectively and total cholesterol/HDL ratio 4.49 (±1.25) vs 4.31 (±1.82) 
vs 4.19 (±1.48); p=0.012, respectively, were significantly greater among the CRTI-A 
compared with the CRTI-NA and healthy controls. These differences were most marked with 
proximal bilateral amputations. 
Conclusion 
Servicemen who have sustained severe CRTI-A have a worse CVD risk profile with evidence 
of greater vascular inflammation and a more adverse lipid profile than those without 
amputations or injury. However, there was no significant difference in arterial stiffness. These 
findings confirm the need for a long-term cohort study to assess whether these differences in 
risk profile will translate into meaningful variance in CVD outcomes. 
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Chapter 1  
General Introduction 
1.1 Background and rationale 
Between 2003 and 2014, the battlefields of Afghanistan (Op Herrick, 2016) and Iraq (Op 
Telic, 2016), left the Defence Medical Services (DMS) with significant numbers of military 
personnel who sustained severe complex injuries which, without the use of body armour and 
cutting-edge battlefield trauma care, they would previously not have survived (Ministry of 
Defence, The National Archives). The rate of war-related amputations is now twice that 
experienced by military personnel in previous wars (Robbins et al., 2009). Consequently, a 
relatively large population of young service members was created with unique healthcare and 
rehabilitation needs. There is emerging evidence that combat related traumatic injury (CRTI) 
is associated with an increased risk of CVD. With heart and circulatory disorders being 
responsible for 1 in 4 deaths in the United Kingdom (UK), there is a need for further 
exploration into the risk of cardiovascular disease (CVD) development in these individuals.  
 
The effects of combat related traumatic injuries (CRTI) on contemporary and subclinical CVD 
risk factors should be examined and determined to facilitate early identification and mitigation 
strategies before the onset of clinical disease to minimise the impact of CVD long term. If 
severe traumatic injury and limb amputations are linked to an increased risk of CVD then it 
could be argued that an increased burden of identifiable subclinical cardiovascular risk factors, 
such as raised fasting blood glucose, lipid profile and high sensitivity C reactive protein (Hs-
CRP) would be present prior to the onset of clinical CVD (Kotsis et al., 2017, Antunes et al., 
2016). 
 
An indirect assessment of the impact of atherosclerotic risk factors acting on the arterial tree 
is now possible using a variety of methods. Non-invasive methods include the quantification 
of arterial stiffness (using pulse wave velocity [PWV] and pulse wave analysis [PWA] to 
measure the arterial augmentation index [AIx] (Magalhaes et al., 2011). These evolving 
techniques have enriched the understanding and quantification of CVD risk and improved the 
ability to detect subclinical cardiovascular risk. 
 
Data from both military and civilian cohort studies suggest that CRTI resulting in limb 
amputations (CRTI-A) are linked to an increased risk of developing CVD (Modan et al., 1998, 
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Kunnas et al., 2011, Robbins et al., 2009). These findings were however refuted by Mundell 
and colleagues who concluded that those with trauma-related limb amputations were at no 
higher risk of a cardiac event than their able bodied controls (Mundell et al., 2018). Mundell 
et al also found that the provision of a prosthesis was not associated with a reduced risk of 
developing CVD (Mundell et al., 2018). 
 
One of the principle limitations of the current studies that have investigated the plausible link 
between CRTI, and cardiovascular risk is that their data mainly relate to retrospective analysis 
of injuries sustained in historical wars fought more than 40 years ago. Furthermore, the 
majority of studies were cross sectional studies with poorly defined comparative controls that 
were often civilians of dissimilar ages and background  (Hrubec and Ryder, 1980, Kunnas et 
al., 2011, Modan et al., 1998), leading to considerable bias in reported outcomes. Limited 
studies are also available about other types of traumatic injuries with the focus primarily on 
established CVD risk markers such as hypertension and diabetes (Rose et al., 1987). 
 
Previous cohorts have not been as severely injured as the UK DMS cohort. Other limited and 
insufficient studies were in long term health related outcomes such as bone health 
(osteoarthritis, osteopenia/osteoporosis and fracture), all-cause mortality and long term 
vocational and quality of life (QOL) outcomes and not transferable to our current uniquely 
severely injured population of casualties (Dutta et al., 2008, Kang and Bullman, 2001, 
Kulkarni et al., 1998, Shahriar et al., 2009, Vollmar et al., 1989). Other shortcomings of 
previous studies include their retrospective design and the fact that cardiovascular risk factors 
were not collected at baseline.  
 
This MPhil study is a cross sectional evaluation of the baseline data of the prospective 
longitudinal ADVANCE (ArmeD SerVices TrAuma RehabilitatioN OutComE) Study 
conducted by the DMS. The ADVANCE Study was designed to examine the medium- and 
longer-term outcomes of British combat casualties who sustained traumatic injuries during 
recent military operations in Afghanistan (www.advancestudydmrc.org.uk). Rehabilitation of 
these casualties takes place at Defence Medical Rehabilitation Centre (DMRC), previously 
residing at Headley Court and now at Stanford Hall, where the long-term outcomes of this 
cohort of severely injured UK armed forces casualties are investigated. Rehabilitation is 
regarded as a crucial step in achieving optimal long-term outcomes and quality of life after 
amputations. Therefore, there is a need to gain as much information as possible to improve 
the potential for optimal rehabilitation of military personnel with combat-related traumatic 
amputations. An increased understanding of the health issues facing the CRTI-NA military 
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personnel, and other CRTI-A, would be invaluable to enhance the long-term function and 
quality of life after amputation. 
 
The DMS has undertaken to ascertain various aspects of the health and psychosocial 
characteristics of service personnel by means of prospective, longitudinal studies. This will 
provide information for future conflicts and offer appropriate and timely support for serving 
and discharged members alike. 
 
1.2 Epidemiology of combat related traumatic injuries and amputations 
A study by Chandler and colleagues confirmed that for the UK military population, extremities 
are involved in the vast majority of combat injuries, which resulted in a large surgical 
workload required for their treatment (Chandler et al., 2017). Therefore, the UK Military Joint 
Theatre Trauma Registry was searched for survivors of extremity injuries during the period 
between 19th March 2003 (Invasion of Iraq) and 27th October 2014 (cessation of combat 
operation in Afghanistan), excluding casualties killed in actions or who died from their 
wounds.  
 
It was found that of 2348 UK combatants who survived injury in Iraq and Afghanistan, 1813 
(77%) had extremity injuries with 205 (11%) having at least one amputation at the wrist or 
ankle or more proximal. Trans-tibial was the most common level of limb loss. Eighty-five 
casualties lost two limbs, with 83 of these (98%) lost both lower limbs and 17 lost three limbs.  
A prospective study of the UK Naval Services to determine casualties, injury patterns, 
recovery and residual burden from conflicts between March 2003 and April 2013 revealed 
there were 277 casualties in the study period of which 63 (23%) were fatalities. 23% were 
medically discharged and 9% were placed in reduced fitness categories in continued military 
service. 46% returned to full service. Injuries to the lower limb were the most common cause 
for medical downgrading or discharge with upper limb traumatic injuries the next most 
frequent. The conclusion was that extremity injuries were the most challenging in 
rehabilitation and reconstruction services with the aim to achieve maximal outcomes for the 
injured personnel (Penn-Barwell et al., 2014). 
 
Examining US injury trends between 2005-2009, information was extracted from the Joint 
Theatre Trauma Registry (JTTR) to obtain all relevant injury information about all US 
military. A total of 1,992,232 military service members were deployed with 7,877 combat 
casualties resulting in 29,624 distinct combat wounds. The mean age of the combat casualty 
cohort was 26.0 years old (98.8% male). Combat wounds were distributed as follows: 
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head/neck, 28.1%; thorax, 9.9%; abdomen, 10.1%; and extremities, 51.9%, which confirms 
that the majority of combat related injuries could involve amputation or at least compromised 
ambulation. Explosive related injuries were more prevalent than gunshot injuries (74.4% vs 
19.9%, p<0.001). Explosive related injuries became more common in Iraq than Afghanistan 
between 2005-07 equaling towards 2009.The conclusion was that wounding patterns in 
Afghanistan and Iraq differed from previous US conflicts with explosive mechanisms 
accounting for 74.4% of combat casualties (Belmont et al., 2012). 
 
Further traumatic injury statistics are: 1530 fractures with 501 (33%) involving upper limbs 
and 1029 (67%) lower limbs and pelvis. The tibia was reported to be the most frequently 
fractured bone. 597 (58%) of lower limb fractures were open compared to 344 (69%) in upper 
limbs. An average of seven surgical procedures was reported per limb.  
 
While mortality rates were lower in current than in past conflicts, the survivors were left with 
complex soft and bone tissue damage following traumatic injuries resulting in multiple 
surgeries. These interventions often lead to infection complicating the recovery and care 
process (Weintrob et al., 2018). Such infections are associated with the development of CVD 
(Khademi et al., 2019). It was reported that one third of combat injuries from Iraq and 
Afghanistan developed infection during their initial hospitalisation (more than 52,000 US 
military were wounded in action). Injury severity, amputations and blood transfusions were 
associated with risk of infection (Weintrob et al., 2018). Infection therefore played a 
significant role in the development of cardiovascular disease risk. During 2009-12, 1807 US 
casualties were evacuated with 34% developing infection of which 50% was skin, soft tissue 
or bone infections (Weintrob et al., 2018).  
 
To stratify injury severity for The ADVANCE Study, the New Injury Severity Score (NISS) 
was applied. The New Injury Severity Score is defined as the sum of the squares of the 
Abbreviated Injury Scale scores of each of the patient's three most severe injuries, regardless 
of the body region in which they occur (Samin, 1999). Equally, the New Injury Severity Score 
can be applied for predicting the length of hospital stay in multiple trauma patients (Salehi et 
al., 2016). The NISS, associated with 50% chance of survival, increased each year from 32 in 
2003 to 60 in 2012 concluding an improvement in survival during a ten-year period, 
confirming the increased potential of survival relative to the severity of the injuries sustained 
on the battlefield (Penn-Barwell et al., 2015). This finding confirms the need for measuring 
performance of combat casualty care systems to include measures of morbidity, functional 
recovery and survival (Penn-Barwell et al., 2015). 
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1.3 Cardiovascular disease risk associated with combat related traumatic 
injuries 
CVD refers to cardiac and vascular system disorders. It is a set of heterogenous conditions of 
which atherosclerosis is one of the principal pathogenic causes. They are chronic diseases 
which develop gradually through life and is usually asymptomatic for a long time. By the time 
symptoms develop the condition is typically in its more advanced stages (US Department of 
Health, 2011). 
 
A previous retrospective study investigating CVD following 667 wounded or injured Finnish 
World War II veterans (injured 1939-45) recorded in 1980, delivered outcome data for only 
102 of the 667 participants (Kunnas et al., 2011). The risk of coronary artery disease (CAD) 
related death with injured war veterans increased 1.7-fold compared to the uninjured (95% CI 
1.1-2.5; p = 0.01) and there was a significant risk of depression (Kunnas et al., 2011). 
However, the study lacked detail in order to be compatible with today’s requirements. For 
example, data on baseline risk factors, population, age and CVD events such as stroke, 
peripheral vascular disease etc., were not defined. In addition, the types of injuries were not 
recorded to allow meaningful comparisons to current UK military battlefield casualties. 
 
Modan et al evaluated the 24-year mortality rates of male traumatic lower limb amputees 
(n=201) of the Israeli army in a longitudinal study (Modan et al., 1998). These soldiers were 
wounded between 1948 and 1974 and were compared with a sample representing the general 
population (n = 1,832). The conclusion was that the incidence of CVD was doubled in 
amputees compared with controls. Mortality rates were also significantly higher (21.9% vs 
12.1%; p<0.001) in amputees compared with controls due to increased CVD-related mortality 
(8.9% vs 3.8%; p<0.001). However, only selected risk factors for CVD were available on the 
101 surviving amputees (aged 50 to 65 years) therefore the risk increase is poorly defined. 
The control sample (n = 96) were matched by age and ethnic origin. 
 
An increase in CVD risk factors with traumatic lower limb amputees may explain an increase 
in recorded mortality. The fact that the study was an evaluation of only a 24-year mortality 
rate of male lower limb amputees and limited defined risk factors were recorded for survivors 
and not for those who died, makes the results extremely difficult to apply to current CRTI-A. 
 
On top of the physical trauma, the patient group assessed was faced with social and 
psychological challenges, including high rates of depression and anxiety disorders, post-
traumatic stress disorder (PTSD), body-image anxiety and reduced social functioning, social 
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discomfort and negative sense of self and identity (Melcer et al., 2012, Melcer et al., 2010, 
Sandweiss et al., 2011). Research in this area is limited, and the majority of the literature is 
from general population samples (Horgan and MacLachlan, 2004). Although only 
cardiovascular risk factors were considered in our study, psychological trauma should not be 
discounted between comparative groups as it could impact on cardiovascular health.  
 
To fully understand the type of injuries with resulting implications on cardiovascular health, 
we researched publications by means of a systematic review that analysed the injury records 
of these recent conflicts. We also wanted to learn how injuries suffered during recent conflicts 
compare with historic wars, for which there are publications available relating to CVD risk 
development due to amputations. We researched which type of injuries were more prevalent 
and at what scales. Although we are analysing injury statistics for UK military personnel, we 
also looked into the US statistics to help us appreciate the scale of the injury problem caused 
by modern conflicts. 
 
In general, CVD is associated with reduced quality of life and is not only the most important 
cause of premature mortality but also of Disability Adjusted Life Years (“DALYS”) in Europe 
(Reiner et al., 2011a). 
 
CVD is caused by invariable and/or variable risk factors. Invariable or fixed risk factors (age, 
gender, genetic heritage) cannot be changed, while variable risk factors such as smoking 
tobacco, physical inactivity, poor eating habits, elevated blood pressure, type 2 diabetes, 
dyslipidemia and obesity can be modified by changing bad habits (Reiner et al., 2011b). The 
goal of managing variable risk factors is to reduce CVD morbidity and mortality. CVD 
mortality can be reduced 45-75% by controlling risk factors and 25-55% by proper CVD 
treatment (Reiner et al., 2011a). 
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1.4 Cardiovascular disease risk markers 
Cardiovascular disease risk markers investigated in this study were physiological and  
biochemical as well as anthropometrical and lifestyle markers of CVD risk. 
 
1.4.1 Physiological markers of CVD risk 
(a) Hypertension (High blood pressure) 
Hypertension, at an estimated cost of £2bn to the NHS (Ettehad et al., 2016) , is defined as 
office systolic pressure (SBP) values ≥140 mmHg and/or diastolic BP (DBP) values ≥90 
mmHg (Lurbe et al., 2016). Elevated blood pressure (BP) was not only the leading contributor 
to premature death in 2015 (10 million deaths) but also accounted for 200 million disability-
adjusted life years (Forouzanfar et al., 2017).  CVD risk is doubled with every 10mmHg 
increase in diastolic and 20mmHg in systolic blood pressure (NICE, 2019). Optimal BP is 
defined as systolic BP<129 mmHg and diastolic BP <80 mmHg (Jelakovic et al., 2007). BP 
has an independent and continuous relationship with the incidence of cardiovascular events 
such as haemorrhagic stroke, ischaemic stroke, myocardial infarction, sudden death, heart 
failure, peripheral artery disease (PAD) and end-stage renal disease (Lewington et al., 2002). 
Epidemiological associations between BP and cardiovascular risk extend from very low levels 
of BP [i.e. systolic BP (SBP) >115 mmHg]. However, ‘hypertension’ is defined as the level 
of BP at which the benefits of treatment (either with lifestyle interventions or drugs) 
unequivocally outweigh the risks of treatment, as documented by clinical trials (Mancia et al., 
2013). 
 
Hypertension is rare to occur as a risk factor in isolation and clusters with other risk factors 
such as dyslipidaemia and glucose intolerance (Bhatt et al., 2006, Berger et al., 2010). This 
clustering of metabolic risk factors exerts a multiplicative effect on the cardiovascular risk-
burden (Berry et al., 2012). 
 
(b) Heart rate variability 
Heart rate variability (HRV) is discussed here as a novel CVD risk factor; however, it was not 
included in this study. It forms part of the longitudinal ADVANCE study and therefore a short 
synopsis explaining HRV is included. 
 
HRV is the physiological phenomenon of variation in the time interval between heartbeats 
and is controlled by a primitive part of the nervous system called the autonomic nervous 
system (ANS)(Kubota et al., 2017). It works regardless of our desire and regulates, among 
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other things, our heart rate, blood pressure, breathing, and digestion. The ANS is subdivided 
into two large components, the sympathetic and the parasympathetic nervous system, also 
known as the fight-or-flight mechanism and the relaxation response (Thayer et al., 2010). The 
hypothalamus, through the ANS, sends signals to the rest of the body either to stimulate or to 
relax different functions in order to maintain a balance between the two nervous systems. 
HRV is a non-invasive way to identify ANS imbalances(Thayer et al., 2010). If a person’s 
system is in more of a fight-or-flight mode, the variation between subsequent heartbeats is 
low. If one is in a more relaxed state, the variation between beats is high. A low HRV is 
associated with an increased risk of death and cardiovascular disease while a high HRV may 
be related to greater cardiovascular fitness and an increased resilient to stress (Kubota et al., 
2017). 
 
A low HRV is associated with a 32-45% increased risk of a first cardiovascular event in 
populations without prior CVD history. An increase in the standard deviation of the inter beat 
intervals (IBI) of normal sinus beats (SDNN) of 1% results in an ~1% reduction in risk of fatal 
or non-fatal CVD (Hillebrand et al., 2013). 
 
 
(c) Arterial stiffness 
Arterial stiffness, characterised by increased carotid-femoral pulse wave velocity (PWV), is a 
known independent predictor of cardiovascular events and mortality alongside the traditional 
classical risk factors, even in healthy individuals (Zoungas and Asmar, 2007, Vlachopoulos et 
al., 2010, Magalhaes et al., 2011, Vasan et al., 2019). Carotid-femoral PWV could therefore 
be considered as a surrogate endpoint for CVD and applied in risk stratification for CVD 
(Laurent et al., 2006). Furthermore, Kotsis and colleagues concluded that vascular 
measurements may be a better indicator of CVD progression from a young healthy vessel to 
an aged diseased vessel responsible for adverse clinical events (Kotsis et al., 2017). 
 
Patients with increasing prevalence of metabolic syndrome (increased BP, high blood sugar, 
excess abdominal fat, and abnormal cholesterol or triglyceride levels) irrespective of age, 
gender and BP, were found to have stiffer arteries with impaired endothelial function, which 
is associated with an increased CVD risk (Gong et al., 2019). 
 
Impaired vascular function, expressed as elevated arterial stiffness, a haemodynamics 
biomarker, is associated with target organ damage and related CVD mortality (Vasan et al., 
2019, Morgillo et al., 2019). Arterial (vascular) stiffness is determined by using numerous 
techniques including assessments of central haemodynamics, aortic arterial stiffness, indices 
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of aortic wave reflection, endothelial dilatation, circulating serum calcium and by means of 
measuring PWV, which is associated with 10-year CVD risk estimates (Park and Lee, 2019).  
 
Large artery stiffness leads to increased PWV and accelerated wave reflections causing an 
increase in myocardial work and central systolic BP, along with a decrease in coronary artery 
perfusion pressure (Salvi, 2017). This increase in PWV as a result of increased arterial 
stiffness is associated with many of the common cardiovascular risk factors, such as age, high 
blood pressure, smoking, cholesterol levels and obesity, and these lead to a dramatic increase 
in risk of heart attack, stroke and heart failure (London et al., 2004). 
 
Arterial stiffness is expressed as either peripheral augmentation index (pAI) where the 
reflected wave is a percentage of the forward wave or as central augmentation index AIx 
where the augmented central pressure is a percentage of the central pulse pressure (Salvi et 
al., 2008). An increase in AIx, reflected by an increase in PWV, relates to the speed at which 
the pulse waves travel down the arteries away from the heart. Increased stiffness in the Aortic 
wall also decreases the sensitivity of the baroreceptors, which impacts negatively on blood 
pressure adjustment. Increased PWV predicts cardiovascular morbidity and mortality 
independently in several population groups, including healthy controls (Cruickshank et al., 
2002, Laurent et al., 2001, London et al., 2004, Shechter et al., 2009, Sutton-Tyrrell et al., 
2005, Weber et al., 2004). 
 
(d) Subendocardial viability ratio (SEVR) 
Subendocardial viability ratio (SEVR) represents a non-invasive measure of myocardial 
perfusion related to the work of the heart (Ekart et al., 2016). SEVR is calculated through 
pulse wave analysis and is an index to verify myocardial oxygen supply and demand (Tsiachris 
et al., 2012). A study by Tsiachris and colleagues (n=24) showed that there was a significant 
association between SEVR (r=0.651; P<0.01) and coronary flow reserve (CFR) with 
hypertensives (Tsiachris et al., 2012). Estimation of SEVR could therefore be applied to assess 
coronary microcirculation where coronary arteries are normal but myocardial ischaemia is 
present to verify CVD risk. Equally with a significant correlation between SEVR and central 
arterial compliance, SEVR could be a useful tool to reflect on the balance between coronary 
perfusion and ventricular afterload (Tagawa et al., 2018). With resistance training-induced 
decrease in central arterial compliance associated with changes in SEVR, this phenomenon 
could be present bearing the nature of our study cohorts in mind where participants are 
generally training to be combat-ready. The comparative non-injured cohort who are still 
serving are assumed to be undertaking regular training, where some of the injured cohort are 
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taking part in the Invictus Games and are therefore exposed to regular strenuous workouts. 
Training-induced changes in central arterial compliance were significantly associated with 
changes in SEVR in young men (Tagawa et al., 2018). With proteinuria and estimated 
glomerular filtration rate (eGFR) being regarded as markers of cardiovascular disease, eGFR 
below 30 mL/min was linked to significantly lower SEVR (Ekart et al., 2016). 
 
(e) Endothelial nitric oxide 
Cardiovascular risk factors such as hypercholesterolemia, hypertension, and DM enhance 
reactive oxygen species (ROS) generation, resulting in oxidative stress (Li et al., 2014). This 
leads to oxidative modification of lipoproteins and phospholipids, mechanisms that contribute 
to atherogenesis and vascular damage and arterial stiffening. Nitric oxide (NO) is a 
multifunctional signalling molecule involved in the maintenance of metabolic and 
cardiovascular homeostasis (Li et al., 2014). Physical exercise and especially aerobic training 
were found to be effective interventions in the prevention and treatment of hypertension and 
cardiovascular disease via NO production and reduction in oxidative stress (Korsager Larsen 
and Matchkov, 2016). 
 
1.4.2 Biochemical markers of CVD risk  
(a) Inflammatory biomarkers 
C-reactive protein (CRP) is a substance produced by the liver that increase in the presence of 
inflammation in the body. An elevated C-reactive protein level, identified by blood tests, can 
signal flare-ups of inflammatory diseases such as rheumatoid arthritis and vasculitis. CRP is 
one of the proteins called “acute phase reactants” produced to heal inflammation. Although 
CRP is not a test for heart disease, it is an indicator of cardiovascular disease (Brito et al., 
2015, Li et al., 2017). One of its most useful clinical assets is its potential utility to assist in 
risk prediction for heart disease and stroke in people who don't already have heart disease 
(Brito et al., 2015, Li et al., 2017, Berger et al., 2010). 
 
A variation of the CRP test, the high-sensitivity CRP (Hs-CRP) test represents the accurate 
quantification of CRP levels within the previously defined normal range with greater 
precision. Elevated Hs-CRP can independently be used to find the risk for heart disease and 
stroke in people previously undiagnosed with heart disease (Berger et al., 2010, Li et al., 
2017). PWV was notably higher in a cohort suffering from inflammation with increased CRP 
than a healthy control (0.7 (SD 0.3-1.4) versus 0.4 (SD 0.2-0.7) mg/dl; P=0.03) (Shen et al., 
2015, Dregan, 2018). There is however insufficient evidence of sufficiently powered clinical 
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trials to evaluate the incremental impact of Hs-CRP on CVD risk (Lin et al., 2018). Similar 
statements were made for fibrinogen (Kaptoge et al., 2007). 
 
(b) Lipids 
Lipids (cholesterol and triglycerides) circulate as lipoproteins in blood plasma. Most of the 
circulating cholesterol is in the form of low-density lipoproteins (LDL), which are 
atherogenic. Lipid values are independently related to blood pressure (Mancia et al., 2005). 
Total LDL cholesterol is positively associated with CVD risk and characterized by 
hypercholesterolemia (Perk et al., 2013, Piepoli et al., 2017).  
 
Dyslipidemia can be hereditary or caused by external factors such as a diet rich in saturated 
fats and carbohydrates, reduced physical activity, chronic kidney disease, certain medication, 
smoking, stress, or a genetic predisposition (Goldberg, 2018). A lipid analysis estimates CVD 
risk whereby Total Cholesterol (TC), Low Density Lipoprotein (LDL), Triglycerides (TG) 
and High-Density Lipoprotein (HDL) is measured. LDL and TC are closely related to CVD 
risk (Reiner et al., 2011b).  
 
(c) Triglycerides 
Epidemiological evidence indicates that high levels of plasma Triglycerides (TG) levels 
predict cardiovascular disease (Harchaoui et al., 2009, Xiaofeng, 2019). It was however found 
that for CVD risk estimation it is recommended to take both high TG and low HDL-C levels 
into account (Harchaoui et al., 2009). Possible causes of hypertriglyceridemia are obesity, 
non-insulin-dependent diabetes mellitus (NIDDM), excessive alcohol consumption, simple 
carbohydrate-rich diets, chronic kidney disease, hypothyroidism, pregnancy, autoimmune 
diseases, drugs (corticosteroids, estrogens, tamoxifen, beta blockers, thiazides, isotretinoin, 
cyclosporine, antiretroviral drugs, psychotropic drugs), but also genetic predisposition (Reiner 
et al., 2011b). 
 
(d) Estimated glomerular filtration rate (eGFR) 
Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function 
and determine the stage of kidney disease. Estimated GFR can be calculated from the results 
of a blood creatinine test, age, body size and gender. Modest reductions in eGFR from the 
normal range variably predict cardiovascular morbidity (Mathisen et al., 2011). According to 
NICE guidelines, people with an estimated glomerular filtration rate (eGFR) less than 60 
ml/min/1.73 m2 and/or albuminuria are at increased risk of CVD (NICE, 2014). 
26 
 
(e) Creatinine 
Elevated creatinine levels are indicative of compromised kidney function. Elevated creatinine 
levels predict adverse cardiac outcomes and even minor changes in renal functions are 
associated with adverse cardiac outcomes (Smith et al., 2003). However, Patients with 
traumatic amputations have significantly lower creatinine levels compared to the general 
population and could overestimate renal function if applied as an indicator (Im et al., 2012). 
 
1.4.3 Glycaemic indices 
CVD is the most significant cause of mortality linked to diabetes (DM) (Ryden et al., 2013). 
The World Health Organisation and the American Diabetes Society classify DM as either type 
l, type ll and "other specific types" DM and gestational DM (Ryden et al., 2013).  
 
A healthy diet plays a significant role with respect to CVD. Among men, high glycaemic load, 
glycaemic index, and high carbohydrate and starch intake, were associated with increased risk 
of CVD (Burger et al., 2011). Furthermore, HbA1c is a reliable risk factor of all-cause and 
cardiovascular mortality in both diabetics and non-diabetics (Cavero-Redondo et al., 2017). 
 
 
1.4.4 Anthropometric markers of CVD risk 
(a) Abdominal waist circumference 
Sedentary lifestyle and bad nutrition habits cause obesity (increased BMI and abdominal waist 
circumference [AWC]) which has a linear association with CVD mortality. People with a 
sedentary lifestyle or physical inactivity have their CVD risk increased 1.5 times (Perk et al., 
2013).  Healthy eating habits are the basis of CVD prevention as it affects the levels of fat and 
blood sugar, blood pressure and body weight (Perk et al., 2012, Piepoli et al., 2017). The 
lowest mortality rate in BMI ranges from 20 to 25 kg/m2 (Piepoli et al., 2017). Other obesity 
indices are conicity index (CoI), AWC, waist-to-hip ratio (WHR) and waist-to-height ratio 
(WHtR) (Caitano Fontela et al., 2017, Motamed et al., 2015, Segura-Fragoso et al., 2019).  
 
(b) Conicity index 
Conicity index (CoI) is an index of abdominal adiposity, which is significantly associated with 
cardiovascular risk indicators. The conicity index has several advantages over the WHR: (i) it 
has a theoretical (expected) range; (ii) it includes a built-in adjustment for waist 
circumference, height and weight, allowing direct comparisons of abdominal adiposity 
between individuals or even between populations; and (iii) it does not require the hip 
circumference to assess fat distribution (Valdez et al., 1993).  
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In comparison with the Framingham 10-year CVD risk, it was found that CoI, WHR and 
WHtR were superior obesity indices compared to BMI in predicting the 10-year CVD risk 
(Motamed et al., 2015, Segura-Fragoso et al., 2019). 
 
(c) Waist to height ratio (WHtR) 
Madruga et al described a positive association between WHtR and the presence of 
hypertension in adolescents (Madruga et al., 2016). A study of the anthropometric data of 
Chinese adults (n=1022, ages 18-69) comparing body mass index (BMI), waist circumference 
(WC), waist to height ratio (WHtR), waist-hip-ratio (WHR) and body fat percentage (BF%) 
found that WHtR is the best index in predicting the risk of hypertension. It was also noted that 
men are more likely to hoard fat in the abdomen compared to women who hoard fat in the 
thighs, making abdominal fat an easy indicator for CVD risk (Fan et al., 2018). 
 
1.5 Aims 
The main aim of this study is to investigate whether military servicemen who have 
experienced serious CRTI demonstrate a subclinical adverse cardiovascular risk profile than 
that of less and non-injured servicemen exposed to the same operational environment at the 
same time.  
  
1.6 The research hypotheses are as follows: 
1. Military servicemen who have had suffered severe CRTI with limb amputations have 
increased arterial stiffness compared to those less severely injured and non-injured 
servicemen. 
2. Combat-related traumatic amputation is associated with greater 
vascular inflammation and a more adverse lipid profile than that observed with less severe 
combat related injuries and with non-injured servicemen exposed to the same operational 
environment.  
 
1.7 Summary  
In summary, previous studies of CVD risk with Vietnam and World War II veterans were 
inconclusive, focused on PTSD and were retrospective cross-sectional studies. 
Methodologically robust, longitudinal cohort studies are required to better understand CVD 
risk in those who have taken part in modern armed conflicts.  
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Chapter 2  
Systematic Review (Published 2019) 
A systematic review of the literature on cardiovascular risk and 
combat related traumatic injuries with and without amputations  
 
2.1 Introduction 
In this chapter a systematic literature review is described to examine the published medical 
literature relating to combat related traumatic injuries leading to amputation and future 
cardiovascular disease risk. 
 
Cutting edge battlefield trauma care has allowed military personnel to survive complex 
injuries in recent years that previously would have been fatal. There is some evidence to 
suggest that CRTI is associated with an increased CVD risk (Boehmer et al., 2004, Kunnas et 
al., 2011, Modan et al., 1998), which could be mitigated if there was a better understanding of 
these risk factors within an injured population. Studies have been performed after previous 
wars (Boscarino, 2006, Bramsen et al., 2007, Kang and Bullman, 2001, Kunnas et al., 2011, 
Modan et al., 1998, Watanabe and Kang, 1996, Fett et al., 1987). However, this data was 
retrospectively collected, the injuries less severe, and the baseline cardiovascular risk factors 
were not defined. In some cases, only survivors were studied and not those who had died due 
to their injuries, or afterwards, and the cohort was for less than 24 years from injury (Modan 
et al., 1998). 
 
The comparative and in some cases, the compounding effects of the roles of the risk factors 
involved in the developing mechanisms of these enhanced morbidities has not been studied 
comprehensively and the only two literature reviews that were published about this topic were 
in 2008 and 2009 (Naschitz and Lenger, 2008, Robbins et al., 2009). At the time of these 
reviews, only five studies were available, and none had appropriate comparative controls 
(Naschitz and Lenger, 2008). Of the five, only one study revealed an increase in 
cardiovascular morbidity after amputation.  
 
The impact of CRTI, without the impact of PTSD, on cardiovascular outcomes and its 
associated risk factors has not been widely examined. The objective of this review is to 
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systematically search, summarise and compare current understanding of cardiovascular risk 
factors and the mechanisms (not psychological) contributing to increased cardiovascular 
morbidity ensuing serious battlefield injuries and to determine if there is sufficient evidence 
to support this link. 
 
2.2 Literature search strategy 
The strategies applied to the structure of this systematic review evolved from the quest to 
explore what links have been identified between combat related traumatic injuries and 
cardiovascular disease risks. Advanced searches for peer reviewed, full-text empirical 
literature published preferably in English since 1980 were undertaken using the 
comprehensive electronic discovery service provided by EBSCO. Key health and social care 
databases such as MEDLINE (Medical Literature Analysis and Retrieval System Online) and 
CINAHL (Citation Index for Nursing and Allied Health Literature) were searched applying 
Medical Subject Headings (MeSH) or subject terms as well as appropriate keywords. Studies 
that evaluated the impact of combat related traumatic injuries on future cardiovascular risk 
factors were of specific interest and therefore selected and examined. 
 
The systematic review was conducted and reported according to the PRISMA guidelines 
(Stovold et al., 2014). (See Fig 2-1).
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Figure 2-1: PRISMA Flow Chart: the phases of the review  
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The search strategy adhered to the PICO (patient/population, intervention, 
comparison/control, outcome) tool (Eriksen and Frandsen, 2018), to ensure quality of the 
literature search. Eligibility, according to inclusion criteria, was initially assessed by the title, 
followed by examination of the abstract. Full text versions of probable articles were obtained 
for further examination. 
 
Search terms and keywords, according to the PICO tool, are listed in Table 2-1. The searches 
were structured and applied in the MEDLINE and CINAHL databases. The Cochrane database 
was searched for similar current systematic reviews.  
 
2.2.1 Study selection 
Only observational studies (any language) reporting on CVD and cardiovascular risk factor-
related outcomes following military and combat-related injuries and exposure, were included.  
Individual case reports and conference abstracts were excluded. The populations for eligible 
studies had to include currently serving military servicemen or ex-military/veterans, who were 
exposed to combat operations. A non-exposed comparator group had to be identified in the 
study to act as control cohort and more than one year was required from exposure to outcome 
observation. Eligible studies had to comprise more than 50% combat-related traumatic injured 
participants in the active cohort, in order to be categorised as a combat-related injury study. 
 
Keywords in titles and abstracts were searched to identify further records for exclusion. 
Excluded Keywords were: Non-combat, non-explosion injury, traumatic brain injury, PTSD, 
post-traumatic stress disorder, PTSD induced hypertension, Pre-deployment diabetes, Spinal 
cord injuries, paraplegia, quadriplegia, heat, children, animal, in vivo/vitro (Table 2-1). 
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Table 2-1: Search terms according to PICO  
Population:   MeSH 
 
Intervention:  MeSH 
 
Outcomes 
 
Military 
Military personnel 
Afghanistan 
Iraq 
Armed services 
Army 
Marines 
Infantry 
Veterans 
Soldiers 
servicemen 
 
Traumatic 
Traumatic injury 
trauma 
trauma-related 
war related injuries 
amputation  
amputee 
Lower limb amputees 
wounds and injuries 
wounding 
wounded 
injured, injury 
war related injuries 
Combat 
warfare 
battlefield 
 
Cardiovascular disease 
Cardiovascular Risk 
Cardiovascular Death 
Cardiovascular event  
Coronary heart disease  
Ischemic heart disease  
Coronary artery disease  
Coronary disease 
Coronary artery bypass 
Myocardial infarction or heart attack 
Acute coronary syndrome  
Peripheral arterial disease 
peripheral vascular disease  
Hypertension 
Blood pressure 
Atrial fibrillation  
Arterial hypertension  
Heart failure 
Carotid intimal thickness 
Stroke  
aortic aneurysm 
coronary artery intervention Percutaneous 
Coronary Intervention 
coronary artery stenting 
Metabolic syndrome 
Augmentation index 
Arterial stiffness 
Pulse wave velocity 
Obesity 
Diabetes Mellitus 
 
 
 
2.2.2 Quality Assessment 
The Critical Skills Appraisal Programme (CASP) (www.casp-uk.net, 2007), Oxford, UK was 
applied to critically appraise the shortlisted empirical studies. The CASP checklist is applied 
for appraising quantitative and qualitative research and literature reviews. The checklist can 
be tailored to the specific research paradigm. Reliability and validity of quantitative research 
or the authenticity and generalisability of qualitative methods could be appraised. The tool, as 
adapted for this systematic review, comprises 16 questions relating to study conduct  
(Table 2-2).  
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Table 2-2: Criteria for quality assessment of identified publications 
Item Criteria Study description 
1 Objective Does the paper clearly state the objectives/hypotheses? 
2 Study design Is the study design described? 
3 Target 
population/sample 
Is the target population described? Male, corresponding 
with ADVANCE 
4 Target 
population/sample 
Is the target population representing a random sample 
of the population? 
5 Target 
population/sample 
Is a description of sample selection included? 
6 Target 
population/sample 
Is recruitment of the sample described? 
7 Target 
population/sample 
Are inclusion and/or exclusion criteria stated? 
8 Target 
population/sample 
Is the study sample described? (Minimum criteria = 
sample size, gender, age, military, veteran) 
9 Target 
population/sample 
Are numbers of samples for each stage defined? 
(Numbers recruited, groups, eligible, lost) 
10 Variables Are cardiovascular risk factor measurements described? 
11 Data sources Are data sources described? 
12 Data collection Are the data collection methods described? 
13 Measurement of data Was reliability of the measurement of data referred to? 
14 Data validity Was validity of measurement or collection referred to? 
15 Statistical methods Were appropriate statistical methods applied and 
described? Were confounders addressed?  
16 Statistical methods Was missing data addressed and the methods for 
addressing missing data described? 
17 Total score  
 
 
 
Included studies were assessed according to the criteria listed in Table 2-2 and a quality score 
out of 16 was allocated (Table 2-3, column 17). Most studies complied with at least 13 of the 
items, which is an acceptable score qualifying included studies (Zeng et al., 2015) with one 
study scoring 11. 
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Table 2-3: CASP quality assessment (Critical Skills Appraisal Programme, Oxford, UK) of publications/studies included per list per category (See Table 2-2) 
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Item  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  17 
Etjahed 2017 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Hrubec 1980 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 15 
Kunnas 2011 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 13 
Labouret 1983 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 15 
Linberg 2013 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 15 
Magalhães 2011 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Modan 1998 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Peles 1995 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 15 
Rose 1987 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Rose  1986 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Shariar 2009 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Stewart 2015 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 16 
Yekutiel 1989 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 15 
Volmar 1989 1 1 1 1 1 1 0 1 1 1 1 1 0 0 0 0 11 
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2.2.3 Data Collection 
To summarise and compare the evidence, a table was created to highlight the main 
characteristics of each study (Table 2-4). The study name and year, study design and duration, 
sample/population, age of population (years), hypothesis (relationship combat trauma and 
CVD risk, outcomes), potential confounders/source of bias, covariate adjustments and results 
were tabulated in Table 2-4. The summary of the characteristics of the studies aided the easy 
identification of trends, similarities in study methods and outcomes, populations, comparator 
cohorts and study durations. The summary was also used to assess adherence to  
selection protocol. 
 
2.2.4 Results 
The titles were assessed initially, followed by the abstracts and of the 4198 citations that 
remained, 73 studies were selected for full-text analysis plus one study identified from a 
reference list. A total of 14 studies were selected based on the inclusion criteria (see PRISMA 
flow chart, Figure 2-1) (Stovold et al., 2014).  The reference sections of the full-text articles 
were scrutinised for identification of further suitable studies not identified under the PICO 
search strategy. One more study was identified.
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Table 2-4: Characteristics of studies examining the association of Battlefield Related Traumatic Injury and cardiovascular risk 
Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
Yekutiel 
(1989) 
Cross-
sectional 
>20 years 
from injury 
3 control 
subjects from 
birth year of 
sample 
Israeli War 
Veterans 
(1948-49, 
1956, 1967, 
1973) 
53 Traumatic 
lower limb 
amputees 
159 control 
(age and sex 
matched) 
77 SCIP  
SCIP mean 
40.4 years 
old 
TLLAP 
mean 57.2 
years old 
Male 
 
Spinal cord 
injured and 
traumatic 
lower limb 
amputees are 
more prone to 
develop 
hypertension, 
ischaemic 
heart disease 
and diabetes 
than healthy 
age matched 
controls 
Shortening of 
lifespan after 
SCIP – 70% of 
cases had one 
disease entity 
– reason for 
CVD not 
necessarily 
related to cord 
injury. 
Increase in 
mortality 30 
years after 
TLLAP due to 
cardiac and 
vascular 
diseases 
Control 
group non 
exposed to 
combat  
Unadjusted SCIP: 34% HTN, IHD and DM 
18.6% in controls Due to lack of 
physical activity – decreased 
HDLC 
TLLAP: CHD in amputee vs 
control (32.1% vs 18.2% p<0.01) 
DM (22.6% vs 9.4%) 
HTN: similar (35.8% vs 35.2%) 
 
15 
Kunnas 
(2011) 
Prospective 
longitudinal 
Finnish 
WWII 
Veterans 
(1939-45) 
Caucasian 
102 Combat 
injured 
55 years 
War-time 
activities 
from 17-20 
years old 
Male 
 
Wartime stress 
related to late-
life all course 
mortality – 
wounded 
veterans have 
increased long-
Being 
physically 
wounded or 
injured in war 
may lead to 
increased 
CHD mortality 
Injury – 
self report 
Adjusted for 
BMI and 
depression 
Wounded or injured: death 1.7 
times more likely from CHD than 
control. Adjusted for BMI and 
depression. (CI 95%: 1.1 – 2.5; p = 
0.02) 
HTN and cholesterol similar, DM 
8% vs 4.6% with injured 
13 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
565 non-
injured  
deployed 
veterans 
term coronary 
heart disease 
and coronary 
death at age 55 
Hrubec 
(1980) 
Retrospective 
cohort 
>30 years 
Cause of 
death analysed 
US Military 
WWII (1944-
5) 
3890 
proximal 
amputees 
2917 distal 
amputees 
3890 injured 
US 
population 
(age 
matched) 
<30 years 
old at injury 
3 groups age 
matched 
Male 
 
Cause of death 
- no difference 
between 
proximal 
amputees 
either of the 
two groups 
 
Amputation 
leads to 
increase in 
cardiovascular 
disorder 
incidence 
Proximal 
group – 
mortality 
increase with 
time 
Distal – 
similar to 
population  
 
 Adjusted all-
cause and age 
Proximal vs injured 
CI 90%: CVD (RR 1.58: 1.40-
1.79)  
IHD (RR 1.56: 1.36-1.79) 
All cause (RR 1.36: 1.25-1.48) 
Proximal vs distal amputees and vs 
general population 
CVD (1.44: 1.26-1.64) 
IHD (1.45: 1.24-1.68) 
All cause (1.29: 1.18-1.41) 
15 
Etjahed 
(2017) 
Cross-
sectional 
32.1 years 
from injury 
HRQOL was 
assessed 
Metabolic 
syndrome 
assessed 
Iran-Iraq 
War 
Iranian 
veterans 
235 Bilateral 
traumatic 
lower limb 
amputation 
with MetS vs 
general 
population  
31.5 years at 
injury 
52 years 
mean age at 
follow up 
Comparator 
age not 
reported 
Male 
Lower limb 
amputations 
are related to 
HRQOL and 
MetS with 
veterans 
Response rate 
40.7% 
Amputees 
have 
significantly 
higher plasma 
insulin levels 
and insulin 
response to 
oral glucose 
Very low 
response 
rate; poorly 
defined 
unexposed 
(combat 
control 
group) 
Adjusted for 
age, BMI, 
smoking, 
physical 
activity, blood 
pressure and 
cholesterol 
2x increase in MetS with Lower 
limb amputation (obesity, 
hypertension, hyperlipidaemia and 
hyperinsulinemia 
MetS among amputees 61.2% 
(CI95%: 55.9% - 68.4%) 
MetS 27% in Iranian population 
 
16 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
 
Modan 
(1998) 
 
Retrospective 
cohort study 
24 years 
Wounded 
1948-74 
Israeli army 
201 male 
traumatic 
lower limb 
amputees – 
veterans 
Vs 1832 
general 
population 
<40 years in 
age (50%) 
Male 
 
Increased 
mortality rates 
with traumatic 
lower limb 
amputees 
Amputees - 
CVD main 
cause for 
mortality with 
amputees 
Hyperinsuline
mia, increased 
coagulation, 
increased 
sympathetic 
and 
parasympatheti
c responses 
No 
adjustment 
for time, 
ethnicity, 
smoking 
status   
Adjusted for 
age 
Mortality increased 2-fold with 
amputees vs general population 
(21.9% vs 12.1%, p < 0.001) due 
to CVD 
Amputees - higher plasma insulin 
during fasting 
Amputees - increased coagulation 
Ischaemic heart disease - the same 
Mean age similar, but age 
distribution differed 
16 
Labouret 
(1983) 
Cross-
sectional 
>15 years 
Equal 
diastolic BP in 
both groups 
WWI French 
veterans 
n = 23 WWI 
1914 
n = 67 WWII 
1939 
n = 16 Other 
106 Combat 
related 
amputation 
(49 AKA) 
184 Controls 
age matched, 
no HTN  
Age 
compared 
10-year 
cohorts from 
40-89 years 
Male 
 
Systolic 
hypertension 
in patients 
with combat-
related 
amputation 
Increase in 
systolic 
pressure (not 
diastolic) with 
amputees, 
significant 
effect for each 
age decade 
No 
adjustment
s 
Poor 
definition 
of how 
hypertensio
n define; 
no blinding  
Unadjusted Higher systolic with amputees vs 
controls (56% vs 29%; p £ 0.02) 
Change in viscoelastic properties 
of arteries related to amputation 
could explain the increase in 
systolic pressure 
15 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
Stewart 
(2015) 
Retrospective 
cohort 
Critically 
wounded 
military 
personnel 
1.1-4.3 years 
follow-up 
US Military 
Iraq/Afghani
stan Wars 
2002-11 
3846 severe 
traumatic 
injuries 
Control = 
Millennium 
Cohort 
25-29.2 
years 
98% male 
 
Relationship 
between 
severity of 
injury and 
subsequent 
development 
of HTN, CHD, 
DN and CKD 
Severity of 
combat-related 
injuries is 
related to 
subsequent 
development 
of HTN, CHD, 
DM and CKD. 
AKI increased 
the rate of 
HTN and CKD 
by 66% and 
479% 
respectively 
Retrospecti
ve study  
Adjusted 
for 
covariates 
Observatio
nal 
evidence 
does not 
prove 
causality 
Adjusted for 
age, race, MAP, 
heart rate, 
presence of 
burn injury and 
AKI 
Each 5-point increase in ISS 
relates to a 6%, 13%, 13% and 
15% relative increase in the rate of 
HTN, CHD, DM and CKD 
respectively. 
Adjusted risks CI 95%: 
HTN (OR 1.06; 1.02-1.09; 
p=0.003), CHD (OR1.13; 1.03-
1.25; p=0.01), DM (OR1.13; 1.04-
1.23; p=0.003) 
Increased risk vs Millennium 
control 
16 
Peles 
(1995) 
Cross-
sectional 
Plasma insulin 
response, 
autonomic 
nervous 
system 
response 
33 ± 11 years 
after 
amputation 
Israel 
Defence 
Force 
veterans 
1948-74 
52 amputees 
lower limb 
53 non-
military 
controls, 
matched for 
age and 
ethnic group 
 
50-65 years 
Male 
 
 
Insulin 
resistance and 
autonomic 
nervous 
system activity 
in male lower 
limb 
amputation 
Two groups 
had similar 
atherosclerotic 
cardiovascular 
risk, BP, 
plasma 
lipoprotein 
profile, 
smoking, 
physical 
activity and 
ethnic origin. 
Adjusted 
for co-
variates 
Adjusted for 
age, obesity and 
lipid levels 
Increased insulin resistance in 
amputees independent of CVD risk 
factors (HTN, obesity and lipid 
profile) 
15 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
Rose 
(1987) 
Cross-
sectional 
³ 15 years 
Age similar at 
study and 
amputation 
US Vietnam 
War veterans 
19 BAKA 
(10 
normotensive 
and 9 
hypertensive) 
12 UBEA, 
age matched 
controls 
20-22 at 
injury 
35-36 years 
at analysis 
Male 
Caucasian 
1 Black 
Traumatic leg 
amputation 
(not arm) is 
associated with 
IHD mortality 
in veterans 
with a mean 
age of 35-36 
years and 14-
15 years after 
injury 
BAKA had 
increased IHD 
UBEA not 
significant 
increased IHD 
rates 
Unadjusted Unadjusted Hypertensive BAKA has a 
significant increase in glucose 
after glucose intolerance test, 
increase in hypertension and 
obesity. 
Normotensive BAKA had similar 
cardiovascular risk factors than 
control 
 
16 
Shariar 
(2009) 
Cross-
sectional 
22.3 years 
mean follow-
up 
Iranian Wars 
327 Bilateral 
lower limb 
amputees 
Control 
Iranian 
general 
population 
(undefined) 
42 years at 
analysis 
20.6 years at 
injury 
Control 
group age 
not specified 
Male 
 
Cardiovascular 
risk incidence 
with bilateral 
lower limb 
amputation 
95.4% had one 
modifiable risk 
factor  
Most common 
– abdominal 
obesity 
Susceptibility 
to CVD in 
near future is 
highly likely 
Adjusted 
for co-
variates 
Adjusted for 
abdominal 
obesity and 
CVD risk 
factors 
CHD similar to general population 
Higher prevalence CVD risk 
factors with bilateral lower limb 
amputees 
Hypertension 28.5% vs 20.4%: 
p<0.05 
Obesity 82.5% vs 14.4%: p<0.05 
TCL 36.5% vs19.3%: p<0.05 
Smoking 31.8% vs 22.3% 
 
 
16 
Rose  
(1986) 
Cross-
sectional 
Caucasian 
males (one 
black) 
21 years at 
injury 
US Vietnam 
War veterans 
19 BAKA 
(10 
normotensive 
and 9 
hypertensive) 
Mean age 36 
Male 
Caucasian 
1 Black 
 
Combat-
related 
bilateral 
above-knee 
amputees are 
at increased 
risk of 
9 leg amputees 
were 
hypertensive 
1 arm amputee 
was 
hypertensive 
Unadjusted Unadjusted Insulin response and body fat 
content correlate with diastolic BP 
(r=0.55, p<0.01) 
Mean diastolic BP: 
HPT-BAKA 139 ± 4 mm Hg 
(systolic), 101 ± 2 mmHg 
(Diastolic) 
16 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
12 UBEA, 
age matched 
controls 
cardiovascular 
mortality 
Insulin 
response 
increased: 
Hypertension 
leg amp 260 ± 
60 µU/ml 
Normal BP leg 
amp 125 ± 24 
µU/ml 
Arm amp 101 
± 20 µU/ml 
Increased body 
fat content 
37.2% 
compared to 
23.2% and 
22.6% 
respectively    
NOR-BAKA 123 ± 2 mm Hg 
(sys), 80 ± 2mm Hg (diastolic) 
UBEA 126 ± 3 mm Hg (sys), 83 ± 
3 mm Hg (diastolic) 
Magalhães 
(2011 
Cross-
sectional 
8 years after 
injuries 
Angola 
Males 
60 Unilateral 
TLLAP 
86 - Control 
age matched 
non-amputee, 
non-military 
48 ± 6 mean 
age  
Male 
 
Increased 
PWV related 
to increased 
cardiovascular 
mortality 
Higher arterial 
stiffness in 
amputees after 
adjustment for 
confounders 
Association 
between 
unilateral LL 
amputation 
and aortic 
Control 
civilians 
Small 
sample size 
Male only 
cohorts 
Causality 
not 
established 
with 
arterial 
Adjusted for 
age, mean BP, 
BMI, HTN, 
smoking, 
alcohol 
consumption, 
TCL, TG, 
glucose, uric 
acid, LDL, heart 
rate, waist 
Amputees increased: 
Uric acid (7.1 vs 6.2, p < 0.01) 
LDL/HDL  
3.8 vs 2.8, p<0.01) 
Controls increased: 
HDL (45 vs 40, p<0.01) 
Creatinine (1.14 vs 1.03, p <0.01) 
HTN - Amputees higher 
proportion of hypertension (P 
<0.05) 
16 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
stiffness in 
males 
stiffness 
relative to 
multiple 
covariates 
measure (p = 
0.047) 
Smokers and alcohol consumption 
– similar both groups (P > 0.05) 
PWV – Amputees vs non-A (10.8 
vs 9.9 p < 0.05) 
Diastolic BP, PP, HR – 
statistically similar (p > 0.05) 
 
 Linberg 
(2013) 
Cross-
sectional 
6-minute walk 
test 
performance 
US Military 
active and 
retired SMs. 
118 
Traumatic 
lower limb 
97 Without 
LL 
18-40 years 
Male 
 
Comparative 
assessment 
guides of 
physical 
capabilities 
after lower 
limb to non-
injured is 
required to 
help clinicians 
set achievable 
goals for 
optimum 
health 
TTA had 
better 6MWT 
than all other 
amputation 
level 
Skilled 
rehabilitation 
improves 
walking ability 
Appropriate 
goals to be set 
for individuals 
to achieve 
6MWT 
Preserve knee 
joint where 
possible 
Self-
motivation 
to cover 
distance in 
6MWT 
Adjusted for 
age, height, 
weight and 
waist 
circumference 
Significant difference between 
non-LL and TTA (p < 0.001) 
Set appropriate goals for amputees 
to optimise movement to minimise 
CVD risk development 
15 
Volmar 
(1989) 
Prospective 
cross-
sectional 
Male war 
veterans 
WW II 
veterans – 
both groups 
329 AKA 
group I702 
Male  
Age means 
67.2SD 7.9 
yrs and 68.1 
SD 5.3 yrs 
Change in 
unilateral flow 
after leg 
amputation 
causes 
Increased level 
of amputation 
= increased 
level of 
Diagnosis 
confirmed 
by 
arteriograp
Adjusted for 
Hypertension, 
hyperlipidaemia
,smoking, DM, 
obesity 
5.8% aneurysms in amputees 
1.1% aneurysms in non-amputees 
84% of amputees had infrarenal 
aorta axial shifting – non-amputee 
= none 
11 
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Study Study design 
and duration 
Sample/pop
ulation 
Age of 
population 
(years) 
Hypothesis: 
Relationship 
combat 
Trauma and 
CVD risk 
Outcomes Potential 
confounde
rs / source 
of bias  
Covariate 
Adjustments 
Results Quality 
Score 
43.8 years 
average after 
injury 
without 
amputation 
group II 
asymmetrical 
flow patterns 
at the aorta 
bifurcation 
haemodynamic 
changes 
Flow level in 
terminal aorta 
reduced by 
25% 
Leg 
amputation 
causes more 
aneurysms 
than non-
amputations 
hy in all 
cases 
12 patients with left leg 
amputation had leftward convexity 
of terminal aorta 
Same with right leg amputation = 
rightward convexity 
ICD International Classification of diseases CVD Cardiovascular Disease CI Confidence interval, DM Diabetes Mellitus, HR Heart Rate,  CKD Chronic Kidney Disease, AKI Acute 
Kidney Injury, CHD Coronary Heart Disease, HTN hypertension, IS Ischaemic Stroke, IHD Ischaemic Heart Disease, MAP Mean Arterial Blood Pressure, SES socioeconomic status, 
OR Odds Ratio, TLLAP Traumatic Lower Limb Amputee, HDLC High Density Lipoprotein Cholesterol, HRQOL Health-related quality of life, MetS Metabolic syndrome, AKA 
Above knee amputation, BAKA Bilateral above knee amputations, HPT-BAKA Hypertensive BAKA, NOR-BAKA Normotensive BAKA,  UBEA Unilateral Below Elbow Amputees,  
ISS Injury Severity Score, TCL Total Cholesterol, Non-A non-amputee, PP pulse pressure, TTA trans tibial amputation, 6MWT 6 minute walk test, SM Service Members, LL limb 
loss  
44 
The initial search retrieved 4499 potentially relevant studies. The results were transferred to 
ENDNOTE 9 for Mac and searched for duplicates. A total of 345 were identified and removed. 
After further elimination, 4198 studies qualified for further title and abstract scrutiny, leaving 
74 studies for full text eligibility assessment. 61 full-text articles failed to fully meet the 
systemic review inclusion criteria and were excluded (see Figure 2-1, PRISMA Flow chart).  
One additional study, which met the selection criteria, was identified from the reference lists 
(Figure 2-1) and included leaving a total of 14 studies for inclusion in this review.  
 
2.2.5 Study characteristics 
The studies were generally observational with nine being cross-sectional, one being 
prospective longitudinal and three being retrospective cohort studies (Table 2-4). Follow-up 
periods ranged from one to 44 years.  
 
Sample sizes of CRTI-NA military personnel ranged from n=19 to 6807 participants. Five 
studies represented US military war veterans, three studies represented Israeli war veterans. 
Finnish, Iran/Iraq, Angolan and French war veterans were also represented (table 2-4).  
 
Combat operations covered by the included studies were: World War I (1918) and II (1939-
45), Iraq/Afghanistan conflicts (2002-11), Vietnam War (1961–1975), the Iran-Iraq Wars 
(1980-1988), Israeli Conflicts (1948-1974), Gulf War I (1991) and conflicts in Angola. Eight 
studies reported on traumatic lower limb amputations, three on traumatic above knee 
amputations and two on traumatic combat-related injuries. 
 
Age range of the study population cohorts varied from 18 to 89 years. The populations were 
predominantly male (98-100%), Caucasian (62-100%) with the majority, where stated, of non-
officer rank at time of combat injury. 
 
A total of 12 of the included studies described amputations following traumatic injuries while 
two described traumatic injuries only (Table 2-4). Table 2-5 was designed to compare the 
outcomes of the included studies to help form a general assessment. 
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Table 2-5: Comparative assessment of included publication outcomes – cardiovascular risk factors following combat-related traumatic injuries 
- = similar to comparator or no effect, + = Increased risk, blank space = risk not reported as affected 
CHD coronary heart disease, MetS metabolic syndrome, IHD ischemic heart disease, HTN hypertension 
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Etjahed 2017    +  + +  +   +  
Hrubec 1980 + + +  +         
Kunnas 2011 + +    -  +    -  
Labouret 1983      +       + 
Linberg 2013              
Magalhaes 2011      +      + + 
Modan 1998 + - +  - -  + +   -  
Peles 1995      - -  +   -  
Rose 1987      + + +    -  
Rose  1986      + +  +     
Shariar 2009 + +    + + +  -  +  
Stewart 2015  +    +  +  +    
Yekutiel 1989  +    -  +      
Volmar 1989      -  -  - + -  
Score  4+ 0 - 
 
4+ 1 - 
 
2+ 0 - 
 
1+ 0 - 1+ 1-  7+ 5- 
 
4+ 1 - 6+ 1- 
 
4+ 0 - 
 
1+ 2- 
 
1 + 
 
3+ 5- 
 
2+ 0 - 
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2.2.6 Study outcomes 
Four Studies reported an increase in cardiovascular and CHD mortality with one study 
reporting no increase in CHD mortality, while two studies found all-cause mortality increased 
(Table 2-5). Metabolic syndrome (MetS) increase was observed in one study. Hypertension 
was reported in 12 studies with an increase in seven studies and five studies showed no 
difference from control. Obesity increased in four studies with one study reporting no increase. 
Diabetes was reported in seven studies and plasma insulin in four. All the studies reported an 
increase in the two risk factors bar one study that found diabetes was unaffected.  CHD was 
unaffected according to two studies, but an increase was reported in one other. Lipid profiles 
were reported in eight studies with three increased profiles and five had no difference 
compared to control. Abdominal aneurysms were reported in one study and increased arterial 
stiffness in two studies. The main outcomes such as cardiovascular mortality, CHD, mortality, 
hypertension, obesity and diabetes with lipid profile were inconclusive overall (Table 2-5). 
 
2.2.7 Study quality  
Following selection, the data for each study was extracted using the pre-designed data 
extraction form (Table 2-4), which included the year of publication and author, the study 
design and duration, the sample size with military conflict, age of sample, sex, study 
outcomes, covariate adjustments and results. The Critical Skills Appraisal Programme 
(CASP) was applied to critically appraise the quality of each of the 14 selected studies (Table 
2-3). The CASP tool comprised 16 criteria (Table 2-2) relating to study conduct. Studies with 
a total score of >13 were considered to be high quality, those of 10-13 of moderate quality 
and those scoring <10 were deemed poor quality. 
 
The quality scores for the 14 studies range from 11 to 16 (out of a maximum of 16; Table 2-
3). The mean quality score for the 14 studies was 15.07 (SD±1.44). Seven of the studies met 
all the criteria, five had a score of 15 and two studies scored 13 and 11 respectively.
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2.3 Clinical Outcomes 
2.3.1 Cardiovascular Mortality 
The outcome of cardiovascular mortality (Tables 2-4 and 2-5) was reported in four cohort 
studies. Hrubec et al observed an increased risk of adjusted all-cause and CHD-related death 
(RR=1.58: CI 1.40-1.79) among proximal CRTI-A vs injured controls in their retrospective 
analysis of a >30 year follow-up of injured World War II Veterans (Hrubec and Ryder, 1980). 
Modan reported a two-fold higher CVD mortality risk following a 24-year follow-up of 
wounded Israeli veterans with lower limb amputations (Modan et al., 1998). 
Shahriar (2009) found that 95.4% (n=312) of bilateral lower limb CRTI-A had at least one 
modifiable cardiovascular risk factor 22.3 years (22.3 ± 3.9) after injury. A total of 10.7% of 
the injured cohort suffered from coronary artery disease (Shahriar et al., 2009). 
2.3.1.1 Coronary Heart Disease (CHD) Mortality 
CHD-related death was reported in four studies. Hrubec et al observed higher adjusted CHD 
related death amongst combat veterans with traumatic proximal amputations versus controls 
with disfigurement injuries (Hrubec and Ryder, 1980, Kunnas et al., 2011). Kunnas et al 
reported that wounded or injured veterans were 1.7 times more likely to die from CHD 
mortality than non-injured veterans from World War II conflicts (RR 1.7: CI 95%: 1.1 – 2.5; 
p=0.02). However, the nature and severity of the injuries were not defined and were dependent 
on self-report (Kunnas et al., 2011). Shariar et al reported a 10.7% incidence of coronary artery 
disease with bilateral lower limb CRTI-A in later life (Shahriar et al., 2009), while Yekutiel 
et al (1989) reported increased CHD with traumatic lower limb CRTI-A vs an age and sex 
matched control cohort, 32.1% vs 18.2%; p<0.01 (Yekutiel et al., 1989). 
2.3.1.2 Atherosclerosis
One study compared proximal amputation (n=3887) to distal amputation (n=2917) and 3890 
injured veterans, CI 95%, 1.64 vs 1.4 vs 1.55; p<0.001. However, Hrubec et al reflected that 
Enos et al reported evidence of atherosclerosis in young casualties of the Korean conflict. 
Enos et al found that 77.3% of 300 battle casualties with an average age of 21.1 years had 
gross evidence of coronary atherosclerosis (Hrubec and Ryder, 1980, Enos et al., 1986).  
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2.3.1.3 CHD and severity of injury
A further two studies reflected on CHD and injury severity. One reported an increased risk 
of CHD and the other was neutral. Shahriar and colleagues found CHD incidence with 
bilateral lower limb CRTI-A similar to the general population (Shahriar et al., 2009), while 
Stewart et al found the increase in risk of CHD related to the severity of traumatic injury, CI 
95%, Odds Ratio 1.13; 1.03-1.25; p=0.01 (Stewart et al., 2015). 
2.3.2 Metabolic Syndrome 
Only one cross sectional study reported MetS as a specific outcome. Etjahed and colleagues 
observed a two-fold higher risk of MetS with Lower limb amputation (obesity, hypertension, 
hyperlipidaemia and hyperinsulinemia. Incidence of MetS among CRTI-A, CI (95%) 61.2%; 
(55.9% - 68.4%), compared to 27% in the Iranian population.  
2.3.3 Hypertension (HTN) 
Ten studies reported on HTN with five concluded an increase in HTN and five studies found 
HTN similar to controls. Peles et al found that an increase in insulin resistance appears 
independent of HTN and other cardiovascular risk factors (Peles et al., 1995). Yekutiel, 
Kunnas and colleagues both reported similar HTN between the traumatic injured cohort and 
the control irrespective of increase in other cardiovascular risk factors (Yekutiel et al., 1989, 
Kunnas et al., 2011). 
Labouret et al observed that higher systolic blood pressure was observed with CRTI-A vs 
controls (56% vs 29%; p £ 0.02) (Labouret et al., 1983). Magalhães and colleagues observed 
a higher proportional HTN (P <0.05) with CRTI-A (Magalhaes et al., 2011). Bilateral above 
knee amputations presented hypertensive and normotensive with the same statistical regularity 
(Rose et al., 1987, Rose et al., 1986). 
Etjahed and colleagues reported an increased HTN as a risk factor in the two-fold increase in 
MetS observed with CRTI-A (Ejtahed et al., 2017). 
A higher prevalence of HTN with bilateral lower limb CRTI-A vs CRTI-NA (CI 95%, 28.5% 
vs 20.4%: p<0.05) was reported by Shahriar et al (Odds Ratio (OR) 1.06; 1.02-1.09; p=0.003) 
and by Stewart and colleagues (Shahriar et al., 2009, Stewart et al., 2015). 
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2.3.4 Diabetes Mellitus (DM) 
 
Five studies reported on DM as a positive outcome. Kunnas and colleagues observed an 
increase in DM with combat injured vs non-injured (8% vs 4.6%) (Kunnas et al., 2011), while 
Yekutiel et al recorded (22.6% vs 9.4%) traumatic lower limb amputation vs control (Yekutiel 
et al., 1989). 
 
Rose et al compared hypertensive bilateral above knee amputees (BAKA) with normotensive 
BAKA. The hypertensive BAKA had an increased prevalence of body fat and insulin response 
whereas the normotensive BAKA illustrated similar levels of cardiovascular risk factors as 
the control cohort of unilateral below elbow CRTI-A (Rose et al., 1986, Rose et al., 1987). 
The level of severity of injury related to the increase in prevalence of DM (Stewart et al., 
2015). 
 
2.3.5 Plasma Insulin 
Four studies reflected on an increase in plasma insulin. Etjahed, Modan and Rose et al reported 
an increase in plasma insulin with traumatic amputation, while Peles and colleagues recorded 
an increase in insulin resistance (Ejtahed et al., 2017, Modan et al., 1998, Peles et al., 1995). 
 
2.3.6 Obesity 
Four studies reported an increase in obesity related to combat-related traumatic injury. Etjahed 
and colleagues related the increase in obesity with the two-fold increase in MetS with bilateral 
lower limb amputations, CI 95%: 61.2%, 55.9% - 68.4%; p<0.05, (Ejtahed et al., 2017). a total 
of 95.4% of the Iranian war veterans with bilateral lower limb amputations had at least one 
modifiable risk factor with the most common one abdominal obesity, 82.5% vs 14.4%; p<0.05 
(Shahriar et al., 2009). Rose et al found that hypertension with BAKA correlates with 
increased body fat content and obesity (Rose et al., 1986, Rose et al., 1987). 
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2.3.7 Lipid Profile 
Three studies reported an increase in lipoid profile while two studies found no increase 
compared to control. LDL/HDL ratio was increased with CRTI-A, 3.8 vs 2.8; p<0.01 while 
HDL was increased with the control group vs CRTI-A, 45 vs 40; p<0.01 (Magalhaes et al., 
2011). Shahriar et al also observed an increase in total cholesterol (TCL) with bilateral lower 
limb amputees compared to the general population, TCL 36.5% vs 19.3%; p<0.05 (Shahriar 
et al., 2009). Etjahed and colleagues listed hyperlipidaemia under the two-fold increase in 
MetS with CRTI-A (Ejtahed et al., 2017). 
 
Kunnas et al found the lipid profiles statistically equal between injured and non-injured 
cohorts while Peles and colleagues found no statistical differences in the lipid profiles between 
CRTI-A and non-military controls (Kunnas et al., 2011, Peles et al., 1995). 
 
2.3.8 Arterial Stiffness 
Two studies described an increase in arterial stiffness, derived from measuring pulse wave 
velocity non-invasively, with lower limb amputations due to a change in viscoelastic 
properties of the arteries, thereby raising BP (Labouret et al., 1983, Magalhaes et al., 2011). 
 
2.3.9 Aneurysms 
One study reported an increased incidence of abdominal aneurysms due to changes in aortic 
flow patterns associated with the level of leg amputations (Vollmar et al., 1989). 
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2.4 Discussion 
The influence of combat exposure resulting in traumatic injury on cardiovascular mortality 
was assessed in this systematic review. An increase in cardiovascular and CHD mortality as 
well as an increase in cardiovascular risk factors associated with obesity and glucose 
intolerance is described in the studies. However, an increase in risk factors such as 
hypertension and lipid profile related to traumatic injury did not leave conclusive results. The 
effect of combat related traumatic injury on cardiovascular disease risk factors warrants 
further investigation. 
 
The limitations evident in the selected literature are the lack of baseline risk descriptions, risk 
of bias created by self-reporting by participants, lack of adjustments for the influence of 
confounders, causality not proven by observation and comparator cohorts comprising 
civilians, who possibly had a different health report at baseline due to military enlisting 
requirements. Baseline health data captured for servicemen in earlier wars were less stringent 
than with current military enrolment as reported by Hrubec and Ryder reflecting on the 
evidence published by Enos et al that 77.7% of 300 battlefield casualties aged average 21 
years old, were found to have gross evidence of coronary atherosclerosis (Enos et al., 1986, 
Hrubec and Ryder, 1980). 
 
The majority of the studies included in this systematic review were retrospective and 
investigated relative CVD risk 15-43 years after injury. The veterans were often compared 
with a civilian control cohort with a different baseline demographic compared to the injured 
cohort.  
 
A search of MEDLINE and CINAHL databases identified a systematic review relating to the 
long-term effects of traumatic amputation on cardiovascular risk factors (Naschitz and Lenger, 
2008). They concluded that abnormalities in arterial flow proximal to the site of amputation 
might explain the subsequent scale of cardiovascular risk. For example; proximal leg 
amputation vs distal amputation had greater cardiovascular risk and similarly with bilateral vs 
unilateral amputation. Therefore, coronary risk in lower limb CRTI-A may be greater than 
predicted by algorithms, which are not bearing hemodynamic or psychological factors in 
mind. The level of amputation has been found to correlate with the level of haemodynamic 
changes, which leads to arteriosclerotic changes and eventual aneurisms in later life (Vollmar 
et al., 1989). Magalhães (2011) describes a change in arterial wall structure with CRTI-A in a 
small study (n=60), leading to increased pulse wave velocity (PWV) due to increased arterial 
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stiffness. PWV could be applied in routine assessment to stratify cardiovascular risk 
(Magalhaes et al., 2011). 
 
Labouret (1983) described an increase in systolic BP but not diastolic with CRTI-A vs control 
and the increase specifically relates to each decade after the injuries (56% vs 29%; p £ 0.02). 
Therefor longitudinal assessment of CVD risk development is essential. Labouret further 
hypothesises that the change in viscoelastic properties of the arteries after the amputation and 
with time could explain the increase in systolic pressure (Labouret et al., 1983). Another 
consideration is that systemic and/or regional haemodynamics (arterial stiffness) may be 
altered by trauma resulting in increased mortality rates (Modan et al., 1998, Yekutiel et al., 
1989, Vollmar et al., 1989, Paes et al., 1990, Peles et al., 1995, Rose et al., 1987). 
 
Pulse wave velocity (PWV) increases with increase in arterial stiffness. To be able to compare 
cardiovascular function and structure between individuals with varying body compositions, 
cardiovascular parameters have to be adjusted to compensate for differences in body size 
(Chantler and Lakatta, 2009). For example, the body weight for CRTI-A has to be estimated 
before the body mass index is calculated in order for the differences to be corrected. 
Magalhães found that by applying multivariate analyses, adjusting for the effects of major 
confounders, such as body mass index, the PWV remained high in the case of lower limb 
CRTI-A, however he notes that the results were inconclusive as not all the contributing factors 
were assessed in the study (Magalhaes et al., 2011). 
 
A literature review published in 2009 reflects that CRTI-A are at a higher risk of developing 
CVD and that insulin may be associated with blood pressure regulation in maturity onset 
obesity (Robbins et al., 2009). However, injured civilian and military subjects were included 
in their study cohort while our systematic review focuses on injured military. 
Hyperinsulinemia, hypertension and early onset obesity are CVD risk factors, which could 
develop when servicemen/women are discharged and sensible diets and physical fitness 
maintenance are not adhered to as would have been the case while in the military (Robbins et 
al., 2009). This highlights the need for measuring the maintenance of physical ability as a 
contributor to developing CVD risk factors. Linberg and colleagues assessed the effect of 
rehabilitation and reaching pre-injury standards of movement on health outcomes, which will 
impact on development of cardiovascular risk factors (Linberg et al., 2013). Therefore, 
functional differences between comparator groups have to be considered for assessment. 
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The modern application of the term ‘MetS’ (Metabolic Syndrome) could have a different 
impact on outcomes compared to historic studies. Patients with MetS had increased weight, 
waist and hip circumference, fasting blood sugar, triglycerides, low density lipoprotein, and 
liver enzyme levels; P<0.05, (Ejtahed et al., 2017). The National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) III guidelines suggested that a diagnosis of 
metabolic syndrome (previously known as syndrome X) is reached where three or more of the 
following risk factors are present:  
• central obesity 
• elevated triglyceride 
• low HDL 
• raised blood pressure  
• raised fasting plasma glucose 
 
More recently the International Diabetes Federation have defined criteria for metabolic 
syndrome where it is diagnosed if the patient has a 'large waist' plus any other two risk factors 
(Gater et al., 2018). 
 
If the hypothesis that CRTI is associated with increased CVD risk, prevalence of hypertension 
(a traditional CVD risk marker) would be expected to be evident with the majority CRTI 
participants. However, five studies found no increase in hypertension compared to seven 
which reported an increase. 
 
Hrubec and colleagues found an increase in CHD while Modan et al found no increase, which 
adds another inconsistency to the hypothesis that CRTI adds to an increase in CVD risk 
(Hrubec and Ryder, 1980, Modan et al., 1998). 
 
One study observed the increase in CVD risk factors in the short term (1.1-4.3 years follow-
up) after combat injury relative to the severity of injury and reported subsequent development 
of risk factors. However, findings were observational, which does not necessarily prove 
causality (Stewart et al., 2015). 
 
Veterans with PTSD were excluded from this study due to the links with alcohol and substance 
abuse affecting cardiovascular health as well as adverse effects on the central noradrenergic 
system contributing to CVD (Bedi and Arora, 2007, Gunawardena et al., 2007). 
 
This review highlights the limitations in existing available literature. Study cohorts were from 
historical conflicts and were compared with civilian populations without known 
cardiovascular disease at baseline. Most of the studies were cross-sectional and retrospective 
as such with an element of risk of bias and no adjustment for important confounders. 
Confidence interval was not always reported, and population demographics were unclear. 
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A further limitation to the studies is that no more than 50% of cardiovascular events are in 
fact linked to cardiovascular risk factors and some people who experience cardiovascular 
events had no risk factors at all (Naschitz and Lenger, 2008). Some novel haemostatic risk 
factors such as fibrinogen, possibly factor VIII and von Willebrand factor, are associated with 
CHD but are not useful in predicting outcomes (Folsom et al., 1993). Further limitations with 
earlier studies are that haemodinamic factors were not included in CVD risk prediction models 
(Naschitz and Lenger, 2008). 
 
The conclusion is that available literature does not overwhelmingly support the hypothesis 
that CRTI is associated with an increased risk of cardiovascular disease and outcomes 
following the increase in prevalence of a specific CVD risk factor (or risk factors). A 
prospective longitudinal study is required where exposed injured military subjects from 
contemporary conflicts are compared with uninjured military subjects recruited with similar 
exposure and health assessment, age, sex, physical and psychological condition at baseline. 
Traditional and novel cardiovascular risk factors, activity levels and psychological state of 
mind should be assessed at regular time intervals to establish any trends developing thereby 
creating an insight into the development of coronary heart disease risk factors, allowing for 
the development of early intervention protocols.
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Chapter 3  
Methods 
3.1 Study design and population cohorts 
This study is a cross sectional analysis of the first 699 participants recruited into the ongoing 
ADVANCE (ArmeD SerVices TrAuma RehabilitatioN OutComE) Study. The ADVANCE 
Study is a prospective longitudinal cohort study, designed to analyse and examine the 
medium to long term outcomes of British military personnel who sustained traumatic 
injuries (with and without amputations) during recent military conflicts. 
(https://www.advancestudydmrc.org.uk) 
 
The ADVANCE Study is a collaboration between the Defence Medical Rehabilitation Centre 
(DMRC), Imperial College London and King’s College London. The study, a 20-year cohort 
observation, investigates both the physical and psychosocial outcomes of battlefield casualties 
in the long-term and is the first prospective cohort study in this area. Evidence collected will 
provide unique information that will be essential to the care of survivors of serious injuries, 
military or otherwise, across the globe. 
 
A total of 1,200 serving and discharged combat veterans will be recruited, with 6 appointments 
offered over a 20-year period. Participation involves a baseline visit and 5 subsequent follow-
up visits at the Defence Medical Rehabilitation Centre (DMRC) Stanford Hall, where the 
study is based. 
 
Several academic institutions are supporting the ADVANCE Study (Figure 3-1). 
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Figure 3-1: Academic Institutions participating in the ADVANCE Study
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3.2 Data collection and access protocol  
3.2.1 ADVANCE protocol 
The data collection protocol was approved by the Ministry of Defence Research Ethics 
Committee (MoDREC Protocol No: 357/PPE/12, Appendix C). The data collection protocol 
followed by the research personnel employed by ADVANCE is described in paragraphs 3.2.1 
and 3.2.2. 
 
3.3 Study Design, Methodology and Data Analysis 
3.3.1 Study Design 
Prospective longitudinal cohort study with the exposure being CRTI. 
Group 1: “Exposed Group”: n >200 battlefield trauma casualties 
Group 2: “Non-Exposed Group”: n >200  
Frequency matched for age, sex, service, rank, deployment and combat role. 
 
3.3.2 Outcomes 
Primary Outcomes 
a. Cardiovascular risk- as determined by cross sectional differences 
augmentation index and PWV  
 
Secondary Outcomes 
a. Central blood pressure 
b. Cardiovascular risk as determined by more traditional cardiovascular risk 
factors (e.g. blood pressure and diagnosis of hypertension, lipid profile, 
blood glucose/DM, smoking history, HsCRP and abdominal waist 
circumference) 
c. Cardiovascular disease as determined by individual components of the 
primary composite CVD score  
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3.3.3 Trial Subject Selection 
(a) Eligibility Criteria: Group 1: Exposed Group 
 
Inclusion Criteria 
a. UK Armed services personnel 
b. Male  
c. Sustaining physical battlefield trauma, while on deployment, requiring aeromedical 
evacuation and direct UK hospital admission          
d. Injured during 2003 or after 
  
Exclusion Criteria 
a. Females 
b. Patients who were unwilling or unable to give informed consent 
c. Patients with established CVD (previous stroke or transient ischaemic attack [TIA], 
ischaemic heart disease [IHD], peripheral vascular disease) 
d. Past medical history of DM  
e. Past medical history of renal or liver disease 
f. Aged <18 and >50 years 
g. Active acute infection with systemic features of sepsis, at the time of recruitment, as 
defined below. Potential participant with active acute infection will be considered for 
recruitment once the acute illness is treated and resolved. (American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference: definitions for 
sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. 
1992): 
2 of 3 of: 
I.     Temperature >38 0C or <36 0C  
II.      Heart rate >90beats/min  
III. Respiratory rate >20 breaths/min 
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(b) Eligibility Criteria: Group 2: Non-Exposed Group
Frequency matched for age, sex, service, rank, deployment and combat role. 
Inclusion Criteria 
a) UK Armed services personnel
b) Male
c) Previously deployed.
d) No CRTI, as defined in the inclusion criteria.
Exclusion Criteria 
a) Females
b) Patients who are unwilling or unable to give informed consent
c) Patients with established CVD (previous stroke or ischaemic heart disease [IHD],
peripheral vascular disease)
d) Past medical history of DM
e) Past medical history of renal or liver disease
f) Aged <18 years and >50 years
g) Active acute infection with systemic features of sepsis, at the time of recruitment, as
defined below. Potential participant with active acute infection will be considered for
recruitment once the acute illness is treated and resolved. (American College of Chest
Physicians/Society of Critical Care Medicine Consensus Conference: definitions for
sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
1992) :
2 of 3 of: 
I. Temperature >38 0C or <36 0C
II. Heart rate >90beats/min
III. Respiratory rate >20 breaths/min
Recruitment
Potential battlefield trauma exposed volunteers were identified through DMRC Headley Court 
records and were recruited prospectively for newly injured patients and retrospectively back 
to and including 2003 as per the inclusion and exclusion criteria as detailed above. Volunteers 
suitable for the study were identified by their treating clinical team or through their medical 
records or with the assistance of Defence Medical Statistics data. These patients were then 
approached by a member of the research team. A verbal explanation of the trial and patient 
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information sheet was provided by the authorised trial clinician for the participant to consider. 
This included a detailed information about the rationale, design and personal implications of 
the study and include a participant invitation form, participant information sheet and 
participant consent form (Appendix A-C). Following information provision, participants were 
given at least 24 hours to consider participation and were given the opportunity to discuss the 
trial with their family and healthcare professionals before they were asked whether they would 
be willing to take part in the trial. This process was clearly documented into the participant’s 
medical notes. 
 
Non-exposed volunteers were recruited from the same military units as the battlefield exposed 
volunteers. Non-exposed volunteers were approached via poster, e-mail, and presentation 
once approval has been given through the chain of command of the units. Once matched non-
exposed volunteers were identified, the same recruitment proceeds were followed as for the 
patients mentioned above.  
 
Consent 
Assenting participants were formally assessed for eligibility and invited to provide informed, 
written consent. The right of the participant to refuse consent without giving reasons was 
respected. Further, the participant was free to withdraw from the study at any time without 
giving reasons and without prejudicing any further treatment. A copy of the consent will be 
given to the participant, one filed in the Trial Master File, one filed in the hospital.  The written 
consent was taken by an authorized clinician or research nurse and the study was conducted 
in keeping with the Declaration of Helsinki.   
 
Randomisation 
Not applicable 
  
Unblinding 
Not applicable  
 
 
 
 
 
 
 
61 
 
3.4 Data Collection, Source Data and Confidentiality 
 
General 
All information collected during the course of the trial was kept strictly confidential.   
 
Information was held securely on paper and on a secure electronic online database at the 
DMRC Headley Court and linked to Imperial College and King’s College London. An 
anonymised data base was constructed using a unique identification number for each 
participant. Baseline and anthropometric data were transferred to the data base. The study 
cohorts were awarded codes: 0 for controls, 1 for CRTI-NA and 2 for CRTI-A for application 
in data interrogation. 
 
Data access 
For the conduct of this thesis key data from the Clinical Report Forms (CRFs) were entered 
onto a secure personal excel database. This data included anthropometric data, time after 
injury or deployment, laboratory analysis, injury severity, family history, medical and 
smoking history. This database was then integrated with the electronic database created by the 
Vicorder device by means of corresponding participant numbers.   
 
Ability to access the data was made possible by entering into an honorary contract as a 
researcher with Kings College and the Defence Medical Services. Datasets were stored on an 
encrypted device only and are to be destroyed on completion of the research work along with 
other related documents.  
 
I visited the rehabilitation and training facilities to help me understand the various processes 
the CRTI-A encountered and had to deal with on the rehabilitation journey after losing limbs. 
 
I familiarised myself with all the data capturing processes in order to be able to find possible 
weak points in the protocols and standard operating procedures that could affect data 
accuracy and helped staff with retraining where appropriate. I familiarised myself with the 
Vicorder operating software and the outputs expected for data analysis. 
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3.5 Description of protocol elements 
 
3.5.1 Recruitment 
The Department of Defence Statistics (Health) within the UK Ministry of Defence identified 
and matched injured with non-injured groups for recruiting using deployment records. 
Participation was voluntary and all participants received information sheets >24 hours before 
detailed written consent was obtained. Ethical approval was obtained from the Ministry of 
Defence Research and Medical Ethics Committee (MODREC:357PPE12) and the study is 
conducted according to the standards of the declaration of Helsinki.  
 
3.5.2 Capturing data 
Participants were required to fast and refrain from caffeine and alcohol for at least eight hours 
leading up to the examination. The haemodynamic data and blood samples were first priority 
on the examination day to comply with both the Vicorder and fasting tests requirements.  
 
The participants completed baseline questionnaires during a clinical interview with a research 
nurse, which enquired into medical and family history as well as smoking status. Fasting blood 
glucose, HbA1c, renal function, lipid levels, Hs-CRP, and full blood counts were measured 
using venous blood, which was taken at the same visit and processed by the local NHS 
laboratory. Results were written up in paper records. 
 
The recorded data was transcribed for this study at the rehabilitation centre where the data is 
stored from the hard copy into digital format and combined with digital data captured from 
the Vicorder technology to form a comprehensive digital database suitable for interrogation. 
 
3.5.2.1 Anthropometric data 
Anthropometric variables including age, weight, height, hip circumference (HC) and 
abdominal (waist) circumference (WC) were recorded using standard procedures.  
 
 
63 
 
(a) Weight 
For weight, the Seca 704 wireless column scale with a high capacity of up to 250 kilograms 
(Class III Approved) was used. The Seca 956 Chair scales were used for weighing while 
seated when required for CRTI-A. 
 
 
Figure 3-2: Seca 704 wireless column scale 
 
 
 
 
 
 
 
 
 
Figure 3-3: Seca 956 Chair scales 
 
(b) Waist, hip and height measurements 
The waist was measured with a non-stretchable tape midpoint between the lowest costal ridge 
and the upper border of the iliac crest and recorded as abdominal waist circumference (AWC) 
in cm. The hip measurement was taken at the point yielding the maximum circumference 
between the knee and the waist and was recorded as hip circumference (HC) in cm.  
The Seca 213 Height Measuring device (Leicester) was used to determine height in cm. The 
participant stood upright in socs and the sliding scale was touched on the top of the head to 
determine height. Previous height was recorded in the case of bilateral CRTI-A. 
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(c) Calculations and ratios  
 
Waist to height ratio (WHtR) 
 
Waist to height ratio was calculated as (waist circumference (cm)/height (cm)) x 100 and was 
used to assess the fat content in the human body.  
 
Conicity Index (CoI) 
 
Conicity Index is a novel indicator of CVD risk reflecting on waist circumference and obesity. 
It is described by Motamed and colleagues and Segura-Fragoso as a superior CVD risk 
indicator compared to BMI and was calculated using weight (kg), height (m) and AWC (m) 
as follows: (Motamed et al., 2015, Segura-Fragoso et al., 2019).  
 
  
 
Body mass index (BMI) 
 
BMI was determined as weight (kg) divided by height (m2). We disregarded BMI as it would 
technically be inaccurate when applied to CRTI-A. The physical nature of the participants, 
who in most cases were fit and muscular, would also lead to inaccurate assumptions resulting 
in classifying them as clinically obese according to BMI results, which reflects on body weight 
irrespective whether it is due to muscular weight or abdominal fat. 
 
3.5.2.2 Laboratory analysis 
Venous blood was taken and sent to the local NHS laboratory for analysis of full blood counts, 
fasting glucose, HbA1c, renal function, creatinine, lipid profile and Hs-CRP (with lower 
detection limit 0.10 mg/l). 
  
Applied laboratory criteria 
The Cockcroft-Gault equation ([140-age] x [weight in kg] / (72 x serum creatinine [µmol/l]) 
was applied to calculate Creatinine Clearance (Cockcroft and Gault, 1976). 
 
3.5.3 Injury severity 
The New Injury Severity Score (NISS) was applied for injury severity quantification (Osler 
et al., 1997). The scores were provided by the UK Joint Theatre Trauma Registry (JTTR), 
which comprises a prospectively collected trauma database of every casualty admitted to a 
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deployed UK medical facility or killed during deployed operations (Smith et al., 2007). This 
database is securely held and maintained by the Academic Department of Military 
Emergency Medicine (ADMEM). Access to examine the data for research purposes is 
restricted and only provided by the Medical Director (Defence Medical Services). NISS was 
applied to the injured cohort to evaluate and confirm the severity of injuries. 
 
3.5.4 The amputee cohort  
The range of amputations assessed in this study are illustrated in Figure 4-1. 
 
 
(a) Lower limb CRTI-A subgroups 
Lower limb distal:   Unilateral (n=30); Bilateral (n=7) 
Lower limb proximal:   Unilateral (n=12); Bilateral (n=23) 
Lower limb distal and proximal (n=8) 
Knee disarticulation (n=4) 
Both knees disarticulated (n=1) 
Lower limb distal amp plus knee disarticulation (n=2) 
Lower limb proximal amp plus knee (n=4) 
Lower limb proximal bilateral plus hand (n=3) 
Lower limb proximal bilateral plus elbow disarticulation (n=1) 
Lower limb proximal bilateral plus trans radial (n=3) 
 
Lower limb distal subgroups plus proximal, unilateral plus hand (n=1) 
Lower limb distal plus proximal, unilateral plus trans humeral (n=1) 
Both knees plus one disarticulated (n=1) 
 
(b) Upper limb amputee subgroups 
Trans humeral (n=1) 
Hand (n=1) 
 
3.5.5 Haemodynamic characteristics and blood pressure 
Arterial compliance and central BP were measured with the Vicorder device (Skidmore 
Medical, UK)(Milan et al., 2019, Pucci et al., 2013, Shahin et al., 2013). The Vicorder uses 
an oscillometric technique to acquire the pulse waveform. All Vicorder measurements were 
undertaken by trained medical research nurses in a temperature-controlled room following 
stringent standard operating procedures. The participant was made comfortable and rested for 
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Medical, UK) (Milan et al., 2019, Pucci et al., 2013, Shahin et al., 2013). The Vicorder uses 
an oscillometric technique to acquire the pulse waveform. All Vicorder measurements were 
undertaken by trained medical research nurses in an average ambient temperature-controlled 
room following stringent standard operating procedures. The participant was made 
comfortable and rested for at least five minutes prior to examining blood pressure and arterial 
compliance. For the Vicorder readings the participants were required to lie comfortably and 
supine on a medical bed with the head raised at a 30o angle. 
 
Inflatable cuffs (11x85cm Hokanson® SC10TM) were placed around the left thigh (as high 
as possible) and around the left upper arm. A smaller cuff was placed around the neck below 
the Adam’s apple. The cuff’s design is such that both carotid arteries and trachea was not 
compressed at the same time. The head is tilted slightly back to relax the skin and muscles 
during the measurement. The distance between the suprasternal notch and the middle of the 
thigh cough were measured with a non-stretchable flexible tape measure and used as the path 
length in the calculated pulse wave velocity. The value was entered into the Vicorder software 
together with the participant’s details. Brachial systolic and diastolic blood pressures, 
augmented pressure, central augmentation index, brachial augmentation index, stroke volume 
and the Subendocardial Viability Ratio were measured, calculated and recorded by the 
Vicorder in the proprietary software (SEVR) (Pereira et al., 2015, Pucci et al., 2013, Shahin 
et al., 2013). 
 
Figure 3-4: PWV; Vicorder cuff application (SMT medical technology GmbH & Co. KG) 
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(a) Pulse wave velocity 
PWV was calculated using the arterial transit time, which is the time delay due to the 
propagation of the pulse wave along the arterial tree between the upstrokes of two 
simultaneously measured waves at the femoral and carotid arteries (figure 3-5). PWV is the 
linear ratio between the measured distance and the time (Pereira et al., 2015). 
 
Carotid-femoral PWV is considered the gold standard for arterial stiffness assessment and 
underpins quantification of arterial ageing (Weber et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: Measurement and calculation of pulse wave velocity 
 
(b) Systolic blood pressures 
The brachial BP was measured to calibrate the device whereupon the brachial arterial 
waveform analysis is applied at diastolic pressure to estimate central systolic and brachial 
systolic BP.  
 
(c) Augmentation Index 
Augmentation index is an indicator of subclinical atherosclerotic vascular damage. Several 
studies have shown AIx to be predictive of adverse cardiovascular events (Chirinos et al., 
2005, Weber et al., 2005, Ueda et al., 2004, London et al., 2004). 
 
Early atherosclerosis is associated with reduced arterial elasticity and future cardiovascular 
events (Kotsis et al., 2017). Cardiovascular risk factors such as DM or elevated fasting 
glucose, obesity, higher heart rate, hypertension and lipid disorders (particularly higher 
triglycerides and lower HDL) are associated with a stiffer aorta (Mitchell, 2009). 
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Augmentation index is expressed in both central aortic AIx and peripheral or brachial 
augmentation index (pAI). Stiffness of the arteries affects the magnitude of the reflected wave 
generated in the arterial tree at bifurcations or narrowing of the arteries and the resulting effect 
on the function of the heart (Mitchell, 2009). In fact, the pressure waveform at any point is a 
composite of the forward-going and reflected wave (Wilkinson et al., 2000). 
  
Central and brachial augmentation indexes are calculated in different ways: 
Central AIx is defined for a central pressure waveform as the ratio of Augmentation Pressure 
(cAP) to Pulse Pressure (cPP): AIx = cAP / cPP (Figure 3-6) (Wilkinson et al., 2000). 
 
Figure 3-6: Central Augmentation Index (AIx) 
 
Peripheral augmentation index (pAI) on the other hand is defined (as a %) as the ratio of late 
systolic pressure (P2) to early systolic pressure (P1): pAI = P2 / P1 (Figure 3-7) (Wilkinson 
et al., 2000). 
 
 
 
Figure 3-7: Peripheral augmentation index (pAI)     
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The central augmentation pressure represents the additional systolic BP created by the 
reflected waves at the aorta expressed as a percentage. The central AIx, was therefore 
calculated as the percentage proportion of the augmentation pressure to the central pulse 
pressure (Wilkinson et al., 2000). 
 
There is a linear association between heartbeat and AIx, which needs consideration in 
studies. For example, an increase in heartbeat from 60 to 110 beats per minute, is associated 
with a rise in peripheral BP and central diastolic pressure, but no change in central systolic 
BP. Over the same change in pace a linear reduction in AIx was recorded. These effects are 
explained by considering wave reflection and therefore pulse wave analysis should be 
applied to assess systemic arterial stiffness (Wilkinson et al., 2000). 
 
(d) Subendocardial Viability ratio (SEVR) 
SEVR was calculated as the ratio of the pressure time integral (mmHg x s) for diastole divided 
by that for systole and represented as a percentage. SEVR reflects relative myocardial oxygen 
supply versus demand and is strongly associated with coronary blood flow reserve (Tsiachris 
et al., 2012). 
 
SEVR is a useful tool for reflecting the balance between myocardial perfusion and left 
ventricular afterload (Tagawa et al., 2018). SEVR is reflective of myocardial oxygen supply 
versus demand with a strong correlation to coronary blood flow reserve (Tsiachris et al., 
2012). The implications of increased arterial stiffness on the brachial pulse wave with resulting 
increase in systole time (need for oxygen) and decreased coronary perfusion time (diastole) is 
explained by means of the curve moving to the right following increase in arterial stiffness 
(Figure 3-8) (Salvi et al., 2008). 
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Figure 3-8: The effect of increase in Augmentation Index on the pulse wave: 45%-170% 
(Salvi et al., 2008) 
 
 
3.6 Statistical considerations 
3.6.1 Sample size/power calculations 
Sample size calculations were performed for the primary outcomes using GraphPad 
StatMate version 2.00 for Windows (GraphPad Software).  
 
We have also calculated sample size for the other key primary endpoint of PWV. Published 
data on health controls of similar ages to our study population would suggest an average pulse 
wave velocity of 6.0 – 6.5 m/s with a within group standard deviation of 0.8-1.2 m/s (Doonan 
et al., 2011) (Reference Values for Arterial Stiffness' Collaboration., 2010). There is a general 
paucity of data on pulse wave velocity among CRTI-A and multiple trauma patients. However, 
again, using modelling of our average patient demographic and pilot data along with published 
data amongst sedentary controls, age and sex matched controls with subclinical CVD to 
simulate the disease group and allowing for the natural increase in PWV with age, it would be 
anticipated that trauma patients would be expected to have a PWV of >0.4m/s higher than the 
healthy control group (Lazdam et al., 2012).   
 
Hence, a sample size of at least 200 in each group (battlefield trauma exposed versus non 
exposed) would have a 95% power to detect a difference in PWV of >0.36 m/s at a significance 
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level (alpha) of 0.05 (two-tailed) assuming a within-group standard deviation of 1.0m/s 
(Kingwell et al., 1997).  Even if the within-group standard deviation were higher than 
anticipated at up to 1.4 ms/s a minimal sample size of 280 subjects would still have 90% power 
to detect a >0.4 m/s (>7%) difference in PWV between the battlefield trauma exposed group 
and the non-exposed group.  
 
3.6.2 Descriptive statistics 
All statistical analyses were performed by Graphpad Prism 8 for MacOS version 8.1.1 (1994-
2019 Graphpad Software, Inc. San Diego, California 92108). Graphpad Prism was applied for 
the presentation of all graphical figures. Included continuous variables are presented as means 
± standard deviation. 
 
Data inspection and the D’Agostino-Pearson omnibus test (K2) were undertaken to determine 
whether the data fitted (or not) a Gaussian distribution in order to decide on the appropriate 
use of parametric or non-parametric tests. Each column of data was scrutinised for outliers 
applying the outlier search function in Prism 8 before statistical analysis. Spurious data due to 
erroneous input were removed. Outlier data relating to the data in the column was included in 
the analysis. 
 
The level and the patterns of missing data were assessed. For questions which elicit high levels 
of missing data (for example greater than 20%) we were cautious about any analyses based 
on these data.  
 
The frequency of distribution was plotted on histograms to visually assess and help assume 
normality to assist in deciding on parametric or non-parametric testing. Data was presented as 
means ± standard deviation (SD). Unpaired data was examined using an unpaired t-test for 
parametric testing with Welch’s correction where equal standard deviation was not assumed. 
For non-parametric testing, the Mann-Whitney test was applied to compare ranks. Three or 
more groups of continuous data were compared using a one-way Analysis of Variance 
(ANOVA) for parametric data and the Tukey post-hoc test to illustrate differences between 
the columns. For non-parametric data, the Kruskal-Wallis test with Dunn’s post-hoc test was 
applied. Qualitive data was examined with the Fisher’s exact test and Chi-square test. 
Correlations for parametric data were examined with the Pearson test (±95% confidence 
interval) and for non-parametric data the Spearman rank test was applied. A two-tailed P value 
< 0.05 was considered statistically significant for all comparisons. 
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Chapter 4  
Results 
Data of 699 military or ex-military personnel were examined with healthy controls (n=394)   
and CRTI (n=305). The response rate was similar at 41.5% and 37.3% (p=0.268) respectively. 
In the injured cohort n=200 suffered combat-related traumatic injuries without amputations 
(CRTI-NA) and n=105 had limb amputations (CRTI-A) (Table 4-1). A slight variation in the 
sample size for some statistical analysis were noted where data in the columns were 
unavailable.    
 
Amputations included isolated proximal upper limb amputations (n=3), isolated proximal 
upper limb amputations (n=2) and all other proximal and/or distal, unilateral and/or bilateral, 
lower upper limb amputations.  Holm-Sidak’s multiple comparison tests with a single pooled 
variance were applied to measure the level of significant difference between the groups for 
each parameter investigated. Figure 4-1 illustrates the range and proportions of amputations 
represented in the study cohort.  
 
 
Figure 4-1: Range of amputations in groups with number of participants indicated per group 
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4.1 Baseline Demographics 
A total of 90% of the healthy controls were still serving at the time of examination compared 
to 36% of the CRTI-NA and 12% of the amputee groups; p<0.001 (Table 4-3).  
 
4.1.1 Age of the participants 
The average age for the cohort was 33.9years (± 5.40) with the range for the three groups 
statistically similar with ages ranging from 23 to 60 overall (Table 4-3). Ages recorded were 
healthy control, 34.08 years (± 5.34) [23-60] vs CRTI-NA, 34.57years (± 5.95) [24-53] vs 
amputee group, 33.07 years (± 4.91) [23-52]; p=0.20. 
 
4.1.2 The period from deployment/injury to examination  
The period from deployment/injury to examination were significantly longer for the healthy 
control group, 101.40 months (± 21.49) vs the amputee group, 81.06 months (± 20.29); 
p<0.001 and CRTI-NA group 88.83 months (± 1.18); p<0.001. The difference between the 
CRTI-NA and amputee group was significant (Fig 4-2).  
 
 
Figure 4-2: The time in months elapsed from 1st deployment or injury to examination 
compared between the groups. 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=360, Injured (CRTI-NA) n=193, amputees (CRTI-A) n= 100 
 
4.2 Family history of CVD 
 
4.2.1 Reported close family history of CVD (father, mother, brother and 
sister) 
The results showed that family history differences between the three groups were not 
statistically significant; p=0.25. 
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4.2.2 Smoking history 
Smoking history between the groups was examined applying the chi-squared test to compare 
smokers and never smoked. The test revealed a difference (however not significant), between 
the smokers (current plus ex-smokers) in control (total 183/54.8%) vs CRTI-A groups (total 
52/52%); p=0.043 (Fig 4-3).  
   
Figure 4-3: Smoking characteristics of the participants compared within the groups 
 
 
4.2.3 Injury severity score (NISS) 
The injury severity scores were significantly higher among the CRTI-A, 36.75 (± 18.01) 
compared to the CRTI-NA group, 20.11 (± 17.99); p<0.0001 (Table 4-3, Fig 4-4).  
 
 
Figure 4-4: Injury severity score (NISS) compared between amputee and CRTI-NA groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=394, Injured (CRTI-NA) n=192, amputees (CRTI-A) n= 101 
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4.3 Haemodynamic characteristics including arterial stiffness 
4.3.1 Resting heart rate  
Resting heart rate (beats/min) was significantly higher amongst CRTI-A, 63.67 m-1 (± 12.53 
m-1) vs CRTI-NA group, 58.35 m-1 (± 9.4 m-1); p<0.001 and healthy control, 56.39 m-1 (± 9.24    
m-1); p<0.0001. (Table 4-1, Fig 4-5) 
 
 
Figure 4-5: Resting heart rate as a CVD risk marker compared between the three groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=390, Injured (CRTI-NA) n=200, amputees (CRTI-A) n= 105 
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4.3.2 Systolic and diastolic blood pressure  
There were no statistically significant differences between aortic and brachial systolic 
pressures or diastolic pressures across the three groups (Table 4-1). 
 
4.3.3 Pulse pressure  
(a) Aortic pulse pressure  
The aortic pulse pressure in the CRTI-A, 51.67mmHg (± 6.90 mmHg) group was statistically 
lower than in the healthy control groups, 54.24mmHg (± 7.84 mmHg); p=0.007. (Table 4-1. 
Fig 4-6) 
 
 
Figure 4-6: Aortic pulse pressure mmHg as a CVD risk marker compared between the 
groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=390, Injured (CRTI-NA) n=201, amputees (CRTI-A) n= 105 
 
 
(b) Peripheral pulse pressure  
The brachial pulse pressures were not significantly different between the groups (Table 4-1). 
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4.3.4 Subendocardial viability ratio (SEVR)  
Subendocardial viability ratio was significantly lower in the CRTI-A group, 194.0 (± 43.32), 
compared to the healthy control group, 206.3 (± 46.48); P=0.01. (Table 4-1, Fig 4-7) 
 
Figure 4-7: Comparison of Subendocardial Viability Ratio (SEVR) between the groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=371, Injured (CRTI-NA) n=198, amputees (CRTI-A) n= 101 
 
 
4.3.5 Stroke volume  
The stroke volume was significantly lower in the CRTI-A group, 88.77ml (± 14.3 ml) 
compared to the CRTI-NA group, 93.03ml (± 16.09 ml) and the healthy control group, 95.02ml 
(± 13.77 ml); p<0.001. (Table 4-1, Fig 4-8) 
 
 
Figure 4-8: Stroke volume (ml) was compared between the groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=307, Injured (CRTI-NA) n=168, amputees (CRTI-A) n= 97 
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4.3.6 Pulse wave velocity  
A significantly lower PWV was recorded in the CRTI-A group, 7.61 ms-1 (± 1.51 ms-1) vs the 
CRTI-NA group, 8.03 ms-1 (± 1.64 ms-1); p=0.03. There was no statistically significant 
difference in PWV between the CRTI-A and healthy control groups. (Table 4-1, Fig 4-9) 
 
 
 
Figure 4-9: Pulse wave velocity (ms-1) was compared between the three groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control (HC) n=303, Injured (CRTI-NA) n=166, amputees (CRTI-A) n= 97 
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4.3.7 Augmentation index 
There were no significant differences in central and peripheral augmentation indexes 
between all the groups. (Table 4-1, Fig 4-10) 
Figure 4-10: Central augmentation Index (cAIx) 
Figure 4-11: Peripheral augmentation index (AIx) 
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Table 4-1: Comparative baseline haemodynamic characteristics including arterial stiffness 
(mean ± SD) of the healthy control versus those with traumatic injuries without amputations 
(CRTI-NA) and those with amputations (CRTI-A)  
 Combat related traumatic injury 
Variables Healthy 
control 
Mean ± SD 
Non-amputee 
(CRTI-NA) 
Mean ± SD 
Amputees 
CRTI-A 
Mean ± SD 
Kruskal-
Wallis p 
Cohort (n) 394 200 105  
Resting heart rate, 
minute 1 
56.39 ± 9.24 58.35 ± 9.41 
 
63.67 ± 12.53 
 
<0.001 ans   
            b****                                         
            c***  
Central augmentation 
index, % 
16.63 ± 7.27 
 
17.5 ± 7.67 
 
17.08 ± 8.38 
 
0.456 
 
Peripheral augmentation 
index, % 
90.72 ± 5.22 91.27 ± 5.17 
 
90.59 ± 5.61 
 
0.449 
 
Aortic systolic pressure, 
mmHg 
125.40 ± 10.86 125.70 ± 10.89 
 
124.1 ± 11.18 
 
0.464 
 
Brachial systolic blood 
pressure, mmHg 
71.15 ± 8.05 72.32 ± 8.06 72.48 ± 8.42 0.531 
 
Brachial diastolic blood 
pressure, mmHg 
71.15 ± 8.05 72.32 ± 8.06 
 
72.48 ± 8.42 
 
0.194 
 
Aortic pulse pressure, 
mmHg 
54.24 ± 7.84 
 
53.37 ± 7.65 
 
51.67 ± 6.90 
 
0.007      b** 
 
Peripheral pulse 
pressure, mmHg 
59.76 ± 8.12 
 
58.49 ± 7.98 
 
57.2 ± 7.78 
 
0.008      b* 
 
Subendocardial viability 
ratio (SEVR) 
206.43 ± 46.48 
 
201.30 ± 45.07 
 
194.00± 43.32 
 
0.010      b** 
 
Stroke volume, ml 95.02 ± 13.77 93.03 ± 16.09 88.77 ± 14.3 <0.001   b***                 
Stroke volume Index 
ml/m2 
45.77 ± 7.12 44.99 ± 9.03 44.58 ± 8.25 0.904 
Cardiac index, l/m2 3.90 ± 8.89 3.01 ± 0.65 4.25 ± 7.15 0.017      b* 
Pulse Wave Velocity, 
ms-1 
7.77 ± 1.35 8.03 ± 1.64 7.61 ± 1.51 0.031      c* 
Tukey’s or Dunn’s post hoc test: significant difference between groups: a, CRTI-NA vs HC; 
b, Amputee vs HC; c, Amputee vs CRTI-NA (* = degree of significance) 
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4.4 Biochemical characteristics  
4.4.1 Serum lipid-profiles  
(a) Total cholesterol and LDL cholesterol  
Total cholesterol and LDL cholesterol were lower in the CRTI-A group compared to the 
healthy control and CRTI-NA groups. However, the differences were not statistically 
significant; p=0.22; p=0.51 respectively. (Table 4-2) 
 
(b) HDL Cholesterol  
HDL cholesterol (mmol/l) was significantly lower in the CRTI-A group, 1.12 mmol/l (± 0.27 
mmol/l) vs the CRTI-NA, 1.25 mmol/l (± 0.33 mmol/l) vs the control group, 1.25 mmol/l (± 
0.27 mmol/l) respectively; p<0.0001. (Table 4-2; Fig 4-12) 
 
 
Figure 4-12: HDL cholesterol mmol/l compared between the three groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=337, Injured (CRTI-NA) n=183, amputees (CRTI-A) n= 98 
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(c) The total cholesterol/HDL ratio  
The total cholesterol/HDL ratio was significantly higher in the CRTI-A group, 4.49 (± 1.247) 
vs the CRTI-NA group, 4.31 (± 1.82) vs control, 4.19 (± 1.48); p=0.01. (Table 4-2, Fig 4-13) 
 
 
Figure 4-13: Total Cholesterol/HDL ratio compared between the three groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=360, Injured (CRTI-NA) n=191, amputees (CRTI-A) n= 104 
 
(d) Triglycerides  
Triglyceride values were not significantly different between the three groups. (Table 4-2) 
 
4.4.2 Glycaemic Index 
Glucose and HbA1C values were not statistically different between all the groups  
(Table 4-2). 
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4.4.3 Inflammatory markers 
(a) Hs-CRP  
Hs-CRP levels were significantly higher in the CRTI-A, 2.60mg/l (± 3.81 mg/l) vs control, 
1.44mg/l (± 1.69 mg/l); p=0.02. CRTI-A vs CRTI-NA and CRTI-NA vs control did not differ 
significantly. (Table 4-2, Fig 4-14) 
 
 
Figure 4-14: Hs-CRP (mg/l) compared between the three groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=354, Injured (CRTI-NA) n=196, amputees (CRTI-A) n= 104 
 
 
(b) White Cell Count  
The white cell count was significantly higher with the CRTI-A, 6.02 ml-3 (± 2.30 ml-3) vs 
control, 5.50 ml-3 (± 1.31 ml-3); p=0.02 with no significant difference compared to the CRTI-
NA group. (Table 4-2) 
 
4.4.4 Other biochemical markers 
(a) Haemoglobin  
Haemoglobin levels were not significantly different between the groups. (Table 4-2)
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(b) Creatinine  
Creatinine values were significantly lower in the CRTI-A, 76.80µmol/l (± 12.02µmol/l) vs the 
CRTI-NA group, 85.19µmol/l (± 12.66µmol/l) and CRTI-A vs control, 86.78 µmol/l (± 10.87 
µmol/l); p<0.0001. (Table 4-2, Fig 4-15)                              
 
 
Figure 4-15:  Creatinine (µmol/l) compared between the three groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=336, Injured (CRTI-NA) n=187, amputees (CRTI-A) n= 99 
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Table 4-2: Comparative baseline Biochemical characteristics (mean ± SD) of the healthy 
control versus those with traumatic injuries without amputations (CRTI-NA) and those with 
amputations (CRTI-A)  
 Combat related traumatic injury 
Variables Healthy control 
(HC) 
Mean ± SD 
Non-amputee 
(CRTI-NA) 
Mean ± SD 
Amputees 
CRTI-A 
Mean ± SD 
Kruskal-Wallis 
p 
Cohort (n) 394 200 105  
Total Cholesterol, 
mmol/l 
 
5.07 ± 1.06 
 
5.02 ± 0.99 
 
4.82 ± 0.98 
 
0.22 
 
LDL Cholesterol, 
mmol/l 
 
3.17 ± 0.83 
 
3.11 ± 0.86 
 
3.05 ± 0.80 
 
0.51 
 
HDL Cholesterol, 
mmol/l 
 
1.25 ± 0.27 
 
1.25 ± 0.32 
 
1.12 ± 0.27 
 
<0.0001    b***  
                 c***       
Total Cholesterol/HDL 
ratio 
4.15 ± 1.25 
 
4.23 ± 1.48 
 
4.49 ± 1.25 
 
0.01          b * 
                 c * 
Triglycerides, mmol/l 
 
1.37 ± 1.26 1.42 ± 0.94 1.55 ± 1.23 0.03 
Glucose, mmol/l, 
fasting 
 
4.93 ± 0.67 
 
4.98 ± 1.06 
 
4.89 ± 0.55 
 
0.54 
 
HbA1c 
 
34.88 ± 4.01 
 
34.94 ± 4.81 
 
34.11 ± 4.06 
 
0.06 
 
Hs-CRP, mg/l 
 
1.44 ± 1.69 
 
1.96 ± 2.68 
 
2.60 ± 3.81 
 
0.02         b * 
 
White Cell Count, x 
109/l 
 
5.50 ± 1.31 
 
5.59 ± 1.76 
 
6.02 ± 2.30 
 
0.02         b * 
 
Haemoglobin, g/l 
 
152.6 ± 8.70 
 
152.2 ± 10.44 
 
154 ± 9.00 
 
0.75 
 
Creatinine, µmol/l 
 
86.78 ± 10.87 
 
85.19 ± 12.66 
 
76.80 ± 12.02 
 
<0.001    b**** 
               c****                   
Creatinine clearance, 
ml/minute 
134.10±24.05 138.90±30.22 140.80±27.08 0.04         b** 
Tukey’s or Dunn’s post hoc test: significant difference between groups: a, HC vs CRTI-NA; 
b, HC vs Amputee; c, CRTI-NA vs Amputee (*-**** = degree of significance) 
LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1c, haemoglobin A1c; HsCRP, 
high-sensitivity C-reactive protein 
 
86 
4.5 Anthropometric and demographic characteristics 
4.5.1 Height  
There were no significant differences in the height of the three groups; p=0.24. (Table 4-3) 
 
 
4.5.2 Weight  
The mean weight of the CRTI-A group, 81.05 kg (± 13.73 kg) was significantly lower than 
both the CRTI-NA, 88.58 kg (± 14.36 kg) and control groups, 87.51 kg (± 12.00 kg); 
p<0.0001. Weight was not adjusted for loss of limb. (Table 4-3, Fig 4-16) 
 
 
Figure 4-16: Weight comparison between the three cohorts 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=337, Injured (CRTI-NA) n=188, amputees (CRTI-A) n= 100 
 
 
 
4.5.3 Hip circumference  
With respect to hip circumferences, higher values were recorded with the CRTI-A group, 
105.3 cm (± 9.05 cm) comparative to control, 103.2 cm (± 7.06 cm); p=0.05. (Table 4-3)
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4.5.4 Abdominal waist circumference (cm) (AWC)  
The AWC in the CRTI-A group, 96.18cm (± 11.07cm), were significantly higher than the 
control group, 92.95cm (± 8.96cm); p=0.01. (Table 4-3, Fig 4-17) 
 
 
Figure 4-17: Comparison of waist circumference between the groups. 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=361, Injured (CRTI-NA) n=190, amputees (CRTI-A) n= 105 
 
 
4.5.5 Waist/height ratio (WHtR)  
The waist/height ratio in the CRTI-A group, 0.54 (± 0.06), was significantly higher compared 
to the control group, 0.52 (± 0.05); p=0.03. (Table 4-3, Fig 4-18) 
 
 
Figure 4-18: Comparison of Waist/height ratio between the groups as a novel CVD risk 
indicator 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=337 Injured (CRTI-NA) n=181, amputees (CRTI-A) n= 100 
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4.5.6 BMI  
BMI, with no adjustment for loss of limb, was significantly lower with the CRTI-A group, 
25.07 kg/m2 (± 4.17kg/m2) vs control, 27.2 kg/m2 (± 3.28kg/m2) and CRTI-NA groups, 27.61 
kg/m2 (± 3.72kg/m2); p<0.0001. (Table 4-3, Fig 4-19) 
 
 
Figure 4-19: Comparison of BMI between the groups 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=337, Injured (CRTI-NA) n=188, amputees (CRTI-A) n= 100 
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4.5.7 Conicity Index (CoI)  
The CRTI-A group was characterized with a significantly higher mean CoI, 1.32 (± 0.09) than 
the control, 1.23 (± 0.06) and CRTI-NA groups, 1.23 (± 0.07); p<0.0001.  
(Table 4-3, Fig 4-20) 
 
 
Figure 4-20: Comparison of mean Conicity Index between the study cohorts 
Dunn’s multiple comparison test: significance **** = p<0.0001; *** = p<0.001; *** = p<0.01;   * = p<0.1); ns = non-significant 
Healthy control n=336, Injured (CRTI-NA) n=181, amputees (CRTI-A) n= 100
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Table 4-3: Comparative baseline Anthropometric and demographic characteristics (mean ± 
SD) of the healthy control versus those with traumatic injuries without amputations (CRTI-
NA) and those with amputations (CRTI-A)   
 Combat related traumatic injury 
Variables Healthy control (HC) 
Mean & SD 
Non-amputee (CRTI-
NA) 
Mean & SD 
Amputees (CRTI-A) 
Mean & SD 
Kruskal-Wallis 
p 
Cohort (n) 394 200 105  
Age, years 
Range 
34.08 ± 5.34 
23-60 
34.57 ± 5.95 
24 -53 
33.07 ± 4.92 
23-52 
0.20 
Height (cm) 179.3 ± 6.12 
 
178.9 ± 7.19 
 
180.3 ± 7.86 
 
0.24 
 
Weight (kg) 87.51 ± 12.00 88.58 ± 14.36 81.05 ± 13.73 0.02 
Hip circumference (cm) 103.2 ± 7.07 
 
103.7 ± 8.52 
 
105.3 ± 9.05 
 
0.05 
 
Abdominal waist 
circumference(cm) 
92.95 ± 8.96 
 
94.48 ± 10.23 
 
96.18 ± 11.07 
 
0.01        b** 
 
Waist/height ratio 0.52 ± 0.05 
 
0.53 ± 0.05 
 
0.54 ± 0.06 
 
0.03        b* 
 
BMI 27.20 ± 3.28 27.61 ± 3.73 25.07 ± 4.17 <0.0001 b****   
               c****                  
Conicity Index 1.23 ± 0.06 
 
1.23 ± 0.07 
 
1.32 ± 0.09 
 
<0.0001 b**** 
              c*** 
Injury Severity Score 
Median (Range) 
 20.11 ± 17.99 36.75 ± 18.01 <0.0001 c**** 
Time – last deployment 
to examination (months) 
81.81 ±18.50 
 
88.83 ± 21.18 
 
81.06 ± 20.29 
 
0.0001 a**** 
            b**** 
            c** 
Still currently serving 
n, (%) 
301/335  
(90%) 
 
67/184  
(36%) 
 
12/99  
(12%) 
 
<0.001 
 
Ethnicity, n (%) 
Caucasian 
Non-Caucasian 
 
 
314 (93.2%) 
23 (6.8%) 
 
169 (90.9%) 
17 (9.1%) 
 
84 (89.4%) 
10 (10.6%) 
 
0.49 
 
Family history of CVD 
# 
124/331 37.5% 
 
80/185 43.2% 
 
43/97 44.3% 
 
0.25 
 
Smoking history n, (%) 
Current 
Ex 
Never 
 
75/334 (22.5%) 
108/334 (32.3%) 
151/334         (45.2%) 
 
 
39/187 (20.9%) 
50/187 (26.7%) 
98/187           (52.4%) 
 
 
15/100 (15.0%) 
37/100 (37.0%) 
48/100           (48.0%) 
 
 
0.04     b* 
Tukey’s or Dunn’s post hoc test: significant difference between groups: a, CRTI-NA vs HC; 
b, Amputee vs HC; c, Amputee vs CRTI-NA (*-**** = degree of significance) 
# history of confirmed CVD in first degree relative 
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4.6 The impact of injury severity on CVD risk 
We were keen to assess if the quantity and the severity (proximal or distal, uni- or bi-lateral) 
of amputations had an impact on prevalence of CVD risk markers. Descriptive statistics with 
mean (± SD), Kruskal-Wallis ‘p’ and Dunn’s multiple comparison tests were applied to 
identify the level of significance of differences between the groups and were compared with 
HC and CRTI-NA (Table 4-5). The number of subjects evaluated in the tests may vary in the 
subgroups due to availability of data in the various columns. A Kruskal-Wallis test was 
performed comparing the mean rank of each column with the mean rank of the control column 
(Fig 4-22 to 4-27). Results (Mean ± SD) are listed in Table 4-4. 
 
4.6.1 Injury severity scores (NISS) 
There was a statistically significant difference in NISS between the CRTI-A and the CRTI-
NA groups: (36.75 ± 18.01) and (20.11 ± 17.99); p<0.0001, respectively confirming the 
measure of human trauma (Osler et al., 1997). 
 
 
Figure 4-21: New Injury severity score (NISS) 
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4.6.2 HDL cholesterol  
HDL cholesterol was significantly affected by amputations compared to HC and CRTI-NA, 
p<0.0001.  Statistically the most significant affects were noted in the proximal amputations 
group, 1.08 (± 0.29); p <0.0001. The quantity of distal and proximal CRTI-A affected HDL 
cholesterol equally albeit weakly significantly; p<0.1.  HDL cholesterol is protective against 
CVD and has a strong inverse relationship with CVD (Cooney et al., 2009). The statistically 
significant lower HDL value relative to injury severity in our results confirms the increased 
effect of injury severity on CVD risk. (Table 4-4, Fig 4-22) 
 
 
Figure 4-22: Assessing HDL cholesterol (mmol/l) levels affected by the severity of 
amputation  
Healthy Control (n=337), CRTI-NA (Injured) (n=183), Bilateral Proximal/Distal CRTI-A (n=57), Bilateral Proximal/Distal 
(n=32), Total Distal CRTI-A (n=44), Total Proximal CRTI-A (n=45). 
Kruskal-Wallis test significance: **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant 
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4.6.3 Hs-CRP  
Hs-CRP levels as a measure of inflammation were recorded, and it was found that Hs-CRP 
levels were significantly affected by the quantity of amputations compared to HC, 3.82mg/l 
(± 4.5 mg/l) and 1.43mg/l (± 1.68 mg/l) respectively. This finding confirms the increased 
effect of multiple amputations on systemic inflammation. Increased Hs-CRP, as a non-
traditional CVD risk marker, was found to independently predict risk of all-cause CV 
mortality (Li et al., 2017) and is directly related to an increase in injury severity (Li et al., 
2017, Wilson et al., 2006). (Table 4-4, Fig 4-23) 
 
 
Figure 4-23: Assessment of Hs-CRP (mg/l) affected by the severity of amputation 
Healthy Control (n=365), CRTI-NA (Injured) (n=189), Bilateral Proximal/Distal CRTI-A (n=57), Bilateral Proximal/Distal 
(n=31), Total Distal CRTI-A (n=44), Total Proximal CRTI-A (n=44). 
Kruskal-Wallis test significance: **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant 
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4.6.4 Creatinine  
Amputations in general had a statistically significant effect on creatinine level compared to 
HC; p<0.0001. There was no significant effect in the CRTI-NA group. These results are 
consistent with previous studies alluding that patients with traumatic amputation have 
significantly lower serum creatinine values compared to the general population due to muscle 
mass loss (Im et al., 2012, Thurlow et al., 2014). (Table 4-4, Fig 4-24) 
 
 
Figure 4-24: Assessing the effect of the severity of amputation on Creatinine µmol/l  
Healthy Control (n=336), CRTI-NA (Injured) (n=186), Bilateral Proximal/Distal CRTI-A (n=57), Bilateral Proximal/Distal 
(n=32), Total Distal CRTI-A (n=44), Total Proximal CRTI-A (n=45). 
Kruskal-Wallis test significance: **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant 
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4.6.5 Resting heart rate  
Resting heart rate was statistically significantly more affected by both the severity of 
amputation and the quantity of amputation compared to HC, 64.51-1min (± 11.34-1min),    
65.73 -1min (± 11.31-1min) and 56.43-1min (± 8.62-1min) respectively; p<0.0001. The effect of 
CRTI-NA on resting heart rate was not significantly affected compared to HC. An increased 
resting heart rate is associated with death and CV complications (Hillis et al., 2012) 
confirming  increased CVD risk associated with an increased level of injury severity. 
(Table 4-4, Fig 4-25) 
 
 
Figure 4-25: Assessing how the severity of amputation affects resting heart rate (/min) 
Healthy Control (n=330), CRTI-NA (Injured) (n=187), Bilateral Proximal/Distal CRTI-A (n=54), Bilateral Proximal/Distal 
(n=33), Total Distal CRTI-A (n=44), Total Proximal CRTI-A (n=43). 
Kruskal-Wallis test significance: **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant 
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4.6.6 SEVR  
Injury severity did not significantly affect SEVR; however, lower values for SEVR were 
recorded in each injury group compared to the control group, with the lowest value in the 
bilateral proximal/distal CRTI-A group. Therefore, the amount of amputations has an effect 
on SEVR. This finding is consistent with previous studies, alluding there is an inverse 
association of SEVR with injury severity and CVD risk as well as other CVD risk markers 
such as Hs-CRP (Sandoo et al., 2012). (Table 4-4, Fig 4-26) 
 
 
 
Figure 4-26: CRTI-A comparison groups vs SEVR  
Healthy Control (n=372), CRTI-NA (Injured) (n=198), Bilateral Proximal/Distal CRTI-A (n=57), Bilateral Proximal/Distal 
(n=33), Total Distal CRTI-A (n=44), Total Proximal CRTI-A (n=45). 
Kruskal-Wallis test significance: **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant
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4.6.7 Stroke volume  
Stroke volume is significantly affected by the level of amputation (proximal) and the quantity 
of amputations (bilateral proximal plus distal) compared to HC; 85.80 ml (± 11.78), 85.12 ml 
(± 11.97) and 95.02 ml (± 13.77), respectively; p<0.0001. These values are consistent with an 
increase in CVD risk due to vascular remodeling and impairment associated with injury 
severity (Lonnebakken et al., 2011). (Table 4-4, Fig 4-27) 
 
Figure 4-27: Assessing the effect of severity of amputation on stroke volume (ml) 
Healthy Control (n=307), CRTI-NA (Injured) (n=167), Bilateral Proximal/Distal CRTI-A (n=54), Bilateral Proximal/Distal 
(n=33), Total Distal CRTI-A (n=42), Total Proximal CRTI-A (n=45). 
Kruskal-Wallis test significance: **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant 
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Table 4-4: Summary of CVD risk variables affected by CRTI-NA and CRTI-A types (NISS subgroups reflect injury severity relating to quantity and severity 
of amputation). 
Groups (Mean ± SD) p 
Variables Healthy control CRTI-NA 
(Injured) 
Unilateral 
proximal/Distal CRTI-A 
Bilateral 
proximal/Distal CRTI-A 
Distal CRTI-A Proximal CRTI-A Kruskal-Wallis p 
HDL mmol/l 1.25 ± 0.27 1.25 ± 0.33 1.11 ± 0.25 1.11 ± 0.32 1.14 ± 0.26 1.08 ± 0.29 <0.0001 
Hs-CRP mg/ml 1.43 ± 1.68 2.00 ± 2.72 1.80 ± 2.28 3.82 ± 4.5  2.05 ± 2.8 2.97 ± 3.81 0.01 
Creatinine 86.78 ± 10.87 84.93 ± 12.19 76.98 ± 10.02 72.88 ± 12.85 78.59 ± 11.12 72.49 ± 10.59 <0.0001 
Resting heart rate min1 56.43 ± 8.621 58.11 ± 10.01 61.39 ± 10.47 65.73 ± 11.31 61.59 ± 10.46 64.51 ± 11.34 <0.0001 
SEVR 206.3 ± 46.44 201.3 ± 45.07 195.1 ± 39.44 187.7 ± 42.49 192.6 ± 40.74 192.3 ± 40.72 0.01 
Stroke volume ml 95.02 ± 13.77 92.7 ± 15.56 89.83 ± 14.99 85.12 ± 11.97 90.45 ± 15.90 85.80 ± 11.78 <0.0001 
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4.7 Correlation studies 
We examined whether there were any correlations between the haemodynamic CVD risk 
markers and the biochemical or anthropometric CVD risk markers "investigated in this study" 
between the control and the CRTI-A groups or whether the risk factors had associations with 
other external factors. The aim was to determine whether amputations could be linked to 
statistically more significant correlations than in the control group.  Spearman correlations 
between the various CVD risk indices in the control (n=394) and CRTI-A (n=105) groups 
were examined and listed in Table 4-5; p, two-tailed.  
 
4.7.1 Arterial stiffness markers and inflammatory markers  
The association of Hs-CRP values between the HC and CRTI-A groups were assessed and 
listed in Table 4-5. 
 
(a) Pulse wave velocity and Hs-CRP. 
There was practically no correlation between PWV and Hs-CRP in the CRTI-A group 
compared to the control group. (Fig 4-28 and Fig 4-29) 
 
 
Figure 4-28: Pulse wave velocity correlation with Hs-CRP (mg/l) in the CRTI-A group  
(r = -0.028, CI -0.23 to 0.18; p = 0.79) 
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Figure 4-29: Pulse wave velocity correlation with Hs-CRP in the control group  
(r = 0.005, CI -0.11 to 0.12; p = 0.93) 
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(b) Central augmentation index and Hs-CRP  
Central augmentation index reveals a weak positive correlation with Hs-CRP in the CRTI-A 
and, the control group, both of which are statistically significant. (Fig 4-30 and Fig 4-31) 
 
 
Figure 4-30: Central augmentation index correlating with Hs-CRP (mg/l) in the CRTI-A 
group (r = 0.23, CI 0.03 to 0.41; p= 0.02; n=105) 
 
 
 
Figure 4-31: Central augmentation index correlating with Hs-CRP (mg/l) in the control group  
(r = 0.20, CI 0.09 to 0.30; p <0.001; n=394) 
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(c) Central augmentation index (AIx) and total cholesterol/HDL ratio  
 
Central augmentation index (AIx) revealed a similar weak positive correlation with total 
cholesterol/HDL ratio in the CRTI-A and control groups, which is statistically significant. 
(Fig 4-32 and Fig 4-33) 
 
 
Figure 4-32: Central augmentation index correlating with Total Cholesterol/HDL Ratio in 
the CRTI-A group (r = 0.21, CI 0.01 to 0.39; p= 0.04) 
 
 
 
Figure 4-33: Central augmentation index correlating with Total Cholesterol/HDL Ratio in the 
control group (r = 0.21, CI 0.10 to 0.30; p <0.001) 
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4.7.2 Haemodynamic characteristics  
(a) SEVR and Resting heart rate (RHR)  
There is an inverse correlation between SEVR and Resting Heart Rate and statistically more 
significant in the control group compared to the CRTI-A group (r = -0.68 and r = -0.60 
respectively); p<0.001. (Table 4-5, Fig 4-34 and Fig 4-35) 
 
 
Figure 4-34: Correlation between SEVR and Resting heart rate in the CRTI-A group  
(r = -0.60, CI -0.72 to -0.46; p<0.001) 
 
 
Figure 4-35: Correlation between SEVR and Resting heart rate in the control group    
(r = -0.68, CI -0.74 to -0.62; p<0.001)
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4.7.3 Arterial stiffness indices and anthropometric CVD risk markers 
(a) AIx and weight-to-height ratio (WHtR) 
There is a positive and statistically significant correlation between peripheral augmentation 
index (AI) and Waist-to-height ratio (WHtR) (Fig4-36) with a stronger correlation revealed 
in the CRTI-A group compared to control (Fig 4-37 and Fig 4-37). 
 
Figure 4-36: Correlation between AIx and WHtR in the CRTI-A group (r= 0.4, CI 0.22 to 
0.56; p<0.001) 
 
 
 
 
Figure 4-37: Correlation between AIx and WHtR in the control group  
(r= 0.34, CI 0.23 to 0.43); p<0.001
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(b) PWV and WHtR 
There is a weak positive correlation between PWV and WHtR in the CRTI-A group, which 
is more positive than in the control group (r = 0.15 and r = -0.007 respectively).  
 
 
 
Figure 4-38: PWV correlation with WHtR (r = 0.15, CI -0.06 to 0.34); p = 0.15 
 
(c) AIx and Conicity Index 
There is a weak positive correlation between AIx and Conicity Index. This correlation is 
statistically significant (p<0.001). (Fig 4-39 and Fig 4-40) 
 
 
Figure 4-39: Correlation between AIx and Conicity Index in the CRTI-A group (r= 0.24, CI 
0.04 to 0.42); p<0.001 
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Figure 4-40: Correlation between AIx and Conicity Index in the control group (r= 0.26, CI 
0.15 to 0.36); p<0.001 
 
4.7.4 Other correlations 
(a) Time elapsed between injury and examination 
There were no significant correlations between the period in time from injury to examination 
and any of the examined parameters. 
 
(b) NISS 
There was a moderate correlation between NISS, weight, time to examination and resting heart 
rate (Fig 4-42).
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Spearman correlation analysis was applied to determine the strength of the relationships 
between the CVD risk factors in relation to the study cohorts. The results were listed in Table 
4-5 and the correlation studies were illustrated in Figure 4-41. 
Table 4-5: Correlation analysis within the groups 
Correlation 
study 
 Control 
xy pairs 394 
CRTI-NA 
xy pairs 200 
CRTI-A 
xy pairs 105 
PWV/Hs-CRP r 0.01 -0.09 -0.03 
 CI (95%) -0.11 to 0.12 -0.25 to 0.07 
 
-0.23 to 0.18 
 
 p 0.93 0.23 0.79 
 Significance ns ns ns 
     
AIx/Hs-CRP r 0.20 0.15 0.23 
 CI (95%) 0.09 to 0.30 
 
-0.0004 to 0.29 
 
0.03 to 0.41 
 
 p <0.001 .04 0.02 
 Significance *** * * 
     
RHR / SEVR r -0.68 -0.73 -0.60 
 CI (95%) -0.74 -0.79 to -0.66 -0.72 to -0.46 
 p <0.001 <0.001 <0.001 
 Significance *** *** *** 
     
WHtR/PWV r -0.007 -0.09 0.15 
 CI (95%) -0.012 to 0.11 -0.25 to 0.07 -0.06 to 0.34 
 p 0.91 0.25 0.15 
 Significance ns ns ns 
     
WHtR / pAI r 0.36 0.42 0.43 
 CI (95%) 0.26 to 0.45 0.29 to 0.54 0.25 to 0.58 
 p <0.001 <0.001 <0.001 
 Significance *** *** *** 
     
WHtR / AIx r 0.34 0.41 0.40 
 CI (95%) 0.23 to 0.43 0.28 to 0.53 0.23 to 0.56 
 p <0.001 <0.001 <0.001 
 Significance *** *** *** 
     
WHtR / 
TC/HDL 
r 0.42 0.40 0.41 
 CI (95%) 0.32 to 0.50 0.26 to 0.52 0.22 to 0.56 
 p <0.001 <0.001 <0.001 
 Significance *** *** *** 
     
WHtR / TG r 0.43 0.33 0.41 
 CI (95%) 0.34 to 0.52 0.19 to 0.46 0.22 to 0.56 
 p <0.001 <0.001 <0.001 
 Significance *** *** *** 
     
WHtR / Hs-
CRP 
r 0.39 0.40 0.52 
 CI (95%) 0.30 to 0.48 0.26 to 0.52 0.36 to 0.66 
 p <0.001 <0.001 <0.001 
 Significance *** *** *** 
     
 
P value summary (significance): **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.1; ns = non-significant 
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Significant correlations between the CVD risk factors are grouped together for comparison 
in the groups (Spearman coefficient “r” is added for comparison) 
   
r = -0.6835 r = -0.7320 r = -0.6044 
   
r = 0.3573 r = 0.4188 r = 0.4315 
   
r = 0.4166 r = 0.3948 r = 0.4050 
   
r = 0.3928 r = 0.3975 r = 0.5218 
 
Figure 4-41: Correlation analysis within groups 
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Figure 4-42: Correlation matrix with Spearman's Rank Correlation Coefficient Rs and Probability (p, two-tailed) Value Calculator
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Chapter 5  
Discussion  
ADVANCE is the first observational prospective study aimed at examining the effects of 
combat related traumatic injuries sustained by military personnel on medium and long-term 
cardiovascular health. A growing amount of evidence suggests that there is a substantial 
reduction in cardiovascular related morbidity and mortality in the general population 
attributed to improved treatment of cardiac risk factors and CVD (Scrinivasan, 2017). The 
aim of this thesis was to analyse the baseline data and specifically assess indices such as PWV 
and augmentation index reflecting on arterial stiffness. We compared a profile of traditional 
CVD risk factors for prediction of cardiovascular risk in a cohort of combat-related 
traumatically injured military personnel of which some have suffered amputations.  Our 
hypotheses are that traumatic limb amputation is associated with a greater burden of 
cardiovascular risk factors than in a frequency matched population of non-injured groups, 
exposed to the same role in the same operational environment at the same time. 
 
During my visits to Headley Court, I had the opportunity to meet some of the injured soldiers 
where they shared experiences with me. I learned how they coped with life after the traumatic 
injuries and how they went about rehabilitation. It helped me create a holistic view of issues 
they face and factors affecting their health and wellbeing. I wanted to learn how CVD risk 
profiles could be affected. 
 
5.1 Haemodynamic indices including augmentation index and  
pulse wave velocity 
5.1.1 Pulse wave velocity (PWV) 
World Health Organisations estimated in 2010 that CVDs are the leading contributions to 
mortality in developed countries and the developing world (Shirwany and Zou, 2010). A 
growing number of studies have demonstrated the association between arterial stiffness and 
stroke (Tuttolomondo et al., 2016, Yoon et al., 2013). As conventional risk factors cannot 
fully account for the pathogenesis, it is essential to detect biomarkers of artery injury for an 
appropriate intervention. We were investigating whether an amputation would alter the 
compliance and distensibility of affected arteries thereby contributing to CVD risk (Shirwany 
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and Zou, 2010). To our knowledge, this is the first study to compare measures of arterial 
stiffness amongst traumatic amputees with frequency matched non-injured military personnel.  
 
As for any hydrodynamic circuit, waves generated by the intermittent function of the heart 
travels down the aorta, arteries, etc. are reflected at reflection sites, generating waves that 
travel back to the heart (Salvi et al., 2008). Under normal circumstances, reflection sites would 
be bifurcations or narrowing of the arteries. The close circuit characteristic of the arterial 
system, the small size of arteries and the fast speed of pressure waves (4-30m/s) causes the 
backward wave to superimpose on the same forward wave (Salvi et al., 2008). As a 
consequence, arterial blood pressure results from the sum of the forward and backward 
pressure waves. Therefore, we expected that an amputated artery would amplify the reflected 
wave more so than a bifurcation or narrowing of the artery diameter. It was further expected 
that a lower limb amputation would affect the distensibility of arteries resulting in a change in 
PWV indicative of a change in arterial stiffness also expressed as augmentation index 
(Mattace-Raso, 2010, Shirwany and Zou, 2010). 
 
The association between stiffening of arteries in the larger central arterial system, such as the 
aortic tree, and CVD is that it significantly contributes to cardiovascular diseases and is 
positively associated with systolic hypertension, coronary artery disease, stroke, heart failure 
and atrial fibrillation (Shirwany and Zou, 2010).  
 
The simplest, most robust, reproducible and non-invasive method of detecting regional arterial 
stiffness is by measuring pulse wave velocity (PWV), also known as pressure wave velocity. 
The fundamental principal of mechanism is that the pressure wave travels faster in a stiffer 
artery (Chen et al., 2017).  
 
In this study there were no statistically significant differences in arterial stiffness as measured 
by PWV (Table 4-1, Fig 4-9) between the three groups. This finding does not support the 
increase in arterial stiffness Malgalhães and colleagues reported when they investigated 
arterial stiffness with male veterans from the Angolan war (n=146) with lower limb 
amputations and compared them with age-matched civilian non-amputees (Magalhaes et al., 
2011). It was anticipated that the CRTI-A group would have higher PWV and hence relatively 
greater arterial stiffness than the CRTI-NA and control groups (Magalhaes et al., 2011, 
Labouret et al., 1983). 
An explanation for the lack of increased PWV following proximal amputation lies in a study 
by Baksi et al who confirmed in a recent study that reflected waves formed at occlusion of an 
artery are dissipated and barely discernible >40cm from the occlusion site in healthy large 
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arteries (Baksi et al., 2016). Our results confirm therefore that traumatic limb amputations are 
not at this early stage associated with an increase in large arterial stiffness as measured by 
PWV. 
 
Our results, contradictory to previous studies, could be attributed to the relatively young age 
33.07 years (± 4.91 years); p=0.20 of the CRTI-A group and relatively recent injuries (6.5-7 
years; time last deployment to examination; (Table 4-1) (Mitchell et al., 2004, Edwards and 
Lang, 2005). Magalhaes et al compared CRTI-A, older subjects than our cohorts, 48.1 years 
(± 6.3 years) with a control where an increase in PWV was recorded with control 9.9 m/sec 
(± 1.8 m/sec) vs CRTI-A 10.8 m/sec (± 1.9 m/sec); p=0.01. 
 
5.1.2 Augmentation Index (AIx) 
 Upon cardiac systole, a forward propagated wave travels down the aorta forming a reflected 
wave when mismatched impedance is encountered (Shirwany and Zou, 2010). The reflected 
wave summates with the forward wave, increasing pulse pressure. This increase in pressure, 
also known as augmented pressure and expressed as augmentation index (AIx) is associated 
with the physical state and the distensibility of the arterial system (Shirwany and Zou, 2010). 
Mitigating arterial stiffness may lower the burden of target organ damage and, in turn, clinical 
CVD (Vasan et al., 2019). 
 
AIx is affected by the magnitude of the reflected wave rather than the velocity (Shirwany and 
Zou, 2010). The vascular structure, function and BP are the major components in arterial 
stiffness. Arterial stiffness is also induced short-term or long-term by inflammation, oxidative 
stress, renin-angiotensin-aldosterone system and genetic factors (Lacolley et al., 2009, Liao et 
al., 2015). Diastolic pressure and the distance from the site of reflection to the heart influences 
the AIx indirectly (Laurent et al., 2006).  
 
An expected resulting increased reflected wave at the point of femoral arterial flow 
interruption lies in the confirmation of the theory linking an increased reflected wave with 
increased augmentation index (Naschitz and Lenger, 2008). The results did however not 
support this theory. There were no statistically significant differences between the peripheral 
and central augmentation indexes between the three groups (Table 4-1, Figures 4-6,7). 
 
An alternative explanation for the lack of variance in AIx between the groups could be 
attributed to the level of fitness of military personnel and the resulting effect on arterial 
stiffness due to the known effect of physical exercise induced availability of nitric oxide (NO). 
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Physical exercise and specifically aerobic training has been noted to be an effective 
intervention in the treatment and prevention of hypertension and CVD due to increased arterial 
stiffness via reduction in oxidative stress of the endothelium and endothelial NO production 
(Korsager Larsen and Matchkov, 2016, Li et al., 2014).  
 
However, Volmar et al observed an asymmetrical flow pattern after leg amputations at the 
aortic bifurcation developing damage to the aorta at a later stage resulting in aneurysms 
(Vollmar et al., 1989). This observation confirms a change in reflected wave flow possibly 
linked to later stage increase in arterial stiffness and needs further investigation at later stages 
following traumatic injuries. 
 
5.1.3 Resting heart rate 
Additional features of increased cardiovascular risk profile included higher resting heart rates 
with CRTI-A significantly higher than control and CRTI-NA; p<0.0001, (Table 4-1, Fig 4-5). 
A resting heart rate of > 65 beats/min has been shown to be a strong independent predictor of 
premature mortality and stroke, but a lesser effect on CVD (Woodward et al., 2014, Hillis et 
al., 2012).  
 
5.1.4 Subendocardial viability ratio (SEVR) 
Parameters characterising SEVR are the systolic pressure-time index (SPTI: reflecting the 
cardiac workload) and the diastolic pressure-time index (DPTI: reflecting the subendocardial 
flow supply).  DTPI:SPTI ratio represents the subendocardial oxygen supply-demand ratio. 
An increase in arterial stiffness generates an increase in ventricular afterload and a reduction 
in oxygen supply to the myocardium, which explains the association between aortic stiffness 
cardiovascular mortality and morbidity (Salvi et al., 2008). 
 
SEVR, (Table 4-1, Fig4-7), an index of myocardial oxygen supply and demand calculated 
through pulse wave analysis and associated with vascular compliance, was significantly lower 
with CRTI-A compared to healthy controls and supports earlier study outcomes (Tsiachris et 
al., 2012, Sandoo et al., 2012). 
 
Although statistically non-significant (possibly due to our sample size), a lower SEVR 
observed with the bilateral distal 181.20 (± 36.27) and bilateral proximal 189.20 (± 44.23) 
CRTI-A groups compared to the control group 206.34 (± 46.44) constitutes a novel finding 
relative to injury severity (Table 4-5, Fig 4-23). SEVR is a new and useful CVD risk marker 
as it is an indirect marker of coronary flow reserve (Tsiachris et al., 2012). Reduced SEVR 
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has been linked to an increased risk of adverse CVD outcomes (Ekart et al., 2016, Tagawa et 
al., 2018). SEVR is potentially an early cardiovascular risk marker as it can be affected by 
even short-term functional changes in coronary microcirculation (Doonan et al., 2011). 
 
Coronary flow reserve and SEVR are reduced by hypertension, poor diastolic function, 
chronic inflammation, increased left ventricular mass, endothelial dysfunction and the 
presence of CVD and its associated risk factors such as diabetes and metabolic syndrome 
(Pirat et al., 2008, Sandoo et al., 2012). 
 
Possible reasons for lower SEVR are supported by our comparative data reflecting on injury 
severity, which include increased HS-CRP levels with Bilateral proximal amputations (Table 
4-5, Fig 4-20) and increased resting heart rate (Table 4-5, Fig 4-22) reflecting on systemic 
inflammation and an increased risk of arterial sheer stress (Sandoo et al., 2012, Tsiachris et 
al., 2012). The statistically significant correlation between SEVR and resting heart rate (r =    
-0.60; p<0.001, Fig 4-34) confirms the significance of SEVR as an early marker for CVD risk. 
 
5.1.5 Brachial and Central BP, pulse pressure 
Brachial Systolic and diastolic pressures did not vary significantly between the groups (Table 
4-1). However, aortic pulse pressure and stroke volume were significantly lower with the 
CRTI-A group compared to the control; p<0.01, (Table 4-1, Fig 4-6). Reduced pulse pressure 
and stroke volume may be associated with poorer heart function, an outcome which is further 
supported by the reported reduced SEVR (Fig 4-7) and related cardiac perfusion in the CRTI-
A group. Aortic pulse pressure is a marginally better predictor of CVD than brachial pulse 
pressure and is associated with multiple adverse cardiovascular outcomes and provides a 
prognostic utility beyond that of mean arterial pressure (Aznaouridis et al., 2016, Selvaraj et 
al., 2016). A raised aortic pulse pressure is normally associated with atherosclerosis and 
increased risk of CVD, however a lower aortic pulse pressure on the other hand is not 
necessarily reassuring and indicative of poor cardiac perfusion, low stroke volume and heart 
failure (Selvaraj et al., 2016).
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5.2 Biochemical indices  
5.2.1 Hs-CRP 
C-reactive protein (CRP) is a non-specific biomarker of inflammation, which is an important 
step in the generation of atherosclerosis and the development of unstable plaque (Wilson et 
al., 2006). Application of high sensitivity assays (Hs-CRP) can demonstrate subclinical 
inflammatory states, which may indicate vascular inflammation. CRP, found in human 
atherosclerotic plaque, has been shown to cause endothelial cell dysfunction, oxidative stress 
and intimal hypertrophy in experimental models (Wilson et al., 2006). Hs-CRP is regarded as 
a non-traditional risk factor which may be included to improve the performance of traditional 
multivariable risk assessments for CVD (Lin et al., 2018). Clinical studies have shown that 
elevated Hs-CRP levels in healthy populations predict vascular events such as myocardial 
infarction (MI), stroke and diabetes development. In patients with acute coronary syndromes, 
higher Hs-CRP levels are associated with adverse outcomes and subsequent vascular events 
(Wilson et al., 2006). In vitro studies suggested an association between CRP, inhibition of 
endothelial nitric oxide synthase and impaired vasoreactivity (Jialal et al., 2009). We would 
therefore investigate if there is a statistically significant association between Hs-CRP and AIx 
in our study cohorts. 
 
A systematic review in 2018 concluded that there were insufficient adequately powered 
clinical trials which evaluated the incremental effect of Hs-CRP in CVD risk assessment to 
initiate preventative therapy (Lin et al., 2018). However, Hs-CRP levels were measured to 
assess the association between Hs-CRP and inflammation linked with traumatic injury and 
amputations. 
 
Hs-CRP levels were significantly higher in the CRTI-A group compared to control (Table 4-
2, Fig 4-14), supporting the concept of elevated Hs-CRP with low grade systemic 
inflammation and greater risk of arterial sheer stress (Park et al., 2019) and independent 
prediction of CV mortality (Li et al., 2017). Elevated Hs-CRP levels associated with the 
severity of injury as found in the comparison proximal vs distal CRTI-A vs the control group 
are consistent with findings by Ejtahed et al observing increased chronic inflammation in the 
bilateral lower limb CRTI-A group (Table 4-5, Fig 4-23) (Ejtahed et al., 2017). 
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5.2.2 The effect of Hs-CRP on NO Synthase 
Hs-CRP has been found to inhibit endothelial nitric oxide synthase (eNOS) activity and 
bioactivity (Jialal et al., 2009). The importance of this clinical implication is that inflammation 
linked to traumatic injury and amputation increases CRP production, which inhibits nitric 
oxide (NO) formation, inducing endothelial dysfunction (Wilson et al., 2006). NO inhibition 
increases arterial stiffness, which increases the risk of hypertension and affects SEVR (Jialal 
et al., 2009). 
 
5.2.3 Creatinine 
An increase in creatine (or decrease in GFR) is associated with reduced kidney function and 
increased CVD risk, even larger than that associated with traditional risk predictors (Smith et 
al., 2003, Fácila et al., 2006). This marker is immediately and readily obtained, and available 
to for example all hospitals, should it be required for a CVD risk profile. However patients 
with amputations have significantly lower serum creatinine values compared to the general 
population (Im et al., 2012). 
 
 A study evaluating the effect and the extent of amputations on creatinine concluded that 
clinicians should interpret creatinine levels for CRTI-A with caution (Thurlow et al., 2014). 
Our findings confirm this conclusion, and it is notable that creatinine levels were lower among 
the CRTI-A (Table 4-2, Fig 4-15; p<0.0001). Serum Cystatin C levels were found to be more 
useful in estimating GFR than serum Creatinine following amputations (Thurlow et al., 2014). 
The falsely lower creatinine is likely explained by less production in creatinine by lower body 
mass in the CRTI-A following limb loss (Im et al., 2012). This is a novel finding that has 
received little attention in the literature, but has been described following polytrauma 
(Minville V, 2011). The mechanisms to explain this observation are uncertain and those cited 
include enhanced urinary creatinine excretion and chronic inflammation (Minville V, 2011). 
Conclusion: Creatinine-based estimators of GFR may overestimate renal function in the 
setting of traumatic amputation (Im et al., 2012). 
 
5.2.4 Total Chol/HDL ratio 
Total Chol/HDL ratio was notably higher (Table 4-2, Fig 4-13; p = 0.01)  with the CRTI-A 
group compared to the CRTI-NA and control groups and HDL cholesterol was significantly 
lower in the CRTI-A group (Table 4-2, Fig 4-12; p<0.0001), adding to the increased  
CVD risk profile. 
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Dyslipidemia is the elevation of cholesterol, triglycerides (TC), or both, or a low HDL 
cholesterol level that contributes to the development of atherosclerosis (Lemieux et al., 2001). 
Dyslipidemias are caused by primary (genetic) or secondary causes such as lifestyle and other 
factors (Goldberg, 2018). The most important secondary causes are a sedentary lifestyle, 
excessive dietary intake of saturated fat, cholesterol and trans fats. Other secondary causes are 
diabetes mellitus, alcohol overuse, chronic kidney disease, hypothyroidism, primary biliary 
cirrhosis and drugs such as thiazides, beta-blockers, retinoids, cyclosporine, etc. 
(Goldberg, 2018). 
 
Patients with hypercholesterolaemia have a higher central pulse pressure and stiffer blood 
vessels than matched controls, despite similar peripheral blood pressures (Wilkinson and 
Cockcroft, 2007). These haemodynamic changes may contribute to the increased risk of 
cardiovascular disease associated with hypercholesterolaemia (Wilkinson and Cockcroft, 
2007). Dyslipidemia itself usually causes no symptoms but can lead to symptomatic vascular 
disease, including coronary artery disease, stroke, and peripheral arterial disease (Goldberg, 
2018). The total cholesterol value is divided by the HDL number to determine the ratio. 
According to the Framingham Heart Study, a cholesterol ratio of 5 indicates an average risk 
of heart disease for men with risk doubled when the ratio reaches 9.6 or the risk is halved with 
a ratio of 3.4 (Lemieux et al., 2001). This study concluded that a variation in the TC/HDL 
ratio may be more associated with a predictive ischemic heart disease risk due to substantial 
alterations in metabolic indices and insulin resistance than a variation in the LDL/HDL ratio 
(Lemieux et al., 2001). 
 
Another systematic review challenged the validity of the hypothesis that cholesterol is 
atherogenic and found that elderly patients with high LDL cholesterol live as long or longer 
than those with low LDL cholesterol (Ravnskov et al., 2016). This finding challenges the use 
of lipid profiles as a CVD risk indicator. In our study there was no statistically significant 
difference in the LDL values between the three groups.  
 
5.2.5 Glycaemic index 
Markers of insulin resistance are waist circumference and fasting insulin levels. Increased 
basal insulin resistance beyond a threshold, strongly predicts adverse cardiac events at 1 year 
in type 2 diabetes mellitus (Scrinivasan, 2017). Those below the threshold, seems to be at 
similar risk to non-diabetics (Scrinivasan, 2017). Glucose (p=0.54) and HbA1C (p=0.06) 
values were not statistically different between all the groups (Table 4-2). Insulin levels were 
not measured in this study due to practical implications at times of data gathering.  It has to 
be noted for future consideration that increased insulin resistance is strongly related to chronic 
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vascular inflammation (Vlachopoulos et al., 2010, Dregan, 2018) and has been described as 
an important aetiological factor explaining the increased CVD risk found with lower limb 
CRTI-A (Peles et al., 1995, Rose et al., 1986, Naschitz and Lenger, 2008). Peles et al observed 
higher mean fasting plasma insulin levels during an oral glucose tolerance test with traumatic 
amputees (n=53) compared with matched controls (n=53), while body mass index, blood 
pressure and lipid profiles were similar (Peles et al., 1995). Rose et al observed increased 
insulin levels and blood pressure among above knee CRTI-A (n=9) versus below-elbow 
normotensive (n=12) CRTI-A (Rose et al., 1987).  
 
5.3 Anthropometric indices affecting the CVD risk profile 
 Obesity 
Obesity is among the leading causes of elevated cardiovascular disease (CVD) mortality and 
morbidity (Akil and Ahmad, 2011, Motamed et al., 2015).  
 
5.3.1 Visceral fat 
The results of this study showed that an increase in visceral fat, as measured by weight, waist 
circumference, WHtR, BMI and conicity index, was significantly associated with the  
CRTI-A group compared to control.  
 
5.3.2 Weight increase 
The significant association of weight increase with amputation underpins the suggestion that 
CRTI-A has an impact on the CVD risk profile. 
 
Weight gain, represented by WHtR, correlates significantly with aortic systolic and diastolic 
BP, triglycerides, lipid profile, Hs-CRP, AI, resting heart rate and SEVR (Table 4-5) 
confirming the importance of visceral fat in the development of CVD risk factors. BMI is not 
appropriate to be applied in this context of CVD risk as weight is reduced due to limb loss and 
the calculation is not corrected as such. The healthy physical nature of most of the participants 
with increased muscle weight adds to the inappropriateness of applying BMI in our 
observations.  
 
Visceral fat is related to arterial stiffness independent of traditional risk factors and indicative 
of cardiovascular risk (Corrigan et al., 2017, Shahriar et al., 2009).  There was a statistically 
strong significant difference in Conicity Index (CI) between the CRTI-A group in comparison 
to the healthy control and CRTI-NA groups (P<0.0001, Table 4-3). Waist circumference 
119 
(P=0.01, Table 4-3) and WHtR (p=0.03, Table 4-3) were significantly different but not 
statistically as strong as CI. However, in correlation studies, WHtR demonstrated stronger 
correlations than CI with CVD risk indices. These findings are consistent with the literature 
with risk factors including hyperglycaemia 13.1%, systolic hypertension 18.9%, diastolic 
hypertension 25.6%, abdominal obesity 82.5%, high total cholesterol 36.7%, low HDL 25.9%, 
high LDL 24.7%, high triglycerides 32.1%, and smoking 31.8%. The most common risk factor 
was abdominal obesity (Shahriar et al., 2009). However, Shariar and colleagues conducted 
their research 22.3years (± 3.9 years) after amputation while the study by Rose et al made 
their observations 14-15 years after amputation compared to the seven years for our study 
cohorts (Shahriar et al., 2009, Rose et al., 1987). Development of metabolic syndrome as CVD 
risk, which includes lipid profile, was observed by Ejtahed et al 31.5 years after amputation 
(Ejtahed et al., 2017). Relatively early observation of the development of CVD risk factors in 
our study cohorts confirms the findings of the presence of these risk factors in earlier studies. 
 
5.4 The importance of injury severity on the CVD risk profile  
The New Injury Severity Score (NISS) (Osler et al., 1997) as provided by the UK Joint Theatre 
Trauma Registry (JTTR) reflects a statistically significant greater value for the CRTI-A group 
36.75 (± 18.01) in comparison to the CRTI-NA (CRTI-NA) group 20.11 (± 17.99); p<0.0001 
(Smith et al., 2007), (Table 4-3, Fig 4-21). 
 
The proximal lower limb CRTI-A group consistently demonstrated an increased 
cardiovascular risk profile in comparison to the distal CRTI-A (bilateral more so than 
unilateral), the CRTI-NA and the healthy control group, thereby revealing a consistent 
correlation between increased subclinical risk profiles and level of injury severity. (Table 4-
5, Fig 4-22 to 4-27). This finding is consistent with literature reporting that each 5-point 
increase in NISS was associated with a 6% increase in the incidence of hypertension, 13% 
increase in coronary artery disease, 13% increase in diabetes mellitus and 15% increase in 
chronic kidney disease (Stewart et al., 2015). Table 4-5 lists the significant differences 
between the level of amputation (injury severity) and the healthy control group. HDL 
cholesterol (Fig 4-22) had significantly lower values for proximal amputations compared to 
the control group (p<0.01). Hs-CRP values (Fig 4-23) were weakly significantly higher in the 
bilateral proximal CRTI-A group compared to the control group (p<0.1) indicating increased 
inflammation. Creatinine values (Fig 4-24) were strongly significantly lower in the proximal 
CRTI-A groups compared to the control group, consistent with the loss of muscle mass 
(P<0.0001). Resting heart rate (Fig 4-25) was significantly higher in the bilateral proximal 
group, consistent with the increase premature mortality and stroke risk (p<0.001) (Woodward 
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et al., 2014). SEVR values (Fig 4-26) were lower but not statistically significant compared to 
the control group (ns). Stroke volume values (Fig 4-27) were significantly lower in the distal 
and proximal CRTI-A groups compared to control (p<0.01). These results confirm the 
increased CVD risk associated with severity of injury and particularly in the case of proximal 
amputations. 
 
5.5 Correlation studies 
We applied Spearman analysis (p, two tailed) to analyse associations between the CVD risk 
parameters (Correlation matrix: Fig 4-42) The most significant correlations were illustrated in 
Fig 4-41. 
 
The statistically most significant correlations involved SEVR and waist-to-height ratio. 
 
We expected PWV to have a significant relationship with Hs-CRP due to the NO inhibiting 
role of CRP. There was however no significant association between Hs-CRP and PWV in the 
CRTI-A. 
 
Augmentation index (AIx) showed a weak positive correlation with Hs-CRP in the CRTI-A 
group more so than the control group. This finding confirms the NO inhibitive effect of CRP 
and confirms that AIx is a more sensitive parameter than PWV as CVD risk indicator as far 
as arterial stiffness is concerned. 
 
AIx showed a weak positive correlation with TC/HDL ratio in the CRTI-A group. There was 
however no difference in correlation compared with the control group. The increase in CVD 
risk associated with TC/HDL ratio correlates with the increase in CVD risk associated with 
AIx, however the correlation in the CRTI-A group was not more significant than in the  
control group. 
 
The linear association between SEVR and resting heart rate showed the strongest, albeit 
negative significant relationship in the CRTI-A group compared to the control group. This 
finding confirms the increased levels of CVD risk as reflected by both SEVR and resting heart 
rate respectively measured in the CRTI-A group and compared with the control group. 
 
Obesity or increase in visceral fat showed the strongest correlation with haemodynamic CVD 
risk markers relating to arterial stiffness. Of the anthropometric risk markers, we have 
reviewed, WHtR had the strongest correlations with other CVD risk markers. WHtR had a 
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non-significant relationship with PWV although the correlation was marginally stronger in the 
CRTI-A group compared to the control group. There is a stronger positive correlation between 
WHtR and AIx in the CRTI-A group compared to the control group. Conicity Index showed 
a weaker correlation with AIx in the CRTI-A group compared to the control group.  
 
WHtR had a positive correlation with lipid profiles, however there were no statistically 
significant differences between the three groups for correlations with TC/HDL ratio and TG 
(Table 4-5). 
 
WHtR and Hs-CRP had a positive correlation with the stronger correlation observed in the 
CRTI-A group compared to the control group (r = 0.52 and r = 0.43; p<0.001), (Table 4-5 
respectively). This finding confirms the increased risk due to vascular inflammation found 
with obesity. 
 
5.6 Confounding factors affecting CVD risk profile  
The time period for traumatic injury or deployment to examination is longer for the controls 
than for CRTI-A and CRTI-NA groups, which could indicate potential bias in recruitment. It 
could be argued that the unequal time periods are allowing for unequal development of CVD 
risk factors. However, we are evaluating CVD risk factors developing over the previous seven-
year period and not clinical outcomes, which will be examined during the ongoing 
longitudinal ADVANCE Study. We cannot therefore determine or predict whether the CVD 
risk factors will develop further or be maintained over time. Given the seven-year period we 
would have anticipated development of general CVD risk factors as determined in the 
systematic review of publications. 
 
The majority of the control group is exposed to different circumstances than most of the CRTI-
NA and CRTI-A groups. A total of 90% of the healthy control cohort were still serving and 
therefore exposed to physical military exercise and organized military life compared to 36% 
of the CRTI-NA cohort and 12% of the CRTI-A cohort still being enlisted. A regular fitness 
regime while serving in the military promotes endothelial functionality and nitric oxide (NO) 
promotion during variable pace or aerobic training. On the other hand, CRTI-NA personnel 
and CRTI-A who have been discharged into the NHS and civilian life, do not receive the same 
benefits of physical training and organized military support. Endothelial dysfunction and lack 
of NO due to physical inactivity does have an adverse effect on the correlation between 
oxidative stress and hypertension (Korsager Larsen and Matchkov, 2016).  
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The negative effects of sustained physical training in the healthy control group, has also been 
noted, which could affect results comparing healthy controls with the CRTI-NA or CRTI-A 
groups. Intense aerobic exercise can also injure the endothelial muscles resulting in collagen 
formation in the endothelium (with calcification as a result) due to mechanical strain on the 
muscles in the arterial walls, which causes stiffening of the arteries (Korsager Larsen and 
Matchkov, 2016). This stiffening of the arterial walls increases systolic blood pressure and is 
reflected in increased augmentation index and pulse wave velocity. This increase in CVD risk 
factors are then recorded for the healthy control group and might mask the milder increase in 
arterial stiffness recorded in the CRTI-NA or CRTI-A groups leading to an insignificant false 
statistical result.  The exercise patterns post injury should therefore be analysed to rule out the 
confounding effects of excess exercise on vascular health and ultimately on CVD risk, which 
could as a matter of fact be prevalent in all the groups. Consideration for factors contributing 
to the production of NO as an endogenous vasodilator and inhibitor of vascular smooth muscle 
contraction should be applied in evaluating arterial stiffness (Zhou et al., 2004).  
 
5.7 Strengths and limitations 
Our considerable sample size, which by far exceeds previous cross-sectional study cohorts, 
underpins findings of previous cardiovascular risk assessments amongst CRTI-A (Rose et al., 
1987, Vollmar et al., 1989, Yekutiel et al., 1989). A sample size of at least 100 in each of the 
subgroups would have more than 80% power to detect a 3% difference in the central AIx and 
a 1.2 mg/l difference in Hs-CRP levels at a significance level of 0.05 (two-tailed). 
 
Further characteristics lending gravitas to the study are the frequency matching of the groups 
by age, height, operational exposure and time of deployment. The NISS reference data 
confirms the severity of injuries sustained by recruited participants in the subgroups (Osler et 
al., 1997).  
 
There are limitations to the study.  
Significant variation in time from injury to examination (Fig 4-2) could suggest potential 
recruitment bias. The impact of psychological factors such as PTSD has not been considered 
in this study and will be subject to future examinations. 
 
The Vicorder measures regional pulse wave velocity, which is affected by protocols 
determining the distance between the test points as well as by obesity. Patients are required to 
stay in the supine position, which could have limitations due to injuries or amputations. The 
accuracy of the measurement of the distance from the carotid to the femoral artery is 
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questionable especially in patients with abdominal obesity (Van Bortel et al., 2002, Laurent 
et al., 2006). The large heterogeneity of arterial structure at different sites, constitutes further 
limitations (Pereira et al., 2015). 
 
The healthy controls were more likely to be still serving and serving military personnel are 
more likely to conform to structured health and fitness regimes, meals and medical care than 
discharged personnel (CRTI-NA and CRTI-A) caring for themselves. 
 
This study did not examine the level of rehabilitation achieved post amputation. Compromised 
mobility could lead to early deposit of visceral fat, elevating the CVD risk profile. Physical 
activity associated with an increase in heart rate correlates with nitric oxide (NO) formation 
in the endothelium. NO antagonises the effect of angiotensin II on vascular tone increasing 
the CVD risk profile (Zhou et al., 2004, Bataineh and Raij, 1998, Hasegawa et al., 2019).  
 
The presence and level of infection after amputations, which has an effect on CVD, (Khademi 
et al., 2019), was not recorded in this study although participants with active disease were 
excluded. Atherosclerosis the underlying cause of CVD and stroke, is an inflammatory (low 
grade) disease with pathobiological mechanisms, which are common to the host’s responses 
to many chronic infectious diseases (Fong, 2009).  With 34% US casualties developing 
infection after amputation, the impact on the development of CVD could be considerable 
(Weintrob et al., 2018). 
 
Further limitations of this study are the absence of PTSD, exercise and activity data, which 
could assist the understanding of mechanisms affecting higher visceral fat levels and the 
adverse lipid and inflammatory profile. 
 
 
.
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5.8 Future directions 
Early stages after amputation in this study did not reveal significant increases in arterial 
stiffness and resulting changes in pulse wave velocity, which could lead to discounting 
vascular damage following amputations due to lack of presence of changes in 
haemodynamics. 
 
Therefore, further studies should consider investigation at later stages after traumatic injuries.  
 
Volmar et al observed an asymmetrical flow pattern after leg amputations at the aortic 
bifurcation developing damage to the aorta at a later stage resulting in aneurysms (Vollmar et 
al., 1989). This observation confirms a change in reflected wave flow possibly linked to a later 
stage increase in arterial stiffness.  
 
Regional determination of PWV, as conducted in this study, could lead to discrepancies due 
to inaccuracy of measuring the distance between the suprasternal notch and the cuff on the 
thigh. Inaccuracies could be because of an increased waistline, operator error or bias or error 
between different operators. The distance is only measured once and applied for three 
measurements of PWV. A local PWV measuring technique is currently under development, 
which should be preferential for an early and precise assessment of arterial distensibility 
(Pereira, 2015).  
 
The finding of this study confirms suggestions that AIx might be a more accurate determinant 
of arterial stiffness and CVD risk marker than PWV (Aminuddin et al., 2014). 
 
The level of physical exercise capabilities after rehabilitation, might have an impact on general 
fitness thereby affecting arterial stiffness and abdominal fat deposits, which affects CVD risk 
as found in this study. Quantification of physical capabilities was measured by means of 
distance walked in a certain time, which measures ability but not necessarily fitness level for 
comparison. A more appropriate Cardiorespiratory Fitness Test (CRF) such as the Chester 
Step Test, which lasts for a maximum duration of 10min and requires an individual to step 
(height is pre-determined by age and physical activity levels) to a metronomic beat. The 
protocol consists of five stages, each lasting for 2min which increases in speed cumulatively. 
CRF is calculated by heart rate responses at the end of each stage (Gray et al., 2017).   
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Future studies need to undertake the daunting task of assessing, evaluating and proving 
causality between infection after traumatic injuries and amputations with ischaemic heart 
disease and stroke (Fong, 2009, Weintrob et al., 2018). 
 
The greater prognostic value of non-invasive assessment of central aortic blood pressure as 
opposed to peripheral blood pressure in the early detection of CVD should be considered in 
future studies (Zuo et al., 2018, Cziraki et al., 2018, Ryuzaki et al., 2017, Sharman and 
Laurent, 2013). 
 
5.9 Conclusion 
Analysis of the baseline data confirmed that military servicemen who have experienced 
serious battlefield related traumatic amputations, demonstrate a more adverse cardiovascular 
risk profile than that of less and non-injured servicemen exposed to the same operational 
environment at the same time. Our major novel findings were that pulse wave velocity, a 
measure of arterial stiffness, was not significantly affected by combat-related traumatic 
injuries and amputations. Our findings confirm results from previous publications that AIx 
may be a better marker to reflect arterial stiffness and CVD risk in young men than PWV 
(Aminuddin et al., 2014). 
 
Based on the results of this study and the review of existing literature, it became clear that 
clinicians caring for combat-related amputees should use easy to apply indices and non-
invasive technology to monitor closely for early onset of obesity, increase in augmentation 
index and hypertension development as prominent risk factors for CVD.  
  
The majority of the risk factors highlighted by this study are modifiable such as resting heart 
rate, abdominal waist and hip circumference and lipid profile by means of lifestyle changes, 
supporting the aim of the ADVANCE Study to identify risk factors that could be addressed 
and mitigated early to prevent progression of subclinical CVD. The importance of the findings 
in this study will be quantified during the progression of the ADVANCE study as hard clinical 
endpoints emerge. 
 
Based on the findings of this study, we hypothesise that if a future increase in arterial stiffness 
and blood pressure is found, it would relate to the composite effects of chronic vascular 
inflammation with probable causes such as increased insulin resistance due to an increase in 
abdominal circumference rather than due to haemodynamic effects of the amputation per se 
on arterial wave reflection. 
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please provide details: 
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8. PURPOSE OF THE STUDY 
1. Background 
The Defence Medical Services (DMS) are in a unique period in their history. For 
the first time in generations the UK is, and has been, sustaining significant numbers 
of battlefield casualties, from the conflicts in Afghanistan and previously in Iraq. 
Many of these casualties have such severe complex injuries that previously they 
would not have survived. If it were not for the world leading, cutting edge 
battlefield trauma care provided by the UK DMS in operational theatre these 
patients would still not be surviving. Rehabilitation of these casualties takes place 
at DMRC Headley Court often over many months. DMRC Headley Court is 
therefore ideally placed to investigate the long-term outcomes of this cohort of 
severely injured UK armed forces battlefield casualties, a critical piece of research 
that it is essential to complete.  
The long-term study of these patients needs to be undertaken to ascertain many 
aspects of their health and psychosocial outcomes and so the DMS can learn for 
future conflicts. Previous studies into war veterans have been completed from 
conflicts such as Vietnam and World War II and have investigated long-term health 
outcomes but some have been inconclusive, others have focused just on Post 
Traumatic Stress Disorder (PTSD) patients and most have been retrospective cross-
sectional studies rather than the more methodologically robust longitudinal cohort 
studies (Boscarino, 2006; Bramsen et al., 2007; Kunnas et al., 2011; Modan et al., 
1998; Kang & Bullman, 2001; Watanabe & Kang, 1996; Fett, et al., 1987a; Fett, 
1987b; Macfarlane et al., 2000).   None of the previous studies have been in as 
severely injured a cohort as the UK DMS are faced with at present. Other studies 
into long term health related outcomes such as bone health, including osteoarthritis 
and osteopenia/osteoporosis and fracture, all cause mortality and long term 
vocational and quality of life outcome are limited and insufficient (Watanabe & 
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Kang, 1996; Dutta et al., 2008; Fett et al., 1987a; Fett et al., 1987b; Johnson et al., 
2010; Kang & Bullman, 2001; Kulkarni, et al., 1998; Macfarlane et al., 2000; 
Shahriar et al., 2009; Sherk et al., 2008; Vollmar et al., 1989) and generally not 
transferable to our current uniquely severely injured population of casualties.  
 
There have been some studies investigating cardiovascular disease (CVD) in war 
veterans (Kunnas et al.; 2011; Modan et al.; 1998; Boehmer et al.; 2004). In a 
recent retrospective study of 667 war veterans followed up for 28 years from 1980, 
outcome data was available for the 102/667 who had been injured or wounded in 
action (Kunnas et al., 2011). Amongst the men who had been injured in action the 
risk of coronary artery disease (CAD) related death was increased 1.7 fold (28.4% 
vs 19.6% at 28 years) and there was also a significant increased risk of depression. 
However, data on baseline risk factors and population age at inclusion were not 
defined, nor were the relative prevalence of other CVD related events (eg. stroke, 
peripheral vascular disease). Furthermore, there was no available data on the types 
of injury sustained in order to allow a meaningful translation to our current UK 
military battlefield casualties. In another longitudinal study Modan et al (1998) 
evaluated the 24-year mortality rates of male traumatic lower limb amputees (n = 
201) of the Israeli army wounded between 1948 and 1974, compared with a sample 
representing the general population (n = 1,832). They noted that CVD was twofold 
higher in amputees than in controls and that crude mortality rates were significantly 
higher (21.9% vs 12.1%, p <0.001) in amputees than in controls due mainly to 
increased CVD-related mortality (8.9% vs 3.8%, p <0.001). However, the 
mechanism for this increase was poorly defined as only selected risk factors for 
CVD were available on the 101 surviving amputees (aged 50 to 65 years) and a 
sample of the controls (n = 96) matched by age and ethnic origin. This limited data 
suggests that the increased mortality may be explained by an increased risk of CVD 
risk factors among the trauma victims. However, this cohort is >24 years from 
injury, the defined risk factors were limited and only available for the survivors and 
not for those who subsequently died. Furthermore the time from injury to 
population sampling is not defined making any applicability extremely difficult.   
Consequently, there is the need for a prospective longitudinal cohort study to more 
accurately determine the changes in CVD risk factors and other health related 
quality of life (QoL) components and their effects on clinical outcomes including 
CVD-related endpoints. 
 
In addition to trauma care, physical rehabilitation and assessment and prevention of 
medical comorbidities, health care challenges for this patient group include 
minimizing the impact of amputation or other severe injury on work, social 
function and mental health, quality of life and well-being. On top of the physical 
trauma, this patient group is faced with social and psychological challenges; 
including high rates of depression and anxiety disorders including, post-traumatic 
stress disorder (PTSD), body-image anxiety and reduced social functioning, social 
discomfort and negative sense of self and identity (Melcer et al., 2010; Melcer et 
al., 2012; Sandweiss et al., 2011). This is an area of research where work has been 
limited and the majority of the literature is from general population samples 
(Horgan & MacLachlan., 2004). 
Our collaborators at Kings College Mental Health Research (KCMHR) have great 
experience in military mental health studies and are the leading civilian UK centre 
of excellence for military health research. KCMHR carries out interdisciplinary 
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research and combines professionals with a wide variety of backgrounds 
(epidemiology, psychiatry, psychology, public health and sociology). Since its 
inception in 1996, KCMHR has conducted several large cohort studies of UK 
military personnel (Fear et al., 2010; Hotopf et al., 2006; Mulligan et al., 2012; 
Rona et al., 2006; Unwin et al., 1999) and the experience of the KCMHR team will 
be essential in this broader and longer medico psychosocial cohort study. 
 
Therefore, although some research has been performed into medical outcomes of 
war veterans the conclusions are generally drawn from less than ideal 
methodologically designed studies and are not transferable to our current unique 
population. The long-term outcomes of our casualties are therefore unknown and 
they are vital to investigate, as these casualties must not be forgotten. Unless a 
comprehensive and rigorous longitudinal cohort study is established the long-term 
outcome of these patients will be unknown as they are discharged out of the Armed 
Forces to different regions of the country and the NHS.  
 
 
 
2. Study Objectives 
To investigate the long-term cardiovascular, musculoskeletal and other health and 
psychosocial related outcomes of UK armed services physical battlefield trauma 
patients.  
 
3. Study Hypotheses 
Long-term outcomes of physical battlefield trauma casualties, in comparison to the 
“non exposed” group, will demonstrate: 
 
• Increased risk of cardiovascular disease 
• Increased cardiovascular disease related events  
• Increased rates of osteoarthritis 
• Different mental health outcomes 
• Different long term quality of life outcomes 
• Different occupational outcomes 
 
9. STUDY DESIGN, METHODOLOGY AND DATA ANALYSIS 
1. Study Design 
 
Cohort study with the exposure being physical battlefield trauma. 
 
Group 1:“Exposed Group”: n = 600 battlefield trauma casualties 
 
Group 2: “Non-Exposed Group”: n = 600  
Frequency matched for age, sex, service, rank, deployment and combat role. 
 
2. Outcomes 
 
Primary Outcomes 
a. Cardiovascular risk- as determined by pulse wave velocity at 20 years. 
b. Major Adverse Cardiovascular Endpoint (MACE) - Composite 
Cardiovascular Disease (CVD) endpoint of cardiovascular death, non fatal 
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myocardial infarction, stroke, transient ischaemic attack (TIA), arterial 
revascularisation (coronary artery bypass grafting, percutaneous coronary 
intervention, carotid endarterectomy or stenting and peripheral arterial stenting or 
bypass) at 20yrs. 
c. Osteoarthritis of the hip and knee- as determined by patient reported outcomes 
and radiographic assessment at 20yrs. 
 
Secondary Outcomes 
a. Cardiovascular risk as determined by pulse wave velocity, augmentation index 
and central blood pressure 
b. Cardiovascular risk as determined by more traditional cardiovascular risk factors 
(eg. blood pressure and diagnosis of hypertension, lipid profile, blood 
glucose/Diabetes mellitus, smoking history, HsCRP and abdominal waist 
circumference) 
c. Cardiovascular disease as determined by individual components of the primary 
composite CVD score and peripheral vascular disease and other CAD (angina). 
d. Musculoskeletal disease (osteoarthritis and osteoporosis), 
e. All cause mortality 
f. Pain - back and stump/phantom (if applicable) 
g. Mental health 
h. Functional status  
i. Quality of life 
j. Employment 
k. Relationship status and sexual function at : 
I. “Baseline” 
II. 3yrs 
III. 5yrs 
IV. 10yrs  
V. 15yrs 
VI. 20yrs 
 
3. Trial Subject Selection 
 
Eligibility Criteria : Group 1 : Exposed Group 
 
Inclusion Criteria 
a. UK Armed services personnel 
b. Male  
c. Sustaining physical battlefield trauma, while on deployment, requiring 
aeromedical evacuation and direct UK hospital admission          
d. Injured during 2003 or after. 
  
Exclusion Criteria 
a. Females 
b. Patients who are unwilling or unable to give informed consent 
c. Patients with established CVD (previous stroke or transient ischaemic attack 
[TIA], ischaemic heart disease [IHD], peripheral vascular disease) 
d. Past medical history of Diabetes   
e. Past medical history of renal or liver disease 
f. Aged <18 and >50 years 
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g. Active acute infection with systemic features of sepsis, at the time of recruitment, 
as defined below. Potential participant with active acute infection will be 
considered for recruitment once the acute illness is treated and resolved. 
 
(American College of Chest Physicians/Society of Critical Care Medicine 
Consensus Conference: definitions for sepsis and organ failure and guidelines for 
the use of innovative therapies in sepsis. 1992): 
2 of 3 of: 
i. Temperature >38ºC or <36ºC 
ii. Heart rate>90beats/min 
iii. Respiratory rate >20 breaths/min 
 
Eligibility Criteria : Group 2 : Non-Exposed Group 
Frequency matched for age, sex, service, rank, deployment and combat role. 
 
Inclusion Criteria 
a. UK Armed services personnel 
b. Male 
c. Previously deployed. 
d. No battlefield trauma, as defined in the inclusion criteria. 
 
 
Exclusion Criteria 
h. Females 
i. Patients who are unwilling or unable to give informed consent 
j. Patients with established CVD (previous stroke or transient ischaemic attack 
[TIA], ischaemic heart disease [IHD], peripheral vascular disease) 
k. Past medical history of Diabetes   
l. Past medical history of renal or liver disease 
m. Aged <18 years and >50 years 
n. Active acute infection with systemic features of sepsis, at the time of recruitment, 
as defined below. Potential participant with active acute infection will be 
considered for recruitment once the acute illness is treated and resolved. 
 
(American College of Chest Physicians/Society of Critical Care Medicine 
Consensus Conference: definitions for sepsis and organ failure and guidelines for 
the use of innovative therapies in sepsis. 1992) : 
2 of 3 of : 
i. Temperature >38ºC or <36ºC 
ii. Heart rate>90beats/min 
iii. Respiratory rate >20 breaths/min 
 
4. Recruitment, Consent and Randomisation Processes 
  
Recruitment  
Both battlefield trauma exposed volunteers and non-exposed volunteers will be 
recruited. Potential battlefield trauma exposed participants and matched non-exposed 
controls will be identified through Defence Statistics using the following data 
sources: Initial NOTICAS, Defence Patient Tracking System, DMICP, DMRC 
Complex Trauma Database, DRMC Prosthetic database, the Joint Theatre Trauma 
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Registry and Joint Personnel Administration (JPA) (including move and track), as per 
the inclusion and exclusion criteria as detailed above. These potential participant 
details will then be transferred to the King’s Centre for Military Health Research 
(KCMHR) at King’s College London and stored on a secure database. Potential 
participants will then be approached by a member of the research team. Those 
potential participants still in the services will be contacted via their military contact 
details recorded on JPA or through their GP. Those potential participants who have 
left the services will be contacted either via their final contact details on leaving the 
armed forces or via their NHS number and NHS GP (NHS REC will be applied for) 
or through other common forms of communication such as social media.  A verbal 
explanation of the trial and patient information sheet will be provided by the 
authorised trial clinician for the participant to consider. This will include detailed 
information about the rationale, design and personal implications of the study and 
include a participant invitation form; participant information sheet and participant 
consent form (Appendix A-C). Following information provision, participants will 
have at least 24 hours to consider participation and will be given the opportunity to 
discuss the trial with their family and healthcare professionals before they are asked 
whether they would be willing to take part in the trial. This process will be clearly 
documented into the participant’s medical notes. 
 
Non-exposed volunteers will be recruited from the same military units as the 
battlefield exposed volunteers. Non-exposed volunteers will be approached via letter, 
e-mail, telephone or social media. Once matched non-exposed volunteers are 
identified the same recruitment proceeds will be followed as for the patients 
mentioned above.  
 
Consent 
Assenting participants will then be formally assessed for eligibility and invited to 
provide informed, written consent. The right of the participant to refuse consent 
without giving reasons will be respected. Further, the participant will remain free to 
withdraw from the study at any time without giving reasons and without prejudicing 
any further treatment. A copy of the consent will be given to the participant, one filed 
in the Trial Master File, one filed in the hospital.  The written consent will be taken 
by an authorized clinician.   
 
Randomisation 
Not applicable 
  
Un-Blinding 
Not applicable  
 
5. Study Outcomes 
 
Cardiovascular Risk 
 
Large artery stiffness and pulse wave analysis 
Cardiovascular disease is the leading cause of mortality in the western world (Yach et 
al., 2004). Consequently, there is growing interest in improved methods to accurately 
predict future cardiovascular risk. Hence, there has been a drive toward the use of a 
“global risk assessment” summating the effects of individual risk factors on CVD risk 
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assessment, rather than relying solely on individual conventional cardiovascular risk 
factors, such as diabetes mellitus (DM), hypertension, elevated cholesterol, and 
smoking (Boos et al., 2007). 
 
Large artery stiffness leads to increased pulse wave velocity (PWV) and accelerated 
wave reflections and causes an increase in myocardial demand and central systolic 
pressure along with a decrease in coronary artery perfusion pressure. This increase in 
pulse wave velocity as a result of increased arterial stiffness is associated with many 
of the common cardiovascular risk factors such as age, high blood pressure, smoking, 
cholesterol levels and obesity, and these lead to a dramatic increase in risk of heart 
attack, stroke and heart failure (London et al., 2004) 
 
Importantly increased pulse wave velocity has also been shown to be an independent 
predictor of cardiovascular morbidity and mortality in several population groups, 
including healthy controls (Shechter et al., 2009; Sutton-Tyrrell et al., 2005; London 
et al., 2001; Cruickshank et al., 2002; Laurent et al., 2001; Weber et al., 2004) 
 
The Vicorder (Skidmore Medical Limited, Bristol, United Kingdom) simultaneously 
records the pulse wave from the carotid and femoral site by using the oscillometric 
method. It has been well validated against the gold standard measures of arterial 
stiffness (van Leeuwen-Segarceanu et al., 2010). It non-invasively analyses central 
systolic blood presure, pulse wave velocity and the augmentation index (AI) (non 
invasive measure of arterial stiffness utilising aspects of the pulse wave reflections 
which may be influenced by traumatic injury) in one integrated system over five 
minutes using an upper thigh cuff and a neck transducer (Pucci et al., 2013). Its 
simulataneous assessment of the carotid and femoral pulse wave generates excellent 
reproducibility with a within-subject coefficient of variation 2.8% (Hickson et al., 
2009).  By utilizing central and peripheral measurements of arterial stiffness this 
allows for accurate quantification of CVD risk (Woodman et al., 2005). Hence this 
system can still be used in a multiple limb amputee. 
 
Heart Rate Variability (HRV) 
HRV refers to the temporal changes in the beat to beat internals in the heart, which 
are subject to continuous autonomic nervous system and competing sympathetic 
versus parasympathetic control. HRV is a marker for altered autonomic balance has 
been linked to adverse clinical conditions such as cardiac death, stroke and ill mental 
health (Cardoso et al., 2014; Fyfe-Johnson et al., 2016; Kemp et al., 2012; Kemp et 
al., 2013;  Sessa et al., 2018; Thayer et al., 2012; Tucker et al., 2012). 
 
A small (13g) portable Electro-Cardiogram (ECG) device (Mega Motion Faros 180 
recorder; Mega, Finland) will be used to record a high quality 5 minute continuous 
single lead ECG. 
 
 
Other CV risk factors 
Other well recognized cardiovascular risk factors will be recorded to establish overall 
cardiovascular risk and change in cardiovascular risk with time, using standard 
cardiovascular risk calculators (Appendix D). 
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• Blood pressure 
• Fasting full lipid profile (including total and HDL cholesterol) 
• Current and past smoking history in pack years 
• Family history of coronary disease in first degree relatives <60 years old  
• Fasting blood glucose/HbA1C 
• BMI 
• Total body fat as per DEXA scanning 
• Abdominal waist circumference  
• High sensitive CRP (Boekholdt et al., 2006; Boos & Lip, 2005) 
• Resting heart rate (Woodward et al., 2012) 
 
Standard assessment of blood pressure, abdominal waist circumference, family 
history of CVD and smoking history in pack years will be taken. BMI via traditional 
methods and total body fat/composition via the gold standard measure of DEXA will 
be measured as described in more detail below. Approximately 50 mL (in total) of 
fasted blood will be taken via a venous puncture to measure renal function, full blood 
count, glucose and HbA1c ad lipid profile and in addition males sex hormones will be 
measured. Approximately 20mL of blood the will be centrifuged to create serum 
which will be stored long term (-80ºC freezer initially at DMRC then Imperial 
College London) for batch testing of HsCRP and for testing any future biomarkers of 
cardiovascular or musculoskeletal disease that are not currently available but may 
become so in the next 20yrs during the course of the study (eg. homocysteine, 
apolipoprotein). Approximately 10mL of whole blood/plasma/DNA will be stored at -
80ºC for genetic or other analysis at later date.  In addition 50mL of urine will be 
stored for future biomarker and genetic testing. Blood and urine will be taken and 
stored at baseline and all subsequent visits.  
 
Cardiovascular Disease 
Participants will be assessed for new onset of CVD since last study visit: 
 
• Major Adverse Cardiovascular Endpoint (MACE)-composite CVD outcome : 
cardiovascular death, non fatal myocardial infarction, stroke, TIA, arterial 
revascularisation (coronary artery bypass grafting, percutaneous coronary 
intervention, carotid endarterectomy or stenting and peripheral arterial stenting 
or bypass)  
• Individual components of the composite CVD outcome 
• Angina  
• Peripheral vascular disease 
• Hypertension- physician/GP diagnosed 
   
The use of composite cardiovascular endpoints is commonplace, internationally 
recognized and validated in cardiovascular outcome research (Heart Protection Study 
Collaborative Group, 2002; Schächinger et al., 2000; AIM-HIGH Investigators et al., 
2011; Ridker et al., 2002; Abola et al., 2012; Raiko et al., 2010; Anderson et al., 
2011; Sehestedt et al., 2012). Clinical trials often use composite outcomes to provide 
an overall estimate of the effect of an intervention. Composite outcomes are 
appropriate under many circumstances such as when no single most important 
outcome exists, when several endpoints are thought to be important and when  two 
endpoints are clinically related (such as non fatal myocardial infarction and death 
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from fatal myocardial infarction). Also, because death is an uncommon occurrence 
very large sample sizes are required to detect differences in deaths among trial 
groups. Composite outcomes are thought to facilitate the evaluation of infrequent 
outcomes, such as death in smaller trials. 
  
Musculoskeletal Disease: Osteoarthritis, Osteoporosis, Spondyloarthritis and 
Body Composition 
• Radiographic assessment of osteoarthritis of the hips and knees 
• DEXA body composition assessment 
• DEXA bone mineral density assessment 
• BMI calculation 
 
Small retrospective studies have also indicated an increased risk of osteoarthritis in 
amputees (Kulkarni et al., 1998) who will form a large proportion of the battlefield 
trauma group. Participants will be assessed radiographically for osteoarthritis of the 
knees. Posterior-anterior views with knees in semi flexed position (7-10 degrees) will 
be used which is the recommended view for the assessment of osteoarthritis 
(Buckland-Wright et al., 2004; Buckland-Wright et al., 1999)  and is used in recent  
cohort studies (Nevitt et al., 2006; Wesseling et al., 2009)  Anterior-lateral views and 
skyline views (inferior-superior) of the  patellofemoral joint with the knees in 30 
degrees of flexion will also be taken (Spector et al., 1996; Wesseling et al., 2009). 
Hips will also be assessed radiographically with an AP pelvis-focal length 100cm, 
hips internally rotated15 degrees) (Leyland et al., 2012). Radiographs will be scored 
according to the Kellgren and Lawrence radiographic osteoarthritis scoring method 
(Kellgren & Lawrence., 1957) for both the hip and the tibiofemoral joint of the knee. 
The patella femoral joint will be scored using the OARSI scoring method (Altman & 
Gold, 2007)  
 
 
In limited populations obesity is a recognized complication of amputation (Shahriar et 
al., 2009) BMI will be recorded using an adjusted formula for amputees 
(Tzamaloukas et al.,1994), and also using the gold standard measure of body 
composition the DEXA scanner (Lohman et al., 2000) which has previously been 
used in a military population  (Nindl et al., 1997; 1996). Measuring body composition 
and in particular total body fat is an important factor in determining long-term risk of 
CVD, diabetes mellitus and osteoarthritis. 
 
DEXA scanning will also be used to assess changes in bone mineral density as 
previous smaller retrospective studies have shown evidence of femoral neck 
osteopenia in amputees (Kulkarni et al., 1998; Leclercq et al., 2003; Sherk et al., 
2008). Incidence of osteoporotic defining hip fracture will be recorded at each follow 
up visit, as although loss of BMD is suggested there is no evidence to date to suggest 
increase fracture rate in this population. 
 
The participants will also complete the Manchester-Oxford Foot Questionnaire 
(Morley et al 2013) (Appendix Z9) to assess pain and functional outcomes related to 
foot and ankle injury 
 
The study population is similar to the at risk population for spondyloarthritis i.e. 
young males, and there is evidence to suggest that trauma precipitates 
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spondyloarthritis/ankylosing spondylitis (Cury et al., 1995; Olivieriet al., 1990; 
Olivieri et al., 1989; Olivieri et al., 1988; Olivieri et al., 2008).  The AP pelvis x-rays 
will also therefore be scored for sacroiliitis via the modified New York score (van der 
Lindenet al., 1984). Sacroiliitis is a key feature of spondyloarthritis as is the insidious 
onset of back pain, a feature that is also present in amputees (Hammarlundet al., 
2011). The presence of the gene HLA-B27 which is strongly associated with 
spondyloarthritis and particularly Ankylosing Spondylitis will therefore be assessed 
as will inflammatory back pain and spondyloarthritis criteria (Sieper et al., 2009a; 
Sieper et al., 2009b) so the nature, cause and course of back pain in both populations 
can be determined.   
 
Mobility, Disability, Function & Pain (amputee specific*)  
• Amputee Mobility Predictor Questionnaire (AMPQ)* 
• Specialist Interest Group in Amputee Medicine (SIGAM) Mobility Grade* 
• Prosthetic satisfaction (Numerical rating scale) * 
• Socket comfort score* 
• Prosthetic use (time in hours per week) * 
• Numerical rating scale (NRS) for stump pain* 
• Numerical rating scale for phantom limb pain (intensity/frequency/impact) * 
• Six minute walk test (including maximal heart rate) 
• Respiratory function (FEV1/FVC) 
• Numerical rating scale for back pain 
• Inflammatory back pain questionnaire 
• Oswestry Disability Index 
• Non arthritic hip score (NAHS) 
• Knee osteoarthritis outcome score (KOOS) 
• Disability arm shoulder hand (DASH) questionnaire 
 
All participants will be assessed for mobility, disability, physical function and pain. 
Standard outcome measures in amputees will be recorded at baseline and at each visit. 
These will include the Amputee Mobility Predictor Questionnaire (AMPQ) (Gailey et 
al., 2002) (Appendix E) (amputees only) to assess the study participants’ subjective 
feeling of functional ability. This assessment is routinely used within amputee 
mobility research (Hafner, et al., 2007; Miller & Deathe., 2004) and also within the 
DMRC as a functional assessment tool. 
 
The SIGAM (Specialist Interest Group in Amputee Medicine) mobility grades (Ryall 
et al., 2003) (Appendix F) will be used as will the six minute walk test  to assess 
overall function (Balke., 1963; Lin & Bose, 2008; Naughton, et al., 1963). Developed 
in 1963 by Balke to evaluate functional capacity (Balke, 1963) the six-minute walk 
test (6MWT) measures the distance an individual is able to walk over a total of six 
minutes on a hard, flat surface and is valid in the able bodied and amputees. The goal 
is for the individual to walk as far as possible in six minutes. The individual is 
allowed to self-pace and rest as needed as they traverse back and forth along a marked 
walkway. The subjects’ respiratory function will also be measured to assess basic 
respiratory capability and its contribution to functional capacity. Prosthetic comfort 
score will be assessed with the socket comfort score (Appendix G) (Hanspal et al., 
2003) and prosthetic satisfaction will be assessed using a numerical rating scale 
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(Appendix H) and prosthetic  use recorded (hours used previous  day and  previous 
week) (Appendix I). 
 
Phantom pain (Desmond & MacLachlan, 2010; Kern et al., 2009; Sherman & 
Sherman, 1983) and stump pain (Byrne, 2011) are common consequences of 
amputation . The frequency, intensity and impact of phantom limb pain and stump 
pain will each be measured using numerical rating scales (Appendix J & K). 
 
Back pain has been reported in amputees in small retrospective studies (Hammarlund 
et al., 2011). Therefore, back pain will be assessed at each study visit in its 
severity/frequency/impact with a numerical rating scale (NRS)(Appendix L). The 
nature of back pain will be assessed with an inflammatory back pain assessment and 
spondyloarthritis assessment (Sieper, et al., 2009b) (Appendix M) and the impact of 
back pain on function will be assessed with the Oswestry Disability Index (ODI) 
(Fairbank et al., 1980) (Appendix N).  
 
There is some association between amputation and osteoarthritis of the knees and hips 
(Kulkarni et al., 1998). Radiographic assessment is planned as noted above. Validated 
and internationally recognized patient reported outcomes relevant to knee (Knee 
osteoarthritis outcomes score) (Roos & Lohmander., 2003; Roos & Toksvig-Larsen, 
2003) (Appendix O) and hip (Non arthritic hip score) (Christensen et al., 2003) 
(Appendix P) pain and osteoarthritis will be completed along with numerical rating 
scales for pain in each of the knee and hip joints (Appendix Q).  
 
Upper limb pain is also a recognized consequence of both upper and lower limb 
amputation (Davidson, 2004; Ostlie et al., 2011). The disability arm, shoulder hand 
questionnaire (DASH) (Germannet et al., 1999; Davidson, 2004) (Appendix R) will 
be used to assess on going upper limb pain and function and a body pain manikin to 
indicate the sites of pain (Appendix S). 
 
Pain will also be assessed using the Brief Pain Inventory (Tan G et al 2004) 
(Appendix Z17), characterized using the Neuropathic pain symptom inventory 
(Bouhassira D et al 2004) (Appendix Z18) the impact of pain will be assessed by the 
Pain Catastrophizing Scale (Sullivan et al 1995) (Appendix Z19)  
 
Audiograms: 
Military personnel are often exposed to loud noise both in combat and in training. The 
MoD has numerous standard operational procedures in place to minimize the risk of 
noise induced hearing loss. However, despite this, this is a feature of some serving 
military personnel and veterans. Those injured participants in the study, many of 
whom will have been injured by an explosive device, are at even higher risk of noise 
induced hearing loss. All military personnel are subject to programmed hearing tests 
throughout their military careers. It is proposed that all participants have their career 
audiograms reviewed and all participants, once they have exited the armed services, 
continue with audiograms as part of the 5yr follow-up program allowing for a more 
definitive assessment of the effect of a military career on hearing levels and a 
comparison between those involved and not involved in blast injury. 
 
Quality of Life 
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Quality of life (QoL) will be measured at baseline and at each follow-up visit using a 
validated QoL outcome measure, the European Quality of life 5 domain (EQ5D) 
(EuroQol--a new facility for the measurement of health-related quality of life. The 
EuroQol Group., 1990; Brooks., 1996; Dorman et al., 1997) (Appendix T). 
 
Mental Health 
Participants will have a mental health screen, specifically for anxiety and depression 
using the Patient Health Questionnaire 9 (PHQ-9) (Spitzer, Kroenke, & Williams, 
1999) (Appendix U), the General Anxiety Scale- 7 Questions (GAD-7) (Spitzer et al., 
2006) (Appendix U1) and  the Post Traumatic Stress Disorder (PTSD) with the 
National Centre for PTSD Check List (PCL-5) (Blevins C et al 2015) (Appendix V). 
Current and past alcohol consumption since injury will be assessed with the Alcohol 
Use Disorders Identification Test (AUDIT) (Berner et al., 2007; Bohn et al., 1995) 
(Appendix W) and current and past drug use will be assessed using the Drug Use 
Disorder Identification test (DUDIT) (Berman et al 2007)(Appendix Z1) 
 
Social support has been shown to be an independent etiological and prognostic factor 
for the development of cardiovascular disease (Hemingway & Marmot, 1999; Barth 
& von Kanel, 2010) and poor mental health (Lehtinen et al, 2005). The well-validated 
Multidimensional Perceived Social Support (MSPSS) measure (Zimet et al., 1988) 
will be used to measure social support in our ADVANCE population (appendix Z5). 
 
Early life experiences have been shown to be linked to adult experiences of both 
physical and mental health in both the general population (Carr et al., 2013; Coelho et 
al., 2014) and military populations (Iverson et al., 2007). Significant childhood 
adversity factors from Iverson’s ( 2007) have been incorporated from the King’s 
Centre for Military Health Research Health and Well-being Study for use with 
ADVANCE (Appendix Z6). 
 
Post-Traumatic Growth (PTG) is highly prevalent in veterans of Iraq/Afghanistan 
(Piertraz et al., 2010). PTG is related to lower pain perception, cortisol and less 
relapse in those who experience both PTG and life threatening illnesses (Barskova & 
Oesterreich, 2009).  The PTG-Inventory (PTG-I) will be used to examine PTG in the 
ADVANCE population (Appendix Z7). 
 
Mild Traumatic Brain Injury 
 
Occurrence of mild traumatic brain injury, a common injury from the Afghanistan 
conflict,  and subsequent symptoms will be assessed using the Ohio State University 
Traumatic Brain Injury Identification Method questionnaire (Appendix Z15) 
(Corrigan et al,2007) and the Rivermead post-concussion questionnaire (Appendix 
Z16) (King et al 1995) respectively. 
 
Sleep 
Quality and duration of sleep, along with insomnia and sleep apnoea, have been 
linked to poorer physical and mental health (Reid et al, 2006; Cappucio et al., 2013; 
Alvaro et al., 2013). In particular, sleep duration has been linked to coronary heart 
disease (Cappuccio et al., 2011). Questions previously investigated by a large scale 
operational mental health examination  (“Operational Mental Health Needs 
Evaluation”, 2011) using an adapted version of the Insomnia Severity Index (ISI) 
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(Bastien et al., 2001) will be used to examine sleep problems in the ADVANCE study 
population. The sleep duration section of the Pittsburgh Sleep Quality Index (Buysse 
et al., 1991) will be used to examine sleep duration.  (Appendix Z8). 
 
Relationship Status & Sexual Function 
Current relationship status and relationship history since injury will be recorded. 
Sexual function will be assessed using the Arizona Sexual Experiences Scale (ASEX) 
(McGahuey, et al., 2000) (Appendix X). 
 
Employment Status & History and Social Outcomes 
Current employment/education and history of employment and education since injury 
will be recorded using an employment history questionnaire (Appendix Y). 
 
Personal reasons for leaving the Armed Forces (Appendix Z10), Highest level of 
education attainment (Appendix Z11), Veteran Specific Outcomes (Appendix Z12), 
Who lives with you? (Appendix Z13) and Friends and Family Network Questionnaire 
(Z14) will also be administered to get in depth information of social outcomes.  
 
Physical Activity 
Current (last week) physical activity will be recorded using a valid patient reported 
questionnaire, the International Physical Activity Questionnaire (IPAQ) (Booth, 
2000) (Appendix Z2). This will be useful to monitor participant’s physical activity 
over the 20yr period as this may be related to the particpant cardiovascular, 
osteoarthritis and mental health outcomes. 
 
Mortality & Cause of Mortality 
In the event of death during the 20 year follow-up period cause of mortality will be 
recorded. The participant will be flagged with the National Health Service Central 
Register (NHSCR) to provide date of death in the unlikely event of this occurring. 
This will avoid unnecessary and potential upset by contact from the study team if a 
patient has died since the previous follow up. 
 
 
6. Trial Schedule 
 
Visit by Visit Schedule (Approximately 4-5 hrs per visit. Patients will be given as 
much time as they require and accommodation will offered if required) (see 
Appendix Z) 
At Baseline and all subsequent visits (unless stated otherwise) : 
 
• Patient demographics 
- Age 
- Sex 
- Regiment/unit 
- Job/role 
- Prosthetic components 
• All injuries documented  
• Date of injury/trauma 
• Injury severity score (Baker & O'Neill., 1976; Baker, O'Neill et al., 1974) 
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• All subsequent trauma, requiring hospital admission, subsequent to commencing 
the study. 
• Past medical history 
• Drug History – prescribed and recreational (Appendix Z1) 
• Method of discharge from Armed Services: 
 - End of engagement/commission 
 - Medical discharge 
 - Administrative discharge 
 - Redundancy 
 -Still serving 
 -Died in service 
• Blood tests (baseline and at each subsequent follow up study visit) 
- Fasting lipids, glucose and HbA1c 
- Full blood count, urea and electrolytes and liver function and gamma GT. 
- Serum to be stored for batched hsCRP testing. 
- HLA-B27 (baseline only) 
- Serum and whole blood/plasma to be stored  
- Testosterone, FSH, LH and SHBG 
 
• Urine: 50mL of urine for storage (baseline and at each subsequent follow up visit) 
• Imaging 
- Pulse wave velocity assessment 
This is a simple, non-invasive and painless test that takes <5 minutes to 
perform. No ionising radiation is involved. The subject is supine and fully 
rested. A three lead ECG electrode is attached to the patient’s chest and a 
pencil-like sensor is gently held against the subject’s wrist to record a blood 
pressure signal from their pulse. With additional data from a second blood 
pressure recoding at the brachial artery the Pulse Wave Analysis system will 
calculate the pressure waveform at the heart to provide a detailed 
cardiovascular risk profile (eg AI, central blood pressure). Aortic pulse wave 
velocity (PWV) is calculated from sequentially recorded pressure waveforms 
of the carotid and femoral artery. 
Heart Rate Variability assessment 
During the Vicorder assessment of arterial stiffness a 5-minute HRV 
recording will be made. This will be followed by a further 5 minute recording 
thereafter with the subjects provided with a sample audio-visual breathing 
prompt to allow controlled respiration at a breathing rate of 5-12 breaths per 
minute.This assessment is non-invasive and requires a single lead ECG via 
two skin electrodes over the right shoulder and apex beat respectively.  
- DEXA- body composition and bone mineral density 
The combined investigation of body composition and bone mineral density 
takes a maximum of 20 minutes. The subject is laying supine on an open 
couch/table in a comfortable position. There is a minimal amount of radiation 
such that DEXA operators do not need to take any special precautions.  
- Radiographs hips and knees 
Posterior- anterior views with knees in semi-flexed position (7-10 degrees) 
will be used performed. Anterior-Lateral views and skyline views (inferior-
superior) of the patellofemoral joint with the knees in 30 degrees of flexion 
will also be taken. Hips will also be assessed radiographically with an AP 
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pelvis-focal length 100cm, hips internally rotated15 degrees. The total length 
of time for all radiographs will be 20 minutes.  
• Questionnaires 
- Amputee Mobility Predictor Questionnaire (AMPQ) 
- Prosthetic satisfaction  (Numerical Rating Scale-NRS) 
- Prosthetic use questionnaire 
- Numerical rating scale- back pain (frequency/intensity/impact)  
- Numerical rating scale- stump pain (frequency/intensity/impact) 
- Numerical rating scale- phantom pain (frequency/intensity /impact)  
- Oswestry Disability Index (ODI) 
- Non Arthritic Hip Score 
- Knee osteoarthritis outcomes score 
- Disability of the arm, shoulder and hand questionnaire 
- Pain manikin 
- European Quality of Life 5 Domains 
- Post Traumatic Stress Disorder Check List (PCL-5) 
- Arizona Sexual Experience Scale (ASEX) 
- Alcohol Use Disorder Identification Test (AUDIT) 
- Patient Health Questionnaire 9 
- Generalized Anxiety and Depression Score-7 (GAD 7) 
- Employment history 
- Insomnia Severity Index (ISI)/ Pittsburgh Sleep Quality Index (PSQI) 
- Post Traumatic Growth Inventory (PTG-I) 
- Multidimensional Scale of Perceived Social Support (MSPSS) 
- Childhood Adversity (CA) 
- Manchester-Oxford Foot Questionnaire (MOXFQ) 
- Drug Use Disorders Identification Test (DUDIT) 
- Personal reason for leaving Armed Forces Question 
- Highest level of education attained question 
- Veteran specific outcome questions 
- Who lives with you question 
- Friends and family network question 
- Ohio State University TBI Identification Method 
- Rivermead Post Concussion Questionnaire 
- Brief Pain Inventory 
- Neuropathic Pain Symptom Inventory 
- Pain Catastrophising Scale 
• Assessment 
- Current medication 
- Smoking history in pack years 
- New fracture history 
- BMI, abdominal waist circumference 
- BP and heart rate 
- SIGAM mobility grade 
- Spirometry (FEV1 and FVC) 
- Inflammatory back pain and SpA criteria 
- Audiogram (if participant has left the armed services) 
 
159
Ministry of Defence Research Ethics Committee (MoDREC) 
MoDREC 
v1.1 - 07 July 2008  Page 18 
Any significant risk or disease that requires medical action/treatment, as per standard 
treatment guidelines, that is detected during the study will be reported to the 
participant’s primary care physician with the consent of the participant. 
 
 
 
 
 
7. Data Collection, Source Data and Confidentiality 
 
General 
All information collected during the course of the trial will be kept strictly 
confidential.   
 
Study data will be held securely on paper and, on an electronic database satisfying 
MoD security requirements at the DMRC Headley Court and KCMHR (King’s 
College London).  Access to the database will be restricted to authenticated, named 
users logged into either the KCL network or MoD network. The data collected will 
strictly only be used in this research and other relevant military research.  
 
All staff are required to sign a confidentiality agreement, reminding them of their 
obligations and the disciplinary action which would result from a breach.  The study 
will comply with MoD standards for handling personal data. No individual will ever 
be identified in reports or publications. All reports will be on aggregated data. 
 
DMRC Headley Court and ADVANCE Study staff will comply with all aspects of the 
Data Protection Act 1998 and operationally this will include: 
 
• Consent from patients to record personal details including name, date of birth, 
address and telephone number, service number, NHS number, GP name and 
address. 
• Appropriate storage, restricted access and disposal arrangements for patient 
personal and clinical details. 
• Consent from patients for access to their military and NHS medical records by 
responsible individuals from the research staff, the sponsor or from regulatory 
authorities, where it is relevant to trial participation. (NHS REC approval will be 
sought)  
• Consent from patients for the data collected for the trial to be used to evaluate 
safety and develop new research. 
 
Archiving 
In line with the principles of GCP / UK Clinical Trial Regulations Guidelines, at the 
end of the trial data will be securely archived at each participating centre for a 
minimum of 15 years. 
 
Arrangements for confidential destruction will then be made. If a patient withdraws 
consent for their data to be used, it will be confidentially destroyed immediately. On 
receipt of a completed questionnaire, all personal identifiers (contact details etc.) will 
be removed and will be stored in locked metal cabinets within the study area.  
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Questionnaires will be kept in separate, locked cupboards in a secure room within the 
study area. Study data will be anonymised, using a unique identification number for 
each participant and the key to personal identification will be kept separately. 
 
 
8. Statistical Considerations 
 
Sample Size/Power Calculations  
Sample size calculations were performed for all 3 primary outcomes using GraphPad 
StatMate version 2.00 for Windows (GraphPad Software).  
 
A sample size of 600 in the battlefield trauma exposed group and 600 in the non-
exposed group was sufficient even with an estimated 10% drop out every 5 years to 
power the study to at least 80% for each of the 3 primary outcomes. 
 
Primary Outcome 1 : Cardiovascular Disease - Composite CVD Endpoint 
Sample size calculations were based on the primary composite CVD end-point.  
Published data have shown CVD event (varying endpoints used) hazard ratio of >1.70 
among those with traumatic injury compared to healthy controls (Hrubec & Ryder, 
1980; Kunnas et al., 2011;  Modan et al., 1998). Given the age and demographic of 
our target population event rates are likely to be low. However, the study is using a 
well defined, published and measurable broad composite CVD primary endpoint and 
has a prolonged follow-up period which both significantly reduce the sample size 
needed to maintain statistical power.  
 
The rate of the primary MACE endpoint has been estimated using a number of 
combined resources and includes : 
 
1. Relevant CVD composite endpoint risk calculators 
 
i. http://www.cks.nhs.uk/cvd_risk_assessment_and_management/manageme
nt/detailed_answers/assessment_of_cvd_risk/cvd_risk_calculators  
ii. http://www.cardiosmart.org/cardiosmart/default.aspx?id=298  
  
 
2. Published data from similarly aged populations (Raiko et al., 2010)  (AIM-HIGH 
Investigators et al., 2011) . 
 
3. Data modelling and applying these to our average patient demographic at 
inclusion (24 year old male with a normal blood pressure and lipid profile).  
 
We have estimated that we would expect a primary composite CVD event rate 
of >10% at 20 years in the healthy control group with a hazard ration of >1.7 in the 
battlefield trauma group. Based on this assumption we have calculated that a sample 
size of at least 400 in both the battlefield trauma exposed group and the non-exposed 
group would provide a >80% power to detect a hazard ratio of >1.7 at a two-sided 
alpha of 0.05 over a 20-year follow up period. The initial recruitment of 600 
participants will have a natural drop out rate of approximately 10% every 5 years. 
This would result in a sample size of approx. 400 at 20 years, and therefore still be 
sufficient to identify differences in composite CVD endpoints between the groups.  
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Even if there was a drop out rate of 15%, every 5 years which could leave 313 
subjects by 20 years from an initial cohort of 600. This would still be a sufficient 
sample size to detect a different in MACE at a hazard ratio of >1.8 with 80% power. 
 
 
Primary Outcome 2: Cardiovascular Risk as Determined by Pulse Wave 
Velocity 
We have also calculated sample size for the other key primary endpoint of pulse wave 
velocity (PWV). Published data on health controls of similar ages to our study 
population would suggest an average pulse wave velocity of 6.0 – 6.5 m/s with a 
within group standard deviation of 0.8-1.2 m/s (Doonan et al., 2011) (Reference 
Values for Arterial Stiffness' Collaboration., 2010). There is a general paucity of data 
on pulse wave velocity among amputees and multiple trauma patients. However, 
again using modelling of our average patient demographic and pilot data along with 
published data amongst sedentary controls, age and sex matched controls with 
subclinical CVD to simulate the disease group and allowing for the natural increase in 
PWV with age it would be anticipated that trauma patients would be expected to have 
a PWV of >0.4m/s higher than the healthy control group (Lazdam et al., 2012)  
Hence, a sample size of at least 200 in each group (battlefield trauma exposed versus 
non exposed) would have a 95% power to detect a difference in PWV of >0.36 m/s at 
a significance level (alpha) of 0.05 (two-tailed) assuming a within group standard 
deviation of 1.0m/s (Kingwell et al., 1997).  Even if the within group standard 
deviation were higher than anticipated at up to 1.4 ms/s, a minimal sample size of 280 
subjects would still have 90% power to detect a >0.4 m/s (>7%) difference in PWV 
between the battlefield trauma exposed group and the non-exposed group. Therefore, 
an initial sample size of 600 would be sufficient, even with a 17.5% drop out every 5 
years which would reduce the cohort to 285, to identify differences in changes in 
PWV between the groups. 
 
Primary Outcome 3: Hip and Knee Osteoarthritis as Determined by 
Radiographic Assessment 
Based on the mean prevalence of hip osteoarthritis in the 40-50 year old age bracket 
of the general population being 2.8%, (standard deviation - 7%) (van Saase et al., 
1989) (Dagenais et al., 2009) and an expected two-fold increase  in hip osteoarthritis 
in the battlefield trauma group (Kulkarni et al., 1998) a two-sided test with an alpha 
value of 0.05 and a power of 95% the sample size would need to be 82 to detect a 
difference between the groups. Therefore, the proposed 600 participants at baseline 
would be more than sufficient, even with a higher than expected drop out rate.  
 
Similarly, a sample size of 600 even with a significant drop out rate is adequate to 
detect difference in osteoarthritis of the knee between the 2 groups (mean prevalence 
in general population aged 40-50 years 8.7%, standard deviation 5.9%, expected 
prevalence in amputees 16.7%) (van Saase et al., 1989) (Burke et al., 1978) with a 
two-sided test, an alpha value of 0.05 and a power of 95%. 
 
Statistical Analysis 
Sample weights will be generated to take account of the sampling frame and how this 
relates to the UK Armed Forces as a whole. The sampling weights will compensate 
for unequal probabilities of selection based on age, rank and combat versus non-
combat role on deployment. We will examine the characteristics of non-responders 
162
Ministry of Defence Research Ethics Committee (MoDREC) 
MoDREC 
v1.1 - 07 July 2008  Page 21 
and also of those who did not participate at follow-up. Predictors of non-response will 
be examined with logistic regression analysis. If there are significant predictors, we 
will take these factors into account in the analyses.  
 
The level and the patterns of missing data will be assessed. For questions which elicit 
high levels of missing data (for example greater than 20%) we would be cautious 
about any analyses based on these data.  
 
Data inspection and the Kolmogorov-Smirnov test will be used to assess normality of 
all continuous data. Paired continuous data comparisons will be undertaken using the 
paired t-test for normally distributed data and the Wilcoxon matched pairs test for 
non-parametric data respectively.  Longitudinal time-dependent comparisons of >2 
time points (baseline, 2, 5 and 10 years etc) will be performed with Repeated 
Measures ANOVA for normally distributed data, with the Tukey post-test for all 
significant results.  Repeated Measures of non-parametric continuous will be 
performed using the Friedman test with post-test for all significant results. Cox 
proportional hazard models will was used to evaluate the effects of previous trauma 
on the event and event-free survival. A two tailed P value <0.05 will be considered 
statistically significant for all comparisons. Logistic regression will be used to 
eliminate confounders and identify predictors of outcome. 
 
10. ETHICAL CONSIDERATIONS 
The trial will be performed in accordance with the recommendations guiding ethical 
research involving human subjects adopted by the 18th World Medical Association 
General Assembly, Helsinki, Finland, June 1964, amended at the 64th World 
Medical Association General Assembly, Fortaleza, Brazil, October 2013. Informed 
written consent will be obtained from the participants prior to registration into the 
study.  The right of a subject to refuse participation without giving reasons will be 
respected.  The participant will remain free to withdraw, and withdraw previously 
collected data, at any time from the study without giving reasons and without 
prejudicing his further treatment.  
The study will be submitted to and approved by MoDREC prior to entering 
participants into the study. 
 
11. PARTICIPANTS TO BE STUDIED 
Number of participants: 1200 
 
Lower age limit: 18 
 
Upper age limit: 50 
 
Gender: Male 
 
Please provide justification for the sample size: 
See Section 9, subsection 8 above. 
 
12. SELECTION CRITERIA 
See Section 9, subsection 3 above. 
 
13. RECRUITMENT 
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13a. Describe how potential participants will be identified: 
See Section 9, subsection 4 above. 
 
13b. Describe how potential participants will be approached: 
See 13a 
 
13c. Describe how potential participants will be recruited: 
See 13a 
 
 
14. CONSENT 
14a. Please describe the process you will use when seeking and obtaining 
consent: 
See Section 9, Paragraph 4 above. 
 
A copy of the participant information sheet and consent form must be attached to this application.  For your 
convenience proformas are provided at the end of this document.  These should be filled in, modified where 
necessary, and attached to the end of your application. 
 
14b. Will the participants be from any of the following groups? 
 
Under 18 : No Subordinates : Yes 
Prisoners : No Pregnant or nursing mothers : No 
Mental Illness : possibly Learning disabilities : Yes, possibly  
 
How will you ensure that participants in the groups listed above are competent 
to consent to take part in this study? 
The experience at DMRC Headley Court is that very few battlefield trauma 
casualties have significant traumatic brain injury. Any that do will be very carefully 
considered for the study and only if the treating team are 100% confident with the 
mental capacity of that patient will they be approached for the study. If there is any 
concern what-so-ever regarding the capacity of a volunteer to give consent then a 
formal assessment of capacity will be performed by the clinical psychologist on the 
unit. 
 
14c. Are there any special pressures that might make it difficult for people to 
refuse to take part in the study? How will you address such issues? 
No 
 
15. PARTICIPANT INVOLVEMENT: RISKS, REQUIREMENTS AND 
BENEFITS 
15a. What are the potential hazards, risks or adverse effects associated with 
the study? 
 
Minimal risk from radiation exposure as detailed below 
 
 
 
1. Details of other ionising radiation 
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Procedure No of procedures Estimated procedure dose 
AP Pelvis X-ray 
1 at baseline and 1 at 
each of following visits – 
3 yr, 5 yr, 10 yr, 15 yr, 
20 yr 
0.4 mSv based on the 
NDRL of 3 Gy cm2 
X-ray examination of 
both knees each 
involving PA, anterior 
lateral and skyline views 
1 at baseline and 1 at 
each of following visits – 
3yr, 5 yr, 10 yr, 15 yr, 20 
yr 
0.002 mSv  
DEXA scan for bone 
mineral density of total 
hip and spine and total 
body composition 
1 at baseline and 1 at 
each of following visits –
3yr, 5 yr, 10 yr, 15 yr, 20 
yr 
<0.02 mSv 
 
2. What is the total participant dose from all the exposures above, and what 
component of this is the additional dose over and above standard practice? 
What are the risks associated with these two doses (total and additional)? 
 
The total effective dose for a participant receiving the full set of X-ray 
examinations at each of the 6 visits is estimated to be 2.5 mSv. Approximately 95% 
of the total dose results from the pelvis X-rays. Some participants will not receive 
X-ray examinations of one or both knees as a result of loss of the knee to 
amputation. The dose from the total body composition DEXA scan will also be 
lower for these patients. 
 
The total effective dose of 2.5 mSv is equivalent to that from approximately 13 
months of exposure to natural background radiation, based on the UK average. 
 
The lifetime risk of fatal cancer for an effective dose of 2.5 mSv is approximately 1 
in 8000 based upon the nominal risk coefficient for an adult published in the 2007 
recommendations of the International Commission on Radiological Protection. This 
can be compared against the natural lifetime risk of fatal cancer of 1 in 3 to 1 in 4. 
 
It is anticipated that the participants will receive some of these X-ray examinations 
as part of their normal clinical care. It is estimated that around 60% of the total dose 
from these examinations will on average be additional to that received in normal 
practice and solely received as a result of participating in the study. 
 
3. Details of person acting as lead Medical Physics Expert 
 
Name:     Mr David M Johnstone 
 
Post:     Principal Physicist 
 
Registration No.:   CS 09130 
 
Organisation: The Radiological Protection Centre, St. 
George’s Healthcare NHS Trust 
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Address:  Unit 5 The Observatory 
 24 Deer Park Road  
 London 
Post Code: SW19 3UA 
 
Telephone: 020 8725 2552 
 
Fax: 020 8417 1338 
 
Email: David.Johnstone@stgeorges.nhs.uk 
 
 
15b. Does your study involve invasive procedures such as blood taking, muscle 
biopsy or the administration of a medicinal product?  
 
Yes - Each participant will have up to 50mL of venous blood drawn at each visit. 
 
If so, please provide details and complete appendix – details of medicines 
and/or healthcare products – as required: 
N/A 
 
15c. Please indicate the experience of the investigators in the use of these 
procedures: 
 
Blood will be taken by staff fully trained in phlebotomy. 
 
15d. If medical devices are to be used on any participant, do they comply with 
the requirements of the Medical Devices Directives? 
Yes 
 
 
15e. Please name the locations or sites where the work will be done: 
DMRC Headley Court 
 
15f. Will group or individual interviews / questionnaires discuss any topics or 
issues that might be sensitive, embarrassing or upsetting?  If so, please list 
these topics and explain how you will prevent, or respond to, volunteer 
discomfort: 
Participant’s relationship status and sexual function will be investigated in the form 
of participant filled questionnaires. Participant can at any time decide not to 
complete any part of the study or withdraw completely without stating a reason. If 
participants are in anyway distressed they will be offered support by clinical staff 
and if necessary referred on for further clinical care. 
 
15g. Is it possible that criminal or other disclosures requiring action (e.g. 
evidence of professional misconduct) could take place during the study?  If 
yes, give details of what procedures will be put in place to deal with these 
issues: 
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This is not anticipated and regarded as being extremely unlikely. If however this 
does occur additional support and advice would be taken at the time. 
 
15h. Please describe any expected benefits to the research participant: 
All participants will be thoroughly assessed for cardiovascular risk and for the 
presence of musculoskeletal disease such as osteoarthritis and osteoporosis. These 
assessments are more detailed than in normal clinical practice and if any treatable 
risk factors or disease is identified then appropriate measures will be taken to do so. 
In most cases this would be to contact the participant’s primary care physician. 
 
15i. Under what circumstances might a participant not continue with the 
study, or the study be terminated in part or as a whole? 
Any participant can decide to stop participating in the study at any time without 
needing to give an explanation and without prejudicing their future care and 
treatment. 
If a participant dies, he will obviously no longer be participating in the study 
however data on that participant will be used up to that point. 
There are no reasons anticipated why the study may be terminated early in part or 
whole. 
 
16. FINANCIAL INCENTIVES, EXPENSES AND COMPENSATION 
16a. Will travel expenses be given? 
 
It is anticipated that participants will travel to DMRC Headley Court for the study 
visits. Travel cost will be covered to and from DMRC Headley Court. 
 
16b. Is any financial or other reward, apart from travel expenses, to be given 
to participants?  If yes, please give details and justification: 
Yes- As suggested by MoDREC to help retention in the study all participant that 
attend each follow-up point will be entered into prize draw of 5 cash prizes.  
As recognition for the participant’s considerable time and effort in taking part in the 
study they will be given £100 per visit as a thank you.  
 
16c. If this is a study in collaboration with a pharmaceutical company or an 
equipment or medical device manufacturer, please give the name of the 
company: 
No 
 
17. CONFIDENTIALITY, ANONYMITY AND DATA STORAGE 
17a. What steps will be taken to ensure confidentiality (including the 
confidentiality and physical security of the research data)?  Give details of the 
anonymisation procedures to be used, and at what stage they will be 
introduced: 
See Section 9, subsection 7 above. 
 
17b. Who will have access to the records and resulting data? 
Study staff only 
 
17c. Where, and for how long, do you intend to store the consent forms and 
other records? 
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See section 9, subsection 7 above. 
 
18. PARTICIPANT INFORMATION SHEET AND CONSENT FORM 
The participant information sheet and consent form should be composed according to the guidelines and 
submitted with this form. 
 
The following, where applicable, are attached to this form (please indicate): 
 
[ x ]  Participant Information Sheet 
[ x ]  Consent Form 
[   ]  Appendix relating to medicines and/or healthcare products 
[   ]  Letter to general practitioners 
[   ]  Letter to parents/guardians  
[   ]  Letter of other research ethics committee approval or other approvals 
[  ]  Copy of e-mail recruitment circular/poster/press advertisement 
[ x ]  Questionnaire/ topic guide/ interview questions 
[   ]  Evidence of permission from organisation (e.g. hospital) where research is to 
take place 
[ x ]  List of acronyms 
[ x ]  CVs of named investigators 
[   ]  CV of supervisor 
[ x ] CV of Independent Medical Officer 
 
Please list any other supporting documents: 
 
 
Appendices A-Z- study outcome measures. 
 
 
Comments about form 
If you have any suggestions for improving this form please e-mail them to ethics@mod.uk 
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ADVANCE Study- List of Acronyms 
 
 
 
 
 
AI - Augmentation Index 
AMPQ - Amputee Mobility Predictor Questionnaire 
AUDIT Alcohol Use Disorder Identification Test 
BMD - Bone Mineral Density 
BMI - Body Mass Index 
CAD - Coronary Artery Disease 
CRP - C-reactive protein 
CVD - Cardiovascular Disease 
DASH - Disability Arm Shoulder Hand 
DEXA - Dual energy X-ray absorptiometry 
DM - Diabetes Mellitus 
DMRC-  Defence Medical Rehabilitation Centre 
DMS -  Defence Medical Services 
ECG - Electrocardiogram 
EQ5D - European Quality of Life 5 Domains 
FEV1 - Force expiratory velocity in 1 second 
FVC - Forced Vital Capacity 
HbA1C Haemoglobin A1c 
HRV  Heart Rate Variability 
HsCRP High Sensitivity C-reactive protein 
HDL - High Density Lipoprotein 
IBP - Inflammatory Back Pain 
IPAQ - International Physical Activity Questionnaire 
ISI  Insomnia Severity Index 
HLA-B27 Human Leucocyte Antigen B27 
IHD - Ischaemic Heart Disease 
KCMHR Kings College Mental Health Research 
KOOS- Knee Osteoarthritis Outcome Score 
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MACE - Major Adverse Cardiovascular Endpoint 
MSPSS Multidimensional Scale of Perceived Social Support 
NAHS - Non Arthritis Hip Score 
NHS - National Health Service 
NRS - Numerical Rating Scale 
QoL - Quality of Life 
PCL - PTSD Check List 
PHQ-9 Patient Health Questionnaire-9 
PSQI  Pittsburgh Sleep Quality Index 
PTG  Post Traumatic Growth 
PTG-I  Post Traumatic Growth Inventory 
PTSD - Post Traumatic Stress Disorder 
PWV - Pulse Wave Velocity 
SIGAM- Specialist Interest Group in amputee Medicine 
SpA - Spondyloarthropathy 
TIA - Transient Ischaemic Attack 
6MWT - 6 Minute Walk Test 
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ANNEX G- RREQUEST TO AMEND A MODREC APPROVED 
PROTOCOL 
Amendment Request 
General Information. 
Protocol No: /MODREC/357/PPE/12 
Protocol Title:  The ADVANCE Study 
Chief Investigator:  Gp Capt Alex Bennett 
Organisation: Academic Department of `Military Rehabilitation, 
DMRC, Headley Court 
Date of Approval:  15th Jan 2013 
Date of Approval of 1st Set of Amendments: 12th March 2015 
Date of Approval of 2nd Set of Amendments: 23th Sep 2015 
Date of Approval: 3rd Set of Amendments:  7th Feb 2016 
Date of Approval: 3rd Set of Amendments:  2nd May 2018 
 
Specific Information. 
Date research started: 31/08/2015 
No. of volunteers involved: 1200 
No. of under 18s involved: 0 
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Amendments 
Description of amendment required and rationale for 
Amendment: 
The ADVANCE Study, the 20yr cohort study investigating long term medical 
(primary outcomes: cardiovascular disease and bone health/osteoarthritis) and 
psychosocial outcomes of military combat casualties was given initial MoDREC 
approval in January 2013 and amendments were approved in March 2015, September 
2015, Feb 2016 and May 2018. 
It is a large and ambitious study that has been logistically complex to organized 
however it is progressing well with 750 participants recruited. The target for 
participant recruitment is 1200 which we aim to complete by the end of 2019. The first 
round of follow up participants (3yr from initial visit) are due in the early spring 2019 
and the investigators have reviewed the data collection and have decided it 
appropriate/necessary to make some minor amendments. The investigators would 
therefore be extremely grateful if MODREC would consider approving this additional 
set of amendments. These proposed amendments are outlined below.  
All additions to the protocol (Version 14. 21.01.19) or appendices are highlighted 
in track changes/comments or in yellow and any deletions are detailed in the 
track-changed boxes in the right-hand margin.  
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Brief Summary of Proposed Amendments: 
Additional/Changes to questionnaires: 
a. Manchester-Oxford Foot Questionnaire (MOXFQ). New questionnaire.  
b. Drug Use Disorders Identification Test (DUDIT). New questionnaire to 
replace existing Drug/Medication history questionnaire. 
c. Reason for leaving Armed Forces questionnaire. New questions 
d. Highest level of education attained question. New question 
e. Veteran specific outcomes questions. New questions  
f. Who lives with you? New question. 
g. Friends and family network. New questions 
h. Mild traumatic brain injury questionnaire. New questionnaire 
i. Rivermead Post Concussion Questionnaire. New Questionnaire 
j. Replacing existing PCL (PTSD questionnaire) with updates PCL-5 
questionnaire  
k. Brief Pain Inventory (BPI) 
l. Neuropathic Pain Symptom Inventory (NPSI) 
m. Pain Catastophising Scale (PCS) 
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Additional assessments: 
n. Collection/storage/testing of Blood and Urine at all follow up visits (3yrs, 
5yrs, 10yrs, 15yrs and 20years post baseline visit) as per currently approved 
MoDREC protocol for initial/baseline visit. 
o. Additional testing of male hormone profile on blood samples. No extra blood 
required.  
Additional wording of consent: 
p. Additional sentence added to consent form to confirm that participants are 
content with their study data being shared with existing and future research 
collaborators 
q. Change existing consent from “…in accordance with the provisions of the 
Data protection Act 1998” to “... in accordance with the provisions of the data 
protection Act 2018.” 
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Detailed Proposed Amendments: 
Additional/Changes to questionnaires: 
a. Manchester-Oxford Foot Questionnaire (MOXFQ). (Appendix 
Z9) 
It has become apparent during the baseline data collection from the 
participants in the ADVANCE study that we are currently not capturing 
problems associated with foot and ankle injury and that this is a common and 
significant problem. The investigators therefore propose including the 
internationally used and validated MOXFQ (Morley et al., 2013) 
1. Morley, D., Jenkinson, C., Doll, H., Lavis, G., Sharp, R., Cooke, P., & Dawson, 
J. (2013). The Manchester-Oxford Foot Questionnaire (MOXFQ): 
Development and validation of a summary index score. Bone & Joint 
Research, 2(4), 66–69. http://doi.org/10.1302/2046-3758.24.2000147 
b. Drug Use Disorders Identification Test (DUDIT). (replacement 
appendix Z1) 
The current drug brief drug history (appendix Z1) has been found by many 
participants to be complicated and long winded and we have had a number of 
negative comments about the questionnaire. We therefore propose 
exchanging it for the DUDIT (Berman, Palmstierna, Källmén, & Bergman, 
2007) an internationally recognised and validated and concise questionnaire. 
1. Berman, A. H., Palmstierna, T., Källmén, H., & Bergman, H. (2007). The self-
report Drug Use Disorders Identification Test: Extended (DUDIT-E): reliability, 
validity, and motivational index. Journal of Substance Abuse Treatment, 32(4), 
357–369. http://doi.org/10.1016/j.jsat.2006.10.001 
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c. Personal reason for leaving the armed forces. (Appendix Z10) 
Although the method of discharge (end of service, medical, redundancy etc) 
from the Armed forces is recorded the participant’s personal reasons was not 
and a simple question has been added to explore this. 
d. Highest level of education attained question (Appendix Z11) 
Highest level of education attained is often linked with many psychosocial 
outcomes. This was not previously recorded so the investigators propose a 
simple question to ascertain this. 
e. Veteran specific outcome questions. (Appendix Z12) 
It is well recognised that some veterans run in to trouble with criminal 
convictions and/or with financial problems. This is not currently being recorded 
in this cohort we therefore proposed 2 simple questions to cover this. 
f. Who lives with you? (Appendix Z13) and g. Family and friends’ 
network (Appendix Z14) 
The investigators propose 2 simple questionnaires to investigate who the 
participants are currently living with the who are important in their family and 
social network to achieve a better understanding of their social outcomes. 
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h. OSU TBI Identification (Appendix Z15) and i. Rivermead Post 
Concussion Questionnaire (Appendix Z16) 
Mild Traumatic Brain injury has been recognised as a common and significant 
injury from the Afghanistan war. Currently the ADVANCE Study is not 
capturing the prevalence of mTBI in the study cohort or the potential 
consequences of it. This additional investigator administrated questionnaire is 
comprehensive but concise and is reliable and valid (Corrigan et al 2007) 
Corrigan JD, Bogner JA. 2007. Initial reliability and validity of the OSU TBI 
Identification Method. J Head Rehabil; 22(6):318-329. 
The outcome of TBI also needs to be assessed. The most commonly used and 
validated questionnaire for this is a quick and simple to use patient reported 
outcome measure, The Rivermead Post concussion Questionnaire (King et al 
1995) 
King, N. S., Crawford, S., Wenden, F.J., Moss, N.E.G. Wade, D.T. (1995). The 
Rivermead Post Concussion Symptoms Questionnaire: a measure of 
symptoms commonly experienced after head injury and its reliability Journal of 
Neurology, 242, 587-592. 
j.  PTSD Checklist – 5 (PCL-5) (Appendix V) 
We are currently investigating symptoms of PTSD with the PTSD check list 
(PCL). This questionnaire has been superseded by the PCL-5 (Blevins, 
Weathers, Davis, Witte, & Domino, 2015) and therefore we now propose to 
use the PCL-5 for the ADVANCE Study.  
Blevins, C. A., Weathers, F. W., Davis, M. T., Witte, T. K., & Domino, J. L. (2015). 
The 
Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial 
Psychometric 
Evaluation. Journal of Traumatic Stress, 28(6), 489–498. 
http://doi.org/10.1002/jts.22059 
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k. Pain assessment, characterisation and impact by the Brief Pain Inventory 
(Appendix Z17),  l. the Neuropathic Pain Symptom Inventory (Appendix Z18) 
and the m. Pain Catastrophising scale (Appendix Z19) 
Chronic pain is a predominant symptom of major trauma patients. Detailed 
information on the degree, character and impact of pain is essential to gather. 
Therefore, it is proposed to use the Brief Pain Inventory (Tan G et al 2004) 
(Appendix Z17), the Neuropathic Pain Symptom Inventory (Bouhassira et al 
2004) (Appendix Z18) and the Pain Catastrophising scale (Sullivan et al 1995) 
(Appendix Z19) 
Validation of the Brief Pain Inventory for Chromic non-malignant Pain. Tan G, 
Jensen MP, Thornby JI, Shanti BF. J Pain. 2004 Mar;5(2):133-7. 
Development and Validation of the Neuropathic Pain Symptom Inventory. 
Bouhassira D, Attal N, Fermanian J, et al. Pain. 2004 Apr;108(3):248-57. 
Sullivan MJ, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development 
and validation. Psychol Assess. 1995;7:524–532. 
 
 
Additional assessments: 
n. Collection/storage/testing of Blood and Urine at all follow up 
visits  
We are currently taking blood and urine for testing/storage on all participants 
at the baseline visit. This is extremely well tolerated by the participants. It was 
an oversight of the investigators not to include blood and urine storage at all 
follow up visits. To fully track the medical outcomes of this cohort the 
investigators have decided it necessary to follow the same procedures of blood 
and urine testing/storing from baseline at all follow up visits and request this 
be approved by MoDREC.  
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o. Additional testing of male hormone profile on blood samples.  
The investigators request that MoDREC approve a standard profile of male 
hormones to include testosterone, follicular stimulating hormone (FSH), 
luteinising hormone (LH) and sex hormone binding globulin (SHBG) to be 
tested on each follow up visit. This was not included in the original blood test 
battery however on consultation with a patient group (Afghan injured) they 
have requested that male hormones be measures due to concerns over long 
term fertility with major trauma. This has been discussed and confirmed as an 
appropriate investigation with Major Martin Moody Defence Consultant Advisor 
for Urology. 
 
Additional wording of consent: (Appendix C) 
p. An additional sentence has been added to the consent form to confirm that 
participants are content with their study data being shared with existing and 
future research collaborators 
q. Change existing consent form wording from “…in accordance with the 
provisions of the Data protection Act 1998” to “... in accordance with the 
provisions of the data protection Act 2018.” 
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Proposed method of data collection: 
The DUDIT and the PCL-5 are replacement questionnaires. The PCL-5 may 
take a minute or 2 extra however the DUDIT is likely to save several minutes 
over the existing questionnaire that it is replacing.  The additional 11 
questionnaires/questions are short and will be able to be completed in 15 
minutes maximum (tested on volunteers) however as mentioned time will bw 
saved (approximately 5 minutes) with the exchange of the DUDIT for the 
existing drug history questionnaire. All questionnaires will be collected 
prospectively in an anonymised format during the 6 hour study visit. The 
additional questions/questionnaires are not expected to impact significantly on 
participant’s time or well-being. Staff will continue to be available to answer 
questions on any specifics in the questionnaire pack.  
The additional hormones tests will not require further blood to be drawn but 
will be tested on the existing volume of 50ml of blood. If an abnormal hormones 
results are identified then MO/GP will be informed and Maj Martin Moody DCA 
Urology will be available to give specialist advice if needed. 
 
Blood and rine collection and storage at follow up visits will follow the exact 
same protocol as the baseline visit with the exception that the genetic test for 
HLA-B27 will not be repeated, 
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Impact of Amendment not being approved: 
This is a unique study in a unique population. The additional requested 
amendments have been carefully thought though by the project board of 
collaborating investigators from MoD, Imperial College London and Kings 
College London.  We now have the benefit of working on the ADVANCE Study 
for 4 years and have the experience of having over 750 participants go through 
the data collection process. The additional data that will be collected from 
these suggested amendments will add valuable information to the long term 
medical and psychosocial outcomes of this severely and uniquely injured 
cohort.  
 
Date Amendments approved/rejected (with reasons): 
Date of Approval:  15th Jan 2013 
Date of Approval of 1st Set of Amendments: 12th March 2015 
Date of Approval of 2nd Set of Amendments: 23th Sep 2015 
Date of Approval: 3rd Set of Amendments:  7th Feb 2016 
Date of Approval: 3rd Set of Amendments:  2nd May 2018 
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Summary of changes to questionnaire (Ref:MODREC/357/PPE/12) 
 
Table 1: Changes to questionnaire  
Version 2 Action Details 
Questionnaire Addition MOXFQ 
 Replacement DUDIT to replace brief drug history 
 Addition Personal reason for leaving Armed Forces Question 
 Addition Highest level of educational attainment 
 Addition Veteran specific outcome questions 
 Addition Who Lives with you question 
 Addition Family and friend network question 
 Addition Ohio State University TBI Identification method 
 Addition Rivermead Post Concussion Questionnaire 
 Replacement Replace PCL with new version PCL-5 
 Addition Brief Pain Inventory 
 Addition Neuropathic Pain Symptom Inventory 
 Addition Pain Catastrophising Scale 
Assessment Addition 50mls or blood and 50ml of urine (as per baseline protocol) to be 
taken/tested/stored (as per baseline protocol) at all follow up visits 
(3yr, 5yr, 10yr, 15yr and 20yr) 
 Addition Male hormone profile of testosterone, FSH, LH and SHBG to be 
tested on existing volume of blood at all follow up visits 
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MOD Research Ethics Committee  
(Personnel, Protection and Effectiveness) 
From the Chairman  
Professor Allister Vale  
National Poisons Information Service (Birmingham Unit), 
City Hospital, Birmingham B18 7QH 
Telephone: 0121 507 4123 
e-mail:allistervale@npis.org
______________________________________________________________________ 
Wg Cdr Alex Bennett 
PhD FRCP  
Head of Research DMRC 
Headley Court, 
Epsom, 
Surrey
Our Reference: 357/PPE/12 
Date: 15 January 2013 
______________________________________________________________________ 
Dear Wg Cdr Bennett, 
First of all I would like to congratulate you for not only submitting a revised 
protocol with tracked changes but also a detailed letter indicating your 
responses. This was most helpful to the Committee and as I said at the time is 
an excellent example of how investigators should resubmit their protocols.  
The revised protocol has been approved by MODREC but you may like to 
correct a small number of typographical errors in the PIS.  
I wish you and your colleagues a successful study and we look forward to 
receiving in due course a brief summary of the results so that these can be filed 
in accordance with the arrangements under which MODREC(PPE) operates. 
With kindest regards, 
Allister Vale MD FRCP FRCPE FRCPG FFOM FAACT FBTS FBPharmacolSocHon FRCPSG 
Cc Dr John Scadding, Professor David Jones, Dr Paul Rice OBE, Marie Jones 
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